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Abstract 
 
Purpose  
 
The research aim has two parts: Firstly, to characterise and evaluate clinical trial 
information and the dissemination of that information by constructing a conceptual 
model structuring the processes of information generation. Secondly, to test the 
model by identifying the dissemination methods used, consider their effectiveness 
and what factors affect dissemination. The research findings contribute to outline a 
framework of recommendations with an optimal model of effective dissemination 
for improved transparency in clinical research.  
 
Design and methodology 
 
Based on the literature review, a conceptual model was constructed outlining the 
structure of information generation throughout the clinical research process. A mixed 
approach with qualitative and quantitative studies were undertaken to form a 
comprehensive picture of the dissemination of clinical trial information and in order 
to test the model.  
 
Key findings  
 
The model identified that clinical trial information is very complex, scattered across 
many resources and many factors affect how, where and what clinical trial 
information is disseminated. A model of effective dissemination and a framework of 
recommendations for improved transparency in dissemination were drawn up for 
three areas; regulations and standards, communication planning and the organisation 
of clinical trial information. 
 
Limitations 
 
This research has been done during a time of significant and rapid change in the 
clinical research environment and therefore this thesis is a snapshot of a time when 
new web tools allows for information to be disseminated rapidly.  A series of small 
studies were made to gather an overall picture of information transparency in clinical 
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trials as we lack evidence in these new areas.  
 
Originality/value 
 
There is no existing conceptual model that explains and tests the dissemination and 
transparency of clinical trial information. Models can structure processes, suggest 
improvements in the processes and be used as a basis for further research.  
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1. Chapter 1 Introduction to this PhD thesis 
1.1. Introduction 
The purpose of this introductory chapter is to outline the statement of the problem 
and the motivations for this study by indicating its importance and relevance for the 
fields of information studies, publishing and clinical research. The aims and 
objectives of this research are explained and the research questions defined. An 
outline of the thesis by chapter is also provided.  
1.2. Statement of the problem  
The crisis at the core of this study is that there is little trust in the clinical research 
process. Part of that distrust is that clinical trial information is scattered across a 
variety of resources, and sometimes information is not made publicly available at all. 
There is no existing model that explains the clinical research process and the 
information that is generated throughout clinical trials. This research firstly aimed to 
model the information generated in clinical trials. Once the model was built, the 
second research aim was to test the model in order to examine the possibility of 
improving the dissemination of that information and to provide a framework of 
recommendations for an optimal model for effective dissemination. 
 
Clinical research is a very regulation heavy environment in which to work. Even 
though research is global, the environment remains fragmented with various 
regulations affecting research. These regulations are global, national and regional, 
some requiring adherence to legislation across regions. There are also ethical 
guidelines on biomedical research to ensure patient safety and the ethics of research 
subjects. Understanding these regulations and requirements were essential before 
embarking on this research process and in order to build a model that shows how 
information is generated throughout the research. 
 
Clinical research into a new promising entity is a long and expensive process which 
generates a lot of information, which are disseminated in various ways. The 
dissemination of clinical trial data is affected by various forces, regulations, 
guidelines, research objectives, research results, market needs, funding agreements, 
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pressures and so on. Dissemination activities can take many forms, such as 
presentation at conferences, via promotional material, in published papers or more 
informally via the web and this research identified rapidly emerging methods of 
dissemination which is changing the process of dissemination and access to 
information. The methods used are not flawless and there is evidence of where 
dissemination has been less than ideal. The clinical research process has come under 
scrutiny by the press with various recent court cases on issues such as falsified 
research data, non-publication of research data, misguided marketing claims etc. 
Again it was important to this research to understand the issues that affect clinical 
research today and perhaps get an insight into what may have caused those issues.  
 
It is clear that clinical trial information is scattered across many different resources 
and that many resources lack standards for the organisation of clinical trial 
information and that there is poor control of such information. This research needed 
to show how complex clinical trial information can be and therefore how difficult it 
is to disseminate it and the reasons why it may not be disseminated. Some of these 
issues are wider than the clinical research community and are embedded in the 
scholarly communication process, e.g. who is responsible for research information 
and its storage?  
 
There is a change in the scholarly communication and the information behaviour of 
researchers. The digital environment allows researchers to disseminate information 
not only through traditional scholarly communication methods, e.g. journals, but also 
in informal ways using social tools or by publishing informal reports or grey 
literature. The boundaries between formal and informal publishing activities are 
blurring. There are issues around quality of such material, searching and finding it, 
version control and ownership etc. but the point is that the web has opened up 
possibilities of informally disseminating clinical trial data rapidly. It became clear 
that there is an urgent need to address what it means to publish on the web. 
1.3. Motivations for this study  
The researcher of this PhD has worked within the pharmaceutical industry and 
during that time wrote her MA thesis on evidence-based medicine (EBM) from an 
information professional‟s point of view. At the time EBM became a force in 
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pharmaceuticals as NICE had recently been set up and changing the existing 
pharmaceutical sales model of convincing the physician to prescribe to providing 
evidence to NICE of the effectiveness of an intervention. NICE draw up intervention 
guidelines on cost-effective treatments and prescribing decisions are usually made 
based on these guidelines
i
. This was also the time of the dot.com boom, the web 
became an everyday tool to share information to a larger audience and there was no 
longer a need for visiting your GP for medical information and indeed no need for 
the GP to call the pharmaceutical rep for information. When moving onto working 
for the professional body of clinical researchers, it became clear that the world of 
information is changing rapidly but that research and researchers do not necessarily 
follow with it. Not deliberately, but because of too much too quickly and the 
inability to keep up.  The public is increasingly information hungry, expecting to 
access information when they need it. Web 2.0 and other emerging developments are 
making interaction with information, other people and with researchers possible.  
Traditional one way communication has transformed into two way communication, 
making communication more interactive. I believe that this is an age of where 
transparency in clinical research is expected, information needs to be shared, 
including research design, objectives, results and summaries of findings. The main 
motivation for this study was an attempt at documenting some of these changes and 
review how new initiatives aim to make research more transparent. 
 
An objective was to model the drug development process and show the complexity 
of information generated before, during and after a clinical trial and the kinds of 
output that information takes. Clinical research is an increasingly complicated area 
involving many individuals for many years, and as new regulations and ethical 
guidelines require more procedures within a clinical trial, research is becoming 
fragmented and potentially more confusing for the public and researchers 
themselves. 
 
                                                 
 
i Note: The new government in England is changing the healthcare service with PCTs disappearing in 
2012 and GPs given responsibility for their own budgets. The way in which NICE works is also 
under review. These changes may mean that prescription may change in the near future. 
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It was important to try to establish the reasons behind the distrust in the clinical 
research industry and arguments for more transparency in the research process.  
There are many factors that affect dissemination, e.g. organisational and journal 
publication policies and guidelines, economic and geopolitical pressures, regulations, 
the quality of the information generated in clinical trials, and the quality of the 
research itself, and many more. To what extent do these factors affect dissemination? 
 
The question „what is publication in the electronic environment?’ also provided a 
motivation for this research. It seemed a useful exercise to compare discussion about 
the scholarly communication process with that of communicating clinical trials.  The 
research therefore draws extensively from research into information dissemination, 
investigations into the trust concept and the scholarly communication process.  
Rapid developments in the digital environment allow researchers to disseminate new 
forms of scholarly material, using various new methods such as blogs, discussion 
forums, own research web pages etc. It seemed interesting to investigate if there is a 
change in dissemination behaviour. Is the divide between formal and informal 
scholarly communication increasingly blurred as has been stated?  The journal model 
has not changed dramatically, even with the possibilities of the Internet, but how 
long can the current journal model last? An examination of methods and processes to 
disseminate may tell us which methods are best fit for purpose, e.g. which methods 
are best suited for disseminating clinical trial information?  
 
There are many methods used for dissemination and I wanted to investigate what 
determines the selection of information for dissemination and the selection of 
dissemination methods. With the rise of the Internet we increasingly discover 
medical information when searching online. To what extent do researchers use 
dissemination opportunities available online? Different search experiment online 
over a period of a few years revealed that access to clinical trial information online 
has increased enormously. It will be interesting to see if electronic dissemination 
methods may increase and even replace the traditional methods of scholarly 
communication, e.g. publishing a journal article. 
 
By evaluating strategies of dissemination, methods used, factors that affect 
dissemination and in examining current practice it seemed useful to document that 
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understanding of dissemination of clinical trial information in a PhD. It also seemed 
possible to use this evaluation as a basis to provide a recommendation and 
framework for improving the dissemination process. 
1.4. Scope 
The topic of dissemination could potentially be a huge area of research within 
information studies or clinical research. In order for this to be a manageable PhD 
there are some inclusion and exclusion criteria that were set. 
  
Inclusion 
 This research aims to demonstrate aspects of discovery and characteristics of 
clinical trial information not all biomedical information. 
 Clinical trials and research are global processes with many global factors 
affecting them. This research gives an overview of clinical trial information 
with no specific references to specific regions, unless it is useful to do so. 
Differences in regions are explained, in particular when discussing 
regulations. 
 It is looking at primary methods of dissemination, e.g. methods where the 
researcher aims to get a clinical trial published or the results released. 
 Information is global, when searching for information, in particular on the 
web, we may not always think about the origins of information. Clinical 
research is also a global industry and many clinical trials are multi-centred, 
e.g. take place in many countries, or regions within countries. In this PhD I 
compare different regions where relevant, e.g. FDA (USA) and EU studies. 
Much published literature comes from the US and where possible I have 
done some UK or EU studies to offer comparison.  
 Trust and quality are two concepts that are important to information 
dissemination and will become even more important aspects when engaging 
with information in the future in particular online. These concepts are 
referred to where relevant. 
 The scholarly communication process is referred to and changes highlighted 
when reviewing methods of dissemination and the assessment of their fit for 
purpose within clinical research.  
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 Exclusion 
 It attempts to establish what pre-conditions are needed for effective access to 
clinical trial information, but does not cover details of information needs and 
information literacy skills of specific groups of people, e.g. the public. 
 It does not examine secondary resources that systematically review clinical 
trials, e.g. libraries that review clinical trials, Cochrane Library or National 
Institute for Clinical Excellence (NICE). They are mentioned briefly where 
relevant. 
 This research does not extend to looking at dissemination or complications of 
information dissemination in developing countries, with efforts to reduce the 
digital divide and the lack of efforts in sharing clinical trial data with clinical 
trial participants world-wide.  
1.5. Choosing diabetes and obesity for research 
In order to conduct manageable studies for this research, it was suggested I narrow 
down the scope of research to a key therapeutic area. There are reasons for selecting 
diabetes and obesity as an area of research for this PhD. According to many 
organisations, the obesity epidemic is an enormous global problem which is 
spiralling out of control. The UK has a large amount of overweight and obese 
people, conditions that often continue to develop into type II diabetes. 
Approximately one in every five adults in the UK is overweight, and one in 15 is 
obese, and this figure is climbing. The cost to the health service of diabetes and 
related conditions is growing and complications of diabetes are very costly to treat. 
Patient numbers with complications of obesity were thought to have doubled 
between 2005 and 2010 according to data analysed by the Foresight team
ii
.  It is 
likely that more people will be seeking out new interventions for obesity including 
clinical trials and very likely turn to the Internet for information seeking. 
 
 
                                                 
 
ii The Foresight team analysed data from health survey England on obesity data, published on 
http://www.idea.gov.uk/idk/core/page.do?pageId=8267926 [Accessed 1 June 2011]. 
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1.6. Geographic coverage 
There are three distinct regions in clinical research, identified by the International 
Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use, ICH
1
 for short. These regions are the EU, USA 
and Japan. The goal of the ICH is to promote international harmonisation on 
technical requirements of clinical trials. ICH has also extended membership to non-
ICH countries, who may their own regional partnerships to harmonise clinical trials. 
Although this harmonisation partnership exists, within the ICH, within regions 
themselves (like in the EU) and in other forms of partnerships, clinical trials are very 
different within the regions due to differing requirements, laws and guidelines. This 
makes clinical trial information a difficult area to research as there are constant 
reminders that things are not the same within these different regions or countries.  
Information is global and the development of technologies allowing information to 
freely flow regardless of borders makes it an interesting topic to research within such 
a regulation heavy environment which is clinical research. 
Much research that I draw upon for this PhD will be global, cross-regional or 
national. There is an attempt to stay within the three ICH regions and not venture 
into the non-ICH regions and as the exclusion criteria already mentioned, not cover 
the differences between developing and developed countries where there are many 
information issues that would make research for this thesis too much. Furthermore 
there is an attempt to compare the EU region to the FDA region, in particular where I 
have found research that has taken place in the US but not in the EU.  In some cases 
I have also conducted research into what is happening in the UK, in particular where 
pointing out the always changing environment in which we live. The change of 
government affects healthcare nationally. Changes on an EU level have to be 
incorporated into national law or regulations. Changes in the FDA region may affect 
the EU, and certainly affects clinical trials taking place in the US sponsored by an 
EU company, or studies in the EU sponsored by a US company. This complexity 
highlights the need for harmonisation across regions and clearer guidelines to those 
conducting research. The global demand for information from clinical trials will 
increase and this PhD is timely considering the growth of online tools and 
opportunities to disseminate information in real-time online. 
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1.7. Research questions 
When the research first began, my initial research questions were around themes. 
The themes allowed me to organise my research and explore how I could best 
present the research. After the initial literature review and organisation of 
information discovered around these themes, I identified gaps and questions that I 
needed  to answer. These became my research questions. After draft 2 of this thesis, 
I was able to simplify and improve the research questions and arrange my research 
into appropriate chapters addressing the research questions in turn. 
 
The research questions became: 
 
1. What is clinical trial information? 
2. What do we mean by dissemination? 
3. What methods are used to disseminate information?  
4. Why is a particular method chosen and what factors affect information 
dissemination? 
5. What is effective dissemination? 
6. Can we improve the dissemination of clinical trial information and make the 
process more transparent? 
 
1.8. Research aim 
The two-part research aim became: firstly, to characterise and evaluate clinical trial 
information and the dissemination of that information by constructing a conceptual 
model structuring the processes of information generation.  Secondly, to test the 
model constructed by identifying the dissemination methods used, consider their 
effectiveness and what factors affect dissemination. 
 
1.9. Research objectives 
 
The objectives of the research were: 
  
 Model the drug development process and the processes by which clinical trial 
information is generated, stored and disseminated 
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 Critically analyse the different methods used to disseminate clinical trial 
information and summarise the factors that affect dissemination 
 Through a survey of clinical research professionals, and the examination of 
publication policies within organisations, explore the understanding and 
practice of registering and disseminating clinical trial information 
 Conduct  Internet search experiments to assess how information is scattered  
 Evaluate different tools for discovering clinical trial information on the 
Internet  
 Make a recommendation for how the dissemination of clinical trial 
information could be improved and more transparent.  
1.10. Contributions of this study 
It is clear that when starting this research, little had been published around clinical 
trial registration and issues of sharing research results. Still to date little previous 
research studies of the kind in this thesis have been published and pulling together 
research studies in this way has proved valuable in getting an overall picture of 
clinical trial information. 
 
Although many models exist for the scientific communication process, no one has as 
far as I am aware modelled the clinical research process and the information 
generated throughout clinical trials. The conceptual model will be useful to those 
who provide training on clinical trials and for anyone who needs a quick overview of 
the research process as well as for building upon as new research findings emerge. 
 
I selected the obesity and diabetes topics for the various studies as these diseases are 
growing in our communities and therefore it is likely that in the future more 
information will be needed by the public who are looking for health information and 
by professionals who need clinical evidence on these disease areas. Obesity and 
diabetes have not previously been used for these types of studies in published 
literature. 
 
This thesis offers a range of recommendations for improvements to the clinical 
research process in making it more transparent. It is hopefully a valuable document 
that offers an insight into the situation of disseminating clinical trial information 
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over a period of five years and what the issues are from an information 
professionals‟ point of view.  It is hoped that these studies form a basis for future 
research. 
 
The research has also highlighted the lack of consistent terminology in this field of 
study, and this could be an area in which the information profession could provide an 
input to improve how we search for and find information about the process of 
clinical trials and the information from clinical trials.  
 
The research has highlighted the evolution of publishing with online methods used 
for disseminating clinical trial information and I have made a suggestion for an 
improved definition on what it means to publish to include the new methods.   
 
I hope that this study contributes to an understanding of the complexity of clinical 
trial information and what happens to the information that is generated throughout 
the process. I also highlighted the many interlinked issues between clinical research 
and informatics, e.g. around data standards, intellectual property, trust, information 
literacy and behaviour etc.7 
 
1.11. Thesis outline - flowchart 
A thematic approach has been taken when compiling the research findings. 
Information and research results are discussed in themes, replicated from the 
literature review, and which follows the order of the research questions.  
 
The thesis is divided into 2 parts of 7 chapters (in brackets below), appendices and a 
bibliography.   
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Introduction to 
the PhD 
(1) 
 
Literature 
Review 
(2) 
 
 
Methodology 
(3) 
Part 1 
Modelling clinical  
trial information 
(4) 
Part 2 
Current state of dissemination of 
clinical trial information 
(5) 
 
Findings and 
recommendations for 
effective dissemination. 
(6) 
Conclusions to 
this PhD 
(7) 
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Chapter Content of chapter 
1 Introduction to the PhD, statement of the problem, motivations for the 
study, research aim and objectives, contribution and research 
questions. 
2 Literature review, setting the scene, introduction to clinical research 
and introduces concepts used through the thesis and describes 
information resources used for this research. Literature is also 
introduced throughout chapters 4, 5, 6 where it is central to the 
discussion around my research findings. 
3 Describes the research methodology adopted in order to respond to the 
research questions, each study is introduced with its study design and 
limitations. 
PART 1 
4 
Explains the drug development process and introduces clinical trial 
information. The conceptual model of the clinical research process and 
information generated within the process is introduced. Responds to 
research question 1. 
PART 2 
5 
Tests the model constructed in part 1. Provides the evidence to 
illustrate the current state of clinical trial information dissemination. It 
summarises the dissemination methods used, what factors affect 
dissemination and how effective the methods are. It also critiques the 
concepts of dissemination and publication. The concept of trust and 
how this is linked to the dissemination of clinical trial information is 
discussed. The results of a survey of clinical trial professionals provide 
an insight into the practice of clinical trial registration and 
dissemination. Responds to research questions 2, 3, 4 and 5. 
6 Provides the framework of recommendations and an effective model of 
dissemination, which may lead to a transparent research culture and 
ultimately improves public health. Responds to research question 6. 
7 Concludes the research and addresses the research questions, 
limitations and future research suggestions. 
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1.12. Conclusion to Chapter 1 
This chapter was an introduction into the research undertaken for this PhD. It 
outlined the statement of the problem and the motivations, the aims and objectives of 
the research and the research questions. An outline of the thesis by chapter was also 
provided.  
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2. Chapter 2: Information sources and literature review  
2.1. Introduction 
This chapter serves as an introduction to the thesis.  It describes in detail what 
resources were used to find relevant research and terminology used clinical research 
and also in this research.  The literature review, which is organised around the 
research questions, introduces briefly what is known, controversies, highlights 
specific gaps and questions that needed answers.  
2.2. Resource discovery 
A number of resources were used to find suitable literature for the review.  
 
Literature in life sciences, and clinical trials, is indexed in PubMed (or Medline) but 
can also be found across many non peer-reviewed sources that cannot be searched 
for in a bibliographic database. Some of these sources are magazines published for 
the clinical research audience, e.g. International Clinical Trials, Applied Clinical 
Trials, etc., but also grey literature such as conference presentations, reports, 
websites, blogs, e-newsletters, newspaper articles etc. The Internet, mainly the 
search engine Google and Google Scholar, and hand searching through the 
bibliographies of books and references of published papers and grey literature aided 
the discovery of other research but it was a time-consuming activity. A large amount 
of time was spent weeding out unsuitable literature. 
 
It was also necessary to search in other subject disciplines that cover publishing and 
electronic communication, the publishing and library and information fields in 
particular. The databases searched were LISA, UCL‟s MetaLib allowing a cross 
search across a variety of databases, e.g SCOPUS, Web of Science etc.  
 
The following broad search strategies were used in different databases: 
“clinical trial*” AND (information OR data) 
 “clinical trial*” AND (information OR data) AND (disseminat* OR publish* OR 
report* OR communic* OR public*) 
“clinical trial*” AND (registr* OR bank) 
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Many other narrower searches were run where necessary in particular in areas where 
concepts such as trust, transparency, regulations, policies and specific topics are 
discussed. 
 
A number of other resources were also consulted, such as clinical trial registers, 
email correspondence with clinical trial professionals, conversations with peers, 
authority websites, regulations, ethical guidelines, journal publisher websites etc. 
2.3. Terminology and difficulty with classification systems  
The Medical Subject Headings (MeSH) from the US National Library of Medicine is 
a reasonably well developed classification system used in Medline and PubMed. 
However, there are difficulties with the lack of terminology when researching the 
clinical research process, including the administration or management of clinical 
trials, the profession of clinical researchers and so on.  
 
Terminology available when searching the MeSH for clinical trials are: 
 Clinical Trial 
 Clinical Trial, Phase I, Phase II... etc. 
 Clinical Trials Data Monitoring Committees 
 Controlled Clinical Trial 
 Early Termination of Clinical Trial 
 Meta-Analysis 
 
And when searching for MESH terminology for clinical research: 
 Biomedical research 
 Clinical research 
 Clinical nursing research 
 Clinical research protocol 
 Nursing Methodology Research 
 
Terms that are often used for clinical trials are simply not covered by the 
classification system in Medline. This was also experienced across other databases 
that were searched for this thesis. One study comparing indexing of randomized 
Korjonen: Clinical Trial Information  30 
 
trials in Medline with EMBASE found that 80,000 records out of nearly a third of a 
million records had not been indexed as randomized in Medline
2
. The lack of 
terminology available to index material has been discussed by others, the lack of 
terms used in indexing means that many articles that are relevant to a search are 
missed out
3;4
 and the quality of indexing of clinical trials in electronic databases has 
been said to be poor
5
 and that search sensitivity and precision within databases 
should improve
4
. 
 
A major challenge in finding relevant resources is the lack of an established 
thesaurus suitable for searching for information on clinical trials and dissemination 
or publishing. Clinical research, clinical trials, clinical investigation and clinical 
study or just trial are used interchangeably, sometimes with a combination of terms, 
e.g. randomised trial, human study etc.,  and literature searches bring back an 
overwhelming amount of papers that are reporting from clinical trials rather than on 
the process and management of the clinical trial.  
 
This thesis refers to the clinical research professional who is a person involved in 
the creation and management of clinical trial information and may constitute many 
types of individuals like authors (those reporting on clinical trials), managers of 
clinical trials, clinical trial site staff, statisticians, research staff etc. These 
individuals are based in different organisations like national health services, 
pharmaceutical companies, research companies, academic institutions etc. 
 
Publishing, reporting, communication, disclosure and dissemination are terms that 
are also used interchangeably making searching complex. This thesis concentrates on 
the term dissemination, which is the interactive process of spreading information 
using one or many methods. Communication is referred to frequently in literature 
and therefore also in this PhD where deemed necessary, in particular where 
published literature refers to the scholarly communication cycle. More terms that 
caused difficulty are the newer concepts of repositories, databases, clinical trial 
register/registry or clinical trial banks as there is no standard terminology as yet 
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developed, although the World Health Organization (WHO) has developed a 
definition trying to standardise the way in which registers are referred to
iii
.  
 
Knowledge, information, data and publication were also search terms used to narrow 
down results in some searches. As scholars use different terminology for these types 
of similar methods or tools, searching became increasingly complex and time 
consuming.  It was also noted that when suitable references were found, many were 
poorly indexed (lack of metatags and keywords on websites and within published 
and grey literature) and it is very likely that many citations go unnoticed due to poor 
indexing, lack of standards and terminology as described above. The difficulty of 
finding common terminology has also meant that it was difficult to choose the most 
suitable terminology for use in this thesis, however throughout there will be 
explanations of terms and these are also discussed more in-depth in the literature 
review next.  
2.4. Literature review 
The purpose of the literature review is to introduce the world of clinical research and 
the dissemination of information.  It will summarise and highlight specific topics that 
will be discussed in later chapters.   
 
The literature review will begin by exploring clinical research and clinical trial 
information. It will then discuss dissemination, publication and scholarly 
communication. It moves onto discussing methods of dissemination and what is 
meant by effective dissemination. The trust and quality concepts are introduced and 
then it will introduce the factors that affect dissemination. The literature review sets 
                                                 
 
iii A clinical trials register is the formal record of an internationally agreed minimum amount of 
information about a clinical trial. This record is usually stored in and managed using a database. A 
clinical trials registry is the entity that houses the register, and is responsible for ensuring the 
completeness and accuracy of the information it contains, and that the registered information is used 
to inform health care decision making. A clinical trials registry is more than its database. Source: 
http://www.who.int/ictrp/faq/en/index.html [Accessed 26 Feb 2011] 
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the scene by introducing terminology, existing research and highlight the areas that 
this research will examine. 
2.1. Criteria for selecting material included in the literature review 
 
For this thesis an exhaustive review with selection citation was adopted
6
. The criteria 
for selecting the material included in the literature review was to collect and 
summarise the most relevant information, published and grey literature, that address 
the themes identified in the research questions, papers that provided useful 
background information to issues, highlighting gaps and that inspired me to ask 
questions. They also serve as core papers that drive this research forward, in a way 
outlining the journey of the research. Other literature is also covered in later 
chapters. The reason for not including everything in the literature review is that 
many papers required greater discussion in relation to the research that took place for 
this thesis. It would be illogical to introduce them early on when setting the scene.  
 
The first searches were run before officially commencing this PhD in 2006 when 
drafting the research proposal. The initial searches were incredibly broad to include 
aspects of research which have since been removed due to constraints and narrowing 
of focus, e.g. literacy skills, fraud and research misconduct and research in 
developing countries. The first sift identified key papers around my themes. Once I 
had organised my research in themes, and the final research questions were set, I 
revisited my literature review, updated it with new papers and removing those that 
were no longer considered key papers. The first literature review chapter was written 
as a draft to guide me in my research. Literature searches were then conducted on a 
regular basis including hand searching cited references.  The final searches were run 
in November 2010 updating the existing bibliography, although a few references 
were added post Nov 2010 if anything „new‟ was published and inclusion was seen 
to add to this thesis. 
2.2. Validity of material 
 
It is difficult to establish the validity of content in literature and specifically in 
content found on the web or in unpublished grey literature. By adopting the 
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exhaustive review with selective citation I made the literature review more 
manageable and allowing the use of grey literature. Grey literature can be 
contaminated with personal opinion of the author and may not have been through 
peer review. A critical appraisal of any citations was required. The goal during the 
critical appraisal was to identify central issues or a line of argument within a theme. I 
focused on findings of literature, based on some substance or evidence, and if the 
material fitted in with the rest of the literature identified around that theme. I wanted 
to take a neutral perspective and not introduce bias to the critical appraisal process. I 
have highlighted contradictions in conclusions or around issues throughout the thesis 
where such was present. 
2.3. Reference Manager – a bibliographic tool 
 
For this research the bibliographic tool Reference Manager 12 was used to collate all 
bibliographic information, and annotated notes, and the final catalogue contains  
1022 citations referred to for this PhD. The „Reference Type‟ field was used to 
distinguish between types of material collected, e.g. journal article, online source etc. 
I could also use the „Notes‟ field available to write own comments. References were 
imported if possible from PubMed or from .txt files, or catalogued manually. 
2.4. Clinical trials information and terminology  
The term “clinical trial” was first used by the British Medical Research Council in 
early 20
th
 century
1;2
.  Some scientific studies comparing treatments were performed 
in the 18
th
 and 19
th
 centuries, e.g. smallpox, cholera, with the most notable 
interventional trial being that of James Lind, a surgeon, in 1747 involving 12 patients 
who had scurvy at sea
7
. The first true randomised clinical trial was conducted by the 
British Medical Council in 1948 involving 100 patients studying streptomycin‟s 
effect in the treatment of tuberculosis
8
.  
 
Very briefly described here, clinical research answers research questions into the 
efficacy and safety of medicines. A promising entity is selected to go through phases 
of research (clinical trials) to establish its behaviour. A clinical trial is the gold 
standard into the discovery of new medicines and devices, or interventions as I will 
refer to them, testing their efficacies before being marketed. 
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Clinical trials, or clinical studies, or clinical investigations, exist for a number of 
different interventions, such as medical devices, herbals, food, medicines and 
nutritional items etc. Due to differences in the way in which trials are regulated and 
performed in these areas, this thesis concerns itself with the broader environment of 
clinical trials and not specifics of particular research entities or areas. This thesis 
may refer to a new potential medicine as an ‘investigational medicinal product’ 
(IMP) but in general it will refer to interventions. 
 
The average cost of researching and developing a new chemical or biological 
intervention was 1,059 million € in 2007, and R&D expenditure globally has been 
estimated at $127.2bn
9
 in 2010. There are around 107,000 individuals working in 
pharmaceutical R&D in the EU and the pharmaceutical industry funds thousands 
more researchers in the health care and university setting
10
. Because of the costs 
involved in developing a new drug, profits must be made in the sales of those drugs 
to sustain the product lifecycle. Only one in 10,000 entities successfully becomes a 
marketed drug, which makes the industry risky but also highly profitable if there is 
success with one intervention on the market. We do not know how many clinical 
trials are conducted annually around the world. According to some rough estimates, 
100,000 clinical trials were underway in 2007 with a growing amount of clinical 
trials taking place outside Food and Drug Administration (FDA) in the US and 
European Medicines Agency (EMA)
iv
 in the EU regions
11
. Recent estimates have 
suggested that every year approximately 4,000 clinical trials are authorised in the 
EU, meaning that around 10,000 clinical trials are ongoing at any time
12
. 
 
There are many research designs that may be appropriate for a clinical trial, however 
every trial must be scientifically sound and incorporate ethical principles regarding 
the treatment of research participants
13
. Although there is no standard for what a 
well-designed and well-executed clinical trial looks like, it has been said that the 
randomised controlled trial is ideal
14
. However, there is no methodology for 
assessing the quality, validity and relevance of a clinical trial including RCTs and 
                                                 
 
iv Used to be called the European Medicines Evaluation Agency (EMEA) 
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many RCTs exclude certain patient populations, e.g. women, children and the 
elderly
15-17
. Other study types, e.g. meta-analyses and expert reviews are also 
additional sources on evidence of treatment efficacy
17
. RCT methods are not applied 
to all therapy areas, a study shows that the cardiovascular, cancer, asthma, post-
operative and anaesthetic therapy areas most often employ RCT methodology in 
trials
14
. More important is the concern is for the quality of the trial itself and the 
quality of the trial reporting
16
. Furthermore the way in which trials are conducted 
and how they are reported are changing over time, and therefore it will be difficult to 
develop tools, e.g. policies, standards, checklists and guidelines, that can be flexible 
with the types of trials that exist and how they develop over time.  
 
There is no exact definition of clinical trial information. Chapter 4 will explain the 
components of clinical trial information and therefore provide a definition of clinical 
trial information in the context of this thesis.  Information is a very broad term which 
is interpreted differently amongst different people. It is sometimes described 
approximately as being (1) raw data (2) specified and organised for a purpose (3) 
presented in a context to give it meaning (4) or that leads to an increase in 
understanding. 
 
The results from trials, raw data, are analysed and interpreted. The data and their 
interpretation become information, and also evidence, of what we know about the 
intervention. This information is documented, disseminated and published in various 
ways, e.g. as supplementary material to a journal article, deposited in a repository, 
published on a website or shared ad hoc by researchers
18
. In healthcare, health 
practitioners use the best available evidence together with their expertise to make 
treatment decisions, coined evidence-based medicine (EBM). Without access to 
current best evidence, a patient (who we are all at some point in our lives) is at risk 
because of out of date practice by health practitioners
19
.  Data are vital in the 
reconstruction of a research process and to evaluate the research process, and data 
can be manipulated to generate new datasets or for re-analysis
20
. 
 
The scientific validity of data, such as peer review, assumes the sharing of data and 
research methodology, or protocol, with other scientists who validate each other‟s 
theories
21
. Sharing of research data is problematic due to intellectual property 
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concerns, data protection reasons (if personal information is present) and difficulty 
in sharing data using appropriate standards. However, sharing of data is increasingly 
being expected in particular as research is becoming more data-intensive and 
rich
22;23
. It has also been argued that sharing research data is an ethical must and 
improves trust in research for transparency effort
24
. I discuss more about sharing 
research data in chapter 4. 
 
Clinical trials improve medical practice but some of the barriers to practicing EBM 
are poor access to clinical trial information as well as the volume and complexity of 
trials taking place
25;26
. Comprehensive systematic reviews attempt to bring together 
results of clinical trials to offer an evidence-based summary of findings for a specific 
therapeutic area. Systematic reviews do not always include information that is 
unpublished or exist in formats such as grey literature. Because not all clinical trials 
are published and all data are not disseminated, the scientific evidence base becomes 
skewed during systematic reviews. Selection bias, the decision to disseminate certain 
results but not others impact systematic review results. Systematic reviews, if they 
did include information from unpublished trials may show a different outcome, even 
suggesting completely different treatment advice
27-31
. Examples of systematic 
reviews are the Cochrane Reviews
32
, which aim to limit bias and error in reviews. 
The Cochrane Library contains around 4500 synthesised original studies. However, 
the Cochrane Collaboration estimate that at least 10,000 reviews are needed each 
year to keep up with healthcare interventions and at least 5,000 need to be updated 
each year
32
. It is a recommendation that systematic reviews should include grey 
literature and unpublished information, but in order to do this, the data and 
information must be made publicly available.  
 
This thesis will define what clinical trial information is in more detail in chapter 4, 
by discussing research data, research information and other information that is 
relevant in clinical research. It will describe the process by which this information is 
generated and how that information is currently made available. It also addresses the 
factors that affect selection of information and the challenges of sharing information 
and data.  
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2.5. Conceptual models, diagrams and road maps 
Conceptual models or process models, e.g. diagrammatic descriptions of systems, 
are designed and used to show how different resources interact within a process or 
between processes
33
. According to Jun et al., the value of process modelling is to 
assist the understanding of a process in order to identify areas of improvement and 
also to help document existing or planned processes to ensure a shared 
understanding
33
. Research into functions of scientific theory and conceptual theory 
by Bunge
34
 and covered in research by Jarvelin and Wilson
35
 suggests that 
conceptual frameworks integrate separate parts of knowledge, guide research 
(existing or new) and map an area of reality.  
 
“The speed of progress in science has always been strongly dependent on how 
efficiently scientists can communicate their results to peers and lay persons willing 
to implement these results in new technology and practices. ”35 Several models have 
been developed for the scientific communication process, notably Hurd
36
 who 
accounted for the effects of the Internet on communication, e.g. listservs, self-
publishing on the web and repositories, Sondergaard et al.
37
 also including the 
effects of the Internet, Tenopir and King
38
 who looked at the scientific publication 
process, Bjork‟s39 models looking at the scientific communication process as an 
information system and of course Wilkes‟40 model of dissemination reviewed 
specifically in this thesis. Bjork stated that there is a clear need for models that 
structure overall scientific communication that can be used as a basis for comparing 
with other studies and building on integrating results from other studies
39
. 
 
All methods of models have their advantages and disadvantages and Jun et al. 
examined the eight most common methods of process modelling used in health care 
and through an evaluation survey reported perceptions for their usefulness and 
utility
33
. According to their findings, the most easily understood diagrams were 
flowcharts, process content diagrams and the stakeholder diagrams. Flowcharts are 
the diagrams that most people are familiar with. However, it has been said that not 
one single diagram can effectively capture every aspect of a complex process
33
. 
Equally not one model can directly argue to be valid, being representative of a 
process and providing exact findings
35
. A model is a simplification of one view of 
reality
41
. It is suggested that multiple diagram types, or multiple diagrams with 
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different diagrams for different sub-activities as part of one large context diagram, 
should be use to deal with complex processes and inter-linked tasks, people and 
information
33;39
.   
 
For this thesis, three models in particular are introduced.  First, the Wilkes‟ model of 
dissemination (p. 40), which I adapted to represent the dissemination process of 
clinical trials. Second, the model of trust adapted from online banking (p.171) to 
outline how trust or distrust forms during the dissemination of information. Trust is a 
key concept which is discussed in this thesis in relation to clinical trial information 
and sources of information because I am trying to establish what are the reasons why 
there is a crisis of trust in clinical research. Third, I produced a conceptual model of 
information that is generated and disseminated in the clinical research process 
(p.93and Appendix A). This third model aims to describe simplistically what 
information is generated through clinical trials and what happens to it and is a 
backbone to the discussion of this thesis. I am not drawing on models on information 
behaviour, which attempt to describe information-seeking activities and  
relationships between activities in seeking information, as we have identified in the 
scoping section to this thesis that I am not in detail researching information literacy 
skills or access to information (p.21). 
2.6. Dissemination, publication and scholarly communication 
Terminology 
Scholarly communication (e.g. forms of communication employed for research) is 
used by scholars for many reasons. Scholarly communication refers to an iterative 
process where scholarship is communicated, used and developed within a 
community
42
 and how scholars used and disseminate information through formal and 
informal channels
43
. It is part of the research culture including linked linked to career 
advancement, collaborations on projects, publishing and engagement with the public.  
 
The terms dissemination, reporting, disclosure and publication are increasingly used 
interchangeably. Dissemination is a description of activities during the scholarly 
communication process of which publishing or sharing data and research are parts in 
the dissemination cycle.  Publication is defined as a formally recognised work, 
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contributing to knowledge and which is a responsibility of a scientist
44
. The process 
of a publication begins when an author publicly presents work, via a conference, 
posting on a web page or another type of announcement. Part of the process of 
publishing is the ability of peers to critique it. The terms reporting and disclosure 
also appear in relation to clinical trials. Reporting is the formal method whereby 
results or particular data are reported to the authorities, or the final results are 
provided to the authorities at the end of a clinical trial. Disclosure refers to what 
extent the data, or information about a clinical trial, are made publicly available.  
 
This thesis examines the communication cycle as a whole but with specific 
concentration on the dissemination process of the output from clinical research, the 
information produced within a clinical trial, about the clinical trial and its 
methodology and the data generated, the research results. The thesis also refers to 
disclosure, in particular during the examination of factors that affect dissemination. 
Dissemination is one part of knowledge transfer and understanding the science of 
dissemination can improve the design and process of clinical trials
45
, in particular to 
make dissemination effective and faster.  
 
It is increasingly difficult to distinguish between formally and informally published 
or disseminated material in particular with the growth of use of the web for 
dissemination activities. The scholarly communication process can be divided into 
three stages
46
: communication within informal networks usually through electronic 
media
47
, conference and preprint dissemination and lastly formal publication in a 
scholarly journal (figure 1). 
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Figure 1: Scholarly communication process of three stages 
 
Both publication and dissemination suggest that information is presented to an 
audience using a mode and process to do so. Dissemination means an interactive 
exchange between researchers and defined target groups
48
. There are two parties 
involved, the information provider and the information recipient. It is more than 
distribution (pushing out information) and for dissemination to be effective 
information is implemented in practice
49
.  Several models have been developed 
looking at the scholarly communication process (see section on models 1.17) and 
specifically Bjork
39
 has developed thirty-nine diagrams of the scientific 
communication process, including dissemination activities. Not one model can fully 
represent all processes. Wilkes‟40 linear description of dissemination (figure 2) was 
chosen for this thesis as it represents communication and dissemination in as a 
simple flowchart, which represents the basic components of dissemination. It can 
easily be adapted for how dissemination has changed and how it will change in the 
future. His original model of 1997  is slightly outdated and does not take into 
account the Internet „revolution‟, however this thesis will make a recommendation of 
how the model could be updated in Chapter 6. 
 
 
Informal network communication 
Scholarly conferences & 
preprints 
Formal publication  
in journal 
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Figure 2: Wilkes model of dissemination (1997) 
 
Introduction into dissemination issues 
 
“Critical to seeking clinical information is the credibility of the source, followed by 
relevance, unlimited access, speed and ease of use.”50  Liberti, Erdelac and Papaj 
continue to say that barriers to finding needed information is too much information, 
lack of specific information and navigation or searching difficulties
50
. Clinical trial 
information is scattered across a number of resources and there are factors that affect 
dissemination which have been investigated by others, some introduced in this 
section. In order to understand what is happening with dissemination of clinical 
research we must look at what is happening in publishing, how researchers 
communicate their research and theories behind dissemination. 
 
A study reviewed the aim of publishing and the evolution of publishing
51
. It 
concluded that publishers are blocking the advancement of science as there is a high 
cost to access research, but they argue that scholarly journals still have a role to play 
in scholarly communication. The research questions what constitutes publication in 
the electronic environment, a question also posed by others
44;51
 and which will be 
addressed in this thesis and which it will aim to respond to.  Without a definition; the 
quality, integrity and authentication of electronic scientific information will be 
difficult to determine
44
.  Further research supported by Joint Information Systems 
Committee (JISC) has made an attempt at clarifying the term scholarly publication 
providing a suggested list of criteria which can be used as a check list against 
emerging formats to establish if they are scholarly publications
52
. I will revisit what 
it means to publish several times in this thesis and a review of the definition will be 
given in the recommendations in chapter 6. 
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A recent report by RIN found that UK researchers across many disciplines publish 
very little but they communicate their research in many different ways with different 
factors affecting their decision in how to communicate
53
. The report claims that 
research funders‟ requirements and institutional guidelines are not that influential 
when making a decision on dissemination and that the scholarly journals are 
increasing their dominance over other methods of dissemination as publishing in a 
journal is an effective form of communication and secures recognition from peers. 
The report also recognised that researchers also use working papers, reports and 
presentations at conferences to disseminate research but these methods have lesser 
status.  Scholars publish research as part of the need to communicate their research 
and there are many reasons for communicating research, e.g. for career advancement 
where publication of either a few or cumulative papers define academic careers
54
, 
and an ethical obligation to publish clinical research results
55
, etc. This thesis will 
examine how clinical researcher professionals disseminate clinical trial information 
and examine how effective are the methods used. 
 
A meta-ethnographic study was conducted into effective information dissemination 
in a crisis
56
 looking at dissemination theory. The research proposed a model of social 
marketing, including training and education, with accompanying multi-method 
dissemination strategies.  The meta-ethnographic method was not successful in 
establishing effective dissemination methods however it identified some key factors 
that relate to effective dissemination, which this PhD will draw upon and expand on. 
As the meta-ethnographic method was not successful in the identification of methods 
and their effectiveness, it was discarded a as a method for this PhD but could 
perhaps be used in future research to build on this research (see Conclusion, section 
1.60). 
 
“The scientific literature is a record of the search for truth”57.   There is an 
expectation that research is a public good that should be made available online
58
. Ng 
wrote of the utopian ideal of scientific research published with online availability of 
full-text, access to every researcher anywhere, interlinking of all papers and 
citations, full searchable, retrievable papers, access to all research data and free 
access for all forever
51
. Online repositories or databases meet some parts of such 
demands. According to Lawrence
59
 there is statistical evidence that electronic 
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publishing has enabled wider dissemination of information, there is a clear 
correlation between the number of times an article is cited and the probability that 
the article is online. Access to organised information online means that researchers 
can identify and use information that is relevant which improves communication and 
scientific progress. Every day, 400,000 users access 700,000 articles in PubMed 
Central 
60
. Zerhouni said that the digital revolution in life sciences had led to greater 
data and knowledge production through information sharing services.  
    
The digital environment is changing the scholarly communication process, blurring 
the informal and formal modes of communication, through tools such as blogs, 
WIKIs, discussion forums, websites and allows for sharing of information and 
commenting by peers. There is evidence that there is a definite move away from 
publishing in monographs and books, which declined over the last five years, into 
publishing in journals or disseminating online
61
. Graham includes electronic media 
and informal network communication in the new scholarly communication cycle
46
. 
The electronic environment satisfies the rapid need to publish research but also 
because electronic dissemination of data allows scholars to re-use, manipulate and 
verify research
18
.  One critical research objective became to establish to what extent 
clinical trial information could be found in the online environment and if informal 
communication methods were used for disseminating clinical trial information. 
What do we mean by effective dissemination? 
To effectively disseminate information means to distribute into implementation, e.g. 
the uptake of new research findings
49
. Effective dissemination is also an interactive 
exchange between researchers and the audience that the information is intending to 
influence
48
 . There are several challenges in effectively disseminating findings from 
health research, e.g. the time required to keep up-to-date with new research and 
organisational barriers in changing existing practice
62
. The uptake of new research 
findings has been described as haphazard and unpredictable
63
.  There is therefore a 
requirement to understand the knowledge acquisition process and behaviour of an 
individual who has needs for new knowledge. Part of knowledge acquisition is the 
individual‟s information literacy skills and their awareness of knowledge sources. 
Miller and Mangan identified two styles of information seekers; the monitors who 
actively seek out information and want high information input and blunters who 
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prefer less information
64;65
. In psychology, the theory of planned behaviour (TPB) 
explains attitude and behaviour in individuals and has been used in advertising, 
marketing and healthcare
66
. TPB is useful when planning dissemination, 
implementation and evaluation strategies
67
 where there is a need to understand 
uptake of new information.  
 
According to Duggan and Banwell
56
, when planning a communication three things 
must be considered: 
1. Targeted dissemination, e.g. target a specific audience with a perceived 
need for knowledge. 
2. The role of opinion leaders in dissemination 
3. The willingness to change as a result of new knowledge. 
 
This thesis will look at effective dissemination and related theories by examining 
publication guidelines and organisational policies on disclosure and communication 
of clinical trial information. By doing this I can establish how to make dissemination 
more effective and at what stage communication strategies and the dissemination of 
information is planned. 
2.7. Methods of dissemination 
It is presumed at the outset of this PhD that there is a public need to access 
information about clinical trials as there have been requests and calls for clinical 
research to be made more transparent. It must be said that it is always going to be 
unlikely that all information generated in a clinical trial will be made publicly 
available. The data sets of clinical trials are complex and data analysis concentrate 
on answering the research questions in the approved clinical trial protocol, other 
information is recorded but kept „on file‟ or discarded when irrelevant. A choice is 
made on what information is selected for reporting and dissemination and what 
methods are used for this purpose. The selection of information occurs to ensure the 
right type of information is available to the right type of audience at the right time
68
.  
Dissemination is therefore „effective‟ when it aims to influence an audience. Duggan 
and Banwell identified a combination of factors that affect effective dissemination
56
, 
and suggested that these factors are considered when preparing a communication. 
This research identified further factors to add to Duggan and Banwell‟s factors, a 
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major one being the timing of delivery of information and the method chosen for 
delivery discussed later. These new factors are relevant in particular when looking at 
new online types of methods used for dissemination of information investigated 
more in this thesis. This research will examine existing methods that are used for 
disseminating clinical trial information and establish if they are fit for that purpose.  
The journal as a method for dissemination 
The journal has existed for hundreds of years as a tool to disseminate research 
findings and opinions and is a key component of the scholarly communication 
process. Each year more than two million research articles are published in 
journals
69
. Journals are a key source of research information
70
 and papers are used as 
sources in promotions, advertising, reports and other outputs. For this thesis we 
define journals as the peer-reviewed regular publications that disseminate research 
findings. The methods used for disseminating clinical trials information are many 
and the journal is a trusted method to provide peer-reviewed evidence-based 
information.  The European Commission has made a claim that the traditional model 
of journal publishing is failing scientists because scientific research is offered with 
limited access at high cost
71
, subscriptions are increasing and the number of journals 
are increasing.  Are therefore our current methods of dissemination effective? 
 
Information is disorganised and cannot be found when health professionals need it
72
. 
Other negative comments state that the journal is restrictive, lack methodological 
rigour and is limited in discussion
73;74
. It has also been accused of being a 
pharmaceutical marketing tool
75;76
. However, others have said that publishing 
research in a journal is the only way to get research checked by peers, through the 
peer-review process, editorial process and that publication guidelines helping 
organise information
77;78
.  
 
A disputed way in which we identify top medical journals today is based on citation 
metrics and impact factors, where a high impact factor suggests a journal is a „top‟ or 
key journal
79-82
. Much research has looked at the role of the impact factor and there 
has also been research around the identification of core journals in different therapy 
areas
14;79;80
.  Part of this research is about identifying the type of journal that 
publishes clinical trials or perhaps the choice of journal to publish in made by the 
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researcher.  It will identify the core journals, and their impact factors, used for 
disseminating clinical trial results in diabetes and obesity, to establish if high impact 
factor journals publish the majority of diabetes and obesity clinical trials. A method 
to establish a core set of journals is bibliometrics, which applies statistical methods 
to communication forms
83
. Some bibliometrics studies have taken place looking at 
either a specific disease area or a specific health journal: RCTs in pato-biliary 
disease
84
, literature of AIDS
85
, RCTs in organisational interventions in healthcare
86
, 
RCTs in surgery
87
, core literature on AIDS in women
88
, cases in general practice in 
general medical journals
89
, citation pattern in the American Journal of 
Epidemiology
90
, RCTs in Intensive Care Medicine
91
. One study specifically 
examined randomized controlled trials (RCTs) in all areas of health sciences
14
. 
Research has shown that although many clinical journals publish high-quality 
original studies and reviews, articles were concentrated in a small subset of journals 
which varies according to health discipline
92
, this is confirmed in a study looking at 
where the core RCT literature is published, concluding that the core is concentrated 
in a small number of journals with diversified subject coverage
14
. The same study 
also shows that many of the important articles were published in broad-based 
healthcare journals rather than discipline or topic specific journals. A study 
conducted in 1999 which found that the best quality evidence on paediatric clinical 
practice is found in a large number of medical journals, but that seven journals were 
cited most frequently
79
. Another study showed that the dissemination strategies of 
pharmaceutical-sponsored and non-profit sponsored oncology studies did not differ, 
both published in low impact factors peer reviewed journals
93
. Falagas and Alexiou 
identified that 60% of the top 25 journals, as ranked by the ISI impact factor (IF), 
only publish reviews and summaries of past research whereas the journals with much 
lower IF publish the best original research, but are not cited frequently
81
.  
 
Clinical trial registers as a method of dissemination and online access to 
information 
The term „clinical trial disclosure‟ refers to publicly available electronic databases 
that present information on new clinical trials at inception, e.g. clinical trial 
registries and results of completed clinical trials; usually referred to as results 
databases although hybrids exist of both and there is no agreement on correct 
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terminology so in this thesis I have adopted Foote‟s94 and WHO‟s terminology and 
refer to them both as clinical trial registries and abbreviated to register or registry for 
ease. These registries are publicly available repositories of information and data. 
Clinical trial registries can be public or private and managed by not-for-profit or 
commercial organisations. They differ from databases that are maintained by 
competent authorities (regulatory bodies), such as EudraCT in the EU, where 
clinical trial applications (CTAs) are submitted electronically and information 
shared amongst authorities and research ethics committees. 
 
The inception of clinical trial registries was as a result of a combination of things. In 
1974 Mary Lasker asked the National Cancer Institute to publish a book listing all 
ongoing cancer treatment protocols in the US, updated every six months. This would 
allow physicians to identify open trials in which their patients could enrol
95
.  Tom 
Chalmers extended this idea to include registers of clinical trials with an aim to 
reduce bias in the reporting of trials
96. “Both recognised an enormous gap in the 
dissemination of good information and both hoped to speed the delivery of the best 
new treatments to the patient.”97.  In 1997, a computer-based approach called the 
trial-bank system was suggested because scientific evidence was not transferred 
effectively or efficiently from the bedside
98
.  Such a bank would not only aid 
presentation of clinical trial information, it would also help with recruitment into 
trials allowing the public to search these banks. Another reason for establishing 
registers was to improve transparency of clinical research so that information would 
be available on the type of trial and investigational medicinal products 
(interventions) used in the trial. This is very useful as not all trials are formally 
published in journals and it allows the user to find information about both trials that 
have been published and those that remain unpublished
99
.  
 
“However, no comprehensive system currently exists for tracking, organising, and 
disseminating information on clinical trials.”100 The current largest clinical trial 
registry is Clinicaltrials.gov set up by the National Library of Medicine (NLM). The 
set up of this first independent register was a result of the FDA Modernization Act
101
 
passed in November 1997. Between May and October 2005 the NLM reported that 
the number of registrations in ClinicalTrials.gov increased by 73% from 13,153 to 
22,174
102
. On the 9
th
 of February 2009, the register contained 68,223 clinical trials 
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from around the world
v
 an increase from May 2005 by nearly 420%. On 12 February 
2011 the register had 102,817 registered clinical trials from 174 countries. The site 
has around 50 million page views per month, with 65,000 visitors per day
vi
.  
 
There is not one comprehensive system for tracking, organising and disseminating 
information about ongoing clinical trials
103
. Clinical trial registries have been in 
existence in some format or other since the 1960s
97
 and there are “hundreds of such 
registers worldwide” today100 some set up for specific diseases, or for a specific 
country and with different aims
103;104
. In 2006, an attempt at collating a list of 
clinical trial registers was made for the book Clinical Trial Registries: a Practical 
Guide for Sponsors and Researchers of Medicinal Products.  The editor, Mary Ann 
Foote 
94
 said; “...the problems faced by a patient in terms of deciding what web sites 
to search about information for a clinical trial for a particular disease.” Thirty-nine 
registers were listed in the publication and divided into international and government 
sites, oncology group sites and sponsor sites.  
 
Liberti et. al
50
 argue that in the current time we should be able to create a clinical 
trial register model that provides a comprehensive up to date listing of results from 
all concluded clinical trials globally. It would provide a comparative view of all 
available data in an easy to understand table that could be printed, saved or used. 
This information would provide 24/7 access to clinically relevant patient treatment 
information with all the data as evidence. Unfortunately as Liberti et al state, no 
single register fulfils this vision as a single source repository of data using uniform 
standards or good enough search engine
50
. The WHO admits that it is impossible to 
consider one single register suitable to all diseases and aims, instead they have set up 
the International Clinical Trial Register Platform (ICTRP) (see figure 3) in 2007 to 
“ensure that a complete view of research is accessible to all those involved in health 
care decision making, this will improve research transparency and will ultimately 
strengthen the validity and value of the scientific evidence base”105. The ICTRP is a 
meta-register allowing the user to search across primary registers. The primary 
                                                 
 
v http://clinicaltrials.gov/ [Accessed 9 Feb 2009] 
vihttp://clinicaltrials.gov/  [Accessed 13 February 2011] 
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registers would „deduplicate‟ and translate information into English from associate 
registers. 
 
 
Figure 3: The ICTRP structure proposed by the WHO104 
 
Although results databases can provide the public with useful clinical trial 
information, current prescription drugs used by the public will not be listed in the 
clinical trial database
106
, because the huge effort involved in uploading old drug 
information would be difficult to implement. Any drug approved before 27 
September 2007 that was no longer involved in trials after this date are not required 
to be registered
107
.   
 
A more serious area is that there are legal requirements in the FDA region that state 
that for confidentiality reasons certain information cannot be released on drugs that 
are undergoing development, even if there is serious concern for the safety of 
individuals who may be taking that drug already available on the market
106
. This 
contradicts ethical standards which makes it unacceptable both ethically and 
scientifically to withhold information about the safety of efficacy of marketed drugs 
from the public
106
. 
 
Another highlighted concern with results databases is that they do not contain 
information on unapproved products. Trials may not have been approved by the 
authorities if a drug application was withdrawn for safety or economic reasons, or 
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clinical development may have stopped for some other reason. At the moment, this 
information is not released publicly in any format. Wood suggests that after a 2-year 
period, all such data should be posted as two year inactivity must be a long enough 
period for protecting confidentiality
108
. 
 
Both Wood and Decullier et al also identified that there is a lack of dissemination of 
Phase I results
106;108
. Clinical trial registries facilitate sharing of trial information but 
previously Phase I trials were not required to be registered and results not shared. 
Potentially the lack of sharing of such information can cause unnecessary serious 
adverse reactions in patients where drugs of similar type are used in other trials. It 
would also be useful if such information was shared from a commercial point of 
view, as studies may have been discontinued for economic reasons which could then 
be re-used in new studies by other companies to the benefit of scientific 
development
108
. In fact, it has been highlighted that clinical trial registration does not 
ensure submission of trial results
109
. 
 
Several studies have analysed websites containing information about cancer clinical 
trials
110-114
.  In 2002, Manheimer
103
 examined the completeness and accessibility of 
ongoing drug trials for prostate or colon cancer in the UK. He concluded that 
existing clinical trial registries were not meeting existing user needs as many 
ongoing drug trials were not listed. A examination by Monaco and Krills
112
 of cancer 
centres websites concluded that websites that provided information about cancer 
clinical trials were providing limited content and the reading level of the information 
was at college level. They also concluded that searching several online registers to 
identify trials was cumbersome and time consuming due to search capacities of the 
websites, lack of standardisation and clarity of the language used to describe the 
trials. Frequently drug names, phase of testing and condition treated were missing.  
 
Another study in 2007 evaluated online resources for cancer clinical trials
113
 and it 
found that the resources varied greatly regarding information provided and called for 
an improvement to content, design and presentation of clinical trials. A further 
content analysis into cancer clinical trial search tools in 2008 also found that 
functionality and content varied greatly
114
.  In 2011, the Cochrane Collaboration 
compared protocol or entry in a clinical trial registry with the content of its published 
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report, which revealed that there are often discrepancies between information in the 
protocol and trial registry entries and what is covered in the published reports
115
. 
 
This thesis will assess the usefulness and effectiveness of clinical trial registries in 
providing clinical trial information and there is a comparison made of functionality 
within different clinical trial registries.  Diabetes and obesity clinical trials were used 
for this research as these therapeutic areas have not been investigated previously and 
it is assumed that in the future this type of research will increase. The risk of diabetes 
due to obesity is rising and there will be increased information needs for research 
into these areas from the public, health professionals and governments. 
 
The Internet as a method of dissemination 
There is no doubt that the invention of the Internet has changed the way in which 
information is disseminated. The Internet is expanding with a number of diverse 
resources related to clinical trials that can be accessed by anyone. New and improved 
technology allows information to be published and disseminated quickly. Alternative 
methods of dissemination to the traditional methods, e.g. journals, are growing, e.g. 
blogs, web 2.0 social media sites, personal websites etc.  
 
A lot of information on the web is disorganised making it time-consuming and costly 
to search for information and it has been said that health professionals cannot find it 
when they need it
72
.  The quality of information provided on the Internet is disputed 
in research, it allows for erroneous ideas to be disseminated widely which may have 
harmful effects
116
 although a recent piece of  research indicates that the completeness 
and accuracy of online medical information has improved
117
. Other research states it 
is a recommendation that patients are referred to websites that are reliable and 
provide accurate information by a health professional
118;119
. Nevertheless, the 
Internet is useful in tracking down unpublished and ongoing clinical trials, even if 
the information is not peer-reviewed
120
 and this research shows what type of 
information was disseminated and on what type of websites by conducting simple 
searches using publicly available tools online.  
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Research has been done into the way in which the public access information about 
clinical trials. It has been said that the primary source of information about clinical 
trials is the patient‟s physician121;122.  One study concluded that individuals rather 
turn to the Internet for information than to a health professional
123
. Another study 
showed that patients prefer conversing with a health professional via a portal or 
email and this type of communication enhances the physician-patient relationship
124
. 
Research has also shown that physicians feel uncomfortable speaking to patients 
about clinical trials
121;125
. It is important to note however that each individual has its 
own unique information needs, which complicates how well physicians are able to 
communicate information about clinical trials to them
121
.  
 
The Internet has revolutionised the way patients access health care 
information
113;114;126
, learn more about health and make decisions about their 
condition. We need a better understanding of patients' information needs regarding 
clinical trials, and their information research behaviour, so that we can better present 
the information to them
112
.  More research is being done looking at the attitudes and 
trends of the public and their access to information. The Pew Internet Project studies 
the social impact of the Internet and they surveyed „health seekers‟ in 2000 and 2002 
which revealed that half the respondents would turn to the Internet for health 
information
127
.  
 
In a study into patients' usage of a University of Washington Orthopaedics and 
Sports Medicine Website, the reasons were to find information about a condition, a 
treatment or symptoms
128
. “Eight in ten Internet users have looked for health 
information online, with increased interest in diet, fitness, drugs, health insurance, 
experimental treatments, and particular doctors and hospitals.”129 One study 
estimated that 12.34 million health-related searches are conducted worldwide every 
day on the web
130
. In 2004, 23% of Internet users have searched for experimental 
treatments or medicines compared to 18% in 2002
129
.   
 
Physicians use the Internet to find medical information too. According to one study 
physicians access targeted sites rather than search engines
131
, e.g. research databases, 
medical journals and portals.  A review
132
 of the information-seeking behaviour of 
physicians spanning over ten years 1996-2006 shows that physicians still use 
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colleagues and print evidence in information-seeking, although this research did not 
specifically ask physicians regarding finding out about clinical trials.  
The role of media in dissemination 
The media remains important in disseminating information about science. Physicians 
and the public often find out about new medical research through the media
133-137
. 
Prior to 1960 the press didn‟t report widely on medicine138. However, over the last 
thirty years the public interest in medicine has changed
40
. The New York Times 
increased its coverage of medical articles by 250% between 1968 and 1978 and 
425% between 1969 and 1988
40
. Journal editors began to see that media coverage is 
valuable to attract attention and increase subscriptions, building brand recognition
139
.  
 
These days the market is flooded with press releases, sometimes deliberately vague 
or even misleading
40
. It is recognised that the journal press releases are also prone to 
exaggeration
133
. A study showed that only 23% (29/127) of the press releases 
included study limitation and 65% (83/127) included results
133
. It has been 
recommended that press releases should put research results into context, provide 
study limitations, reveal author‟s competing interests and provide absolute results133. 
Seven out of nine medical journals routinely issue press releases
133
.  
 
It has been argued that not many sources provide true access
106
, the existence of 
reports available to the public and a database which allows the public to 
conveniently and accurately access those reports. According to Wood
106
 there are 
three types of resources in the US that meet the criteria of providing true access to 
clinical trial results, e.g. links to reports and published papers:  
 
1. PubMed or other bibliographic databases with indexes of publications 
2. FDA analyses and documents on the FDA website (in Europe we would 
rely on our research ethics committees or EMA posting such documents)  
3. Existing industry databases such as the GSK results website140 or the 
PhRMA results database
141
.  
 
Wood also recognises that the clinical trial register clinicaltrials.gov will become an 
additional source of true access information, however, it does not yet contain 
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complete sets of clinical trial results. The public would be better served if they were 
provided with comprehensive reports and reviews for all interventions after approval 
including for additional applications, e.g. new indications etc
106
. On 30 November 
2010, the EMA in the EU announced that they will release all business 
documentation related to clinical trials electronically for public access, e.g. clinical 
trial reports, once a procedure concerning an intervention has been finalised
142
. 
 
We know that clinical trial information is disseminated in many ways and this thesis 
will examine some of the different dissemination methods; abstracts, the journal, the 
Internet, media and clinical trial registers, to try to understand why these methods are 
chosen for dissemination and what affects choice of method.  
Abstracts as a method of dissemination 
There are many kinds of abstracts, e.g. the most obvious ones being a summary of a 
report published on a website, the abstract found in journals describing the content of 
a paper, conference abstracts for a presentation or a poster and abstracts in press 
releases, but there are more types of abstracts than these mentioned here. An abstract 
is meant to summarise the key findings and the „take away‟ message and is usually 
used as a teaser to attract a specific audience or to provide the key information 
quickly for those who do not have time to read the full script, if there is one. In fact 
we know that readers sometimes assess a clinical trial on the abstract alone
143
. 
Abstracts given at meetings are a useful way to disseminate new information 
quickly
144
. 
 
An identified problem with abstracts is that they have been found to underreport 
findings that are covered in main paper
145;146
, 37% of errors found in abstracts of 
psychology journals could be seriously misleading
147
 and some abstracts contain 
data that are inconsistent with the rest of the paper or even missing altogether in the 
main text
148
. It has also been found that of abstracts presented at meetings many fail 
to publish two to five years after presentation
149-153
 and identified reasons for non-
publication have been investigated, e.g. trial still active, lack of time to write, 
disputes with other authors
151;154
.  One study looking at gastrointestinal abstracts 
given at conferences found that papers accepted at that conference were more likely 
to be published later on than abstracts that were not accepted for presentation (54% 
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vs 34%) and the same study found that abstracts reporting statistically significant 
results were likely to be published in journals with higher impact factor
154
. 
 
One study concluded that conference abstracts are time-consuming to find and that 
the content are of questionable value. However they may provide some value in 
health technology assessments if during a systematic review other sources containing 
relevant information are limited
155
. Data presented at conferences should be treated 
with caution
144
.   
 
Abstracts are provided on the web in clinical trial registries, on websites and on 
conference websites as well as other types of websites. Posting abstracts in clinical 
trial registries is still reasonably new and although it is advisable to post an abstract 
within 24 months of a trial end (as well as law in the US), some publishers consider 
some abstracts as publication
156
 making the posting of an abstract difficult for 
researchers who wish to publish in a journal.  
 
It has been suggested that the CONSORT checklist for writing abstracts could 
improve the content of abstracts in journals
143
 and that peer reviewers and editors of 
journals should ensure that abstracts represent the full-text article accurately
157
. 
 
For this thesis, I examined the quality of content in journal abstracts and the value of 
different kinds of abstracts in the dissemination of clinical trial information. These 
findings were fed into the final recommendations provided in chapter 6. 
The relevance of concepts such as trust and quality  
When disseminating research findings it must done in such a manner that recipients 
believe that the information they are receiving is trustworthy, only then can 
information influence and change practice. 
 
Various definitions of trust exist.  Rotter
158
 defined trust: “a generalised expectancy 
held by an individual that the word, promise, oral or written statement of another 
individual or group can be relied on.” The dictionary159 defines trust as: “Firm 
reliance on the integrity, ability, or character of a person or thing”. 
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Misztal 
160
 explained that concepts of trust can be grouped into three:  
1) individual attributes, such as feelings, emotions and values  
2) social attributes, such as common goals (within an organisation for example) 
3) public value, such as institutional trust. 
 
Day
161
 identified the behaviours that either damage or build trust (Table x). 
 
Trust is linked to quality. In science we ensure quality by using a variety of methods, 
e.g. peer review or alternatives, review boards who can assess quality, impact factors 
that show journal quality. By ensuring quality, we ensure trust. 
 
Quality is “Easy to recognise... difficult to define.” 162  Quality exists when we talk 
about products or services; it means that either a product or a service exceed our 
expectations.  It‟s difficult to define quality but we often see its absence; either a 
product breaks or we have a poor service in a delivery for example.  If quality isn‟t 
taken seriously, a „good enough‟ approach is usually adopted 163.  The quality 
concept became popularised in the 1970s, when Japan provided products that 
customers wanted; well designed, reliable, available and reasonably priced
 163
.   
 
The British Standard 4778
164
 defines quality: “The totality of features and 
characteristics of a product or service that bear on its ability to satisfy stated or 
implied needs.”  In other words, what one person wants in a product or service will 
differ to what another person wants depending on his/her definition of fitness for 
purpose. Quality is the concept of an object having a purpose for which it‟s fit and is 
linked to what the customer wants or needs 
163
, e.g. the definition I will use in this 
PhD is that “quality is fitness for purpose”163. The studies in this thesis will look at 
how „fit for purpose‟ existing methods of dissemination are for disseminating 
clinical trial information (chapter 5) and recommendations for the optimal 
dissemination model will be presented (chapter 6). 
Behaviours of trust: damaging or building 
There are behaviours by individuals or organisations that either damage or build 
trust. These trust-damaging and trust-building behaviours have been taken from Day 
and Rennie
161
. 
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Table 1: Trust behaviours 
Trust-damaging behaviours  
Unwarranted interference 
Excessive criticism (especially in the public arena 
without right of reply) 
Coercive or threatening behaviour 
Dishonesty or disingenuity 
Wilfulness or recklessness 
Trust-building behaviours  
Mutual recognition of accountability 
Shared vision 
Explicit strategic objectives 
Tactics left unstated 
Free and frequent flow of information 
 
To have confidence is slightly different from trust.  Confidence builds over time and 
comes from trust.  Renn and Levine stated “Confidence denotes the subjective 
expectation of receiving trustworthy information from a person or an institution.”165  
If what is received is not trustworthy, confidence will be replaced by uncertainty and 
create a climate of distrust.  The concept of trust has been researched in particular in 
relation to the commercial sector, such as the trust placed in banking. A model called  
“five levels of trust”166 was developed for Internet banking showing how confidence 
and trust is formed.  I have adapted this model to include what factors, behaviours 
(Table 1), affect trust in the environment in which clinical research takes place and 
the public opinion of research (chapter 5 p.171). 
Quality indicators in dissemination 
There are different kinds of indicators of quality that are relevant in this thesis when 
thinking of dissemination of clinical trial information. 
 
Examples of good clinical trial quality indicators are good trial design and conduct 
of trials according to Good Clinical Practice (GCP)
167
 and Good Manufacturing 
Practice (GMP)
168
 standards. Unfortunately there are few checks available to check 
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quality of trial design, although the Ethics Committees will review trial design 
before approval of a trial. It is worth noting that Ethics Committees usually consist 
of  some volunteers from the public without specific expertise of trial design.  
Informed consent, e.g. making a decision based on enough information, is an 
important part of gaining trust from those taking part in a clinical trial and an 
important aspect of GCP. The goals of the research and the institution conducting the 
research need to be believed in, and the public need to feel that they can place their 
trust in them. Trust could easily be called into question if people felt that their 
confidence was not being kept and if they felt that medical information was being 
used for commercial gain
169
 and confidence  would improve if competing interests 
were disclosed
170
. Trials are increasingly audited and inspected by authorities to 
ensure trials are managed to good research standards. 
 
Dissemination methods, such as journal articles, are also using standards to assure 
quality. Quality indicators to assess quality in publications have been identified by 
Liberti
171
 and Kling and McKim
42
:  
 
 Results of clinical trials; quality of information provided 
 How well data supports key concepts 
 Methods of delivery: open access, pre-print 
 Format of output: website or journal 
 Persuasive writing; marketeer writing, investigator/researcher 
 Journal publication: impact factor or what type of journal and the reputation  
 Institutional support: who was it funded by? 
 Reputation of publisher, author or institution of author 
 Corner cutting: did the results get published too quickly with poor review  
 Is there advertising attached to the article or a sponsored supplement? 
 Structural and presentational aspect 
 Target journal/audience, therapeutic area 
 Peer review and publication guidelines of journal  
 Use of available checklists to aid authors in writing papers, such as 
CONSORT
143
 
 Long term access/preservation; will it be access after a number of years, 
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preserved indefinitely? 
 
To establish its usefulness for science, a publication needs to have been vetted to 
ensure quality
42;52
 and to establish a high level of trust among readers
44
. This process 
is equally essential for electronic documents and websites, perhaps more so in view 
of the vast quantity of available information and the difficulty in identifying and 
access them.  
 
A concern has been expressed over ghost-writing and guest-authorship of clinical 
trials in journal articles. Both are said to harmful to the public and institutions and 
the paper cannot be trusted or accurately judged 
172;173
. Ghost-writing has been 
relatively common, e.g. the results of a trial have been written up into a peer-
reviewed journal by someone who conducted some work towards the paper but not 
accredited authorship. In a study by Goezsche et al, there was evidence of ghost 
authorship in 91% of trials approved by ethics committees between 1994 and 
1995
173
.  An opposite argument is that  ghost-authorship is better than the paper not 
being published at all as physicians are becoming busier and medical writers have 
the skills to write and analyse data 
174
.  Guest-authorship is when individuals are 
invited to appear as authors on a paper, when they have had very little input into 
writing the paper, possibly a head of department or a key opinion leader.  It has been 
argued that guest and ghost authorship can make a drug look good
175
, either through 
an author‟s  influence as a subject expert or as a professional medical writer who 
knows what should be pushed in papers, e.g. marketing messages. Most journals 
now demand transparency of authorship asking for each contributor to be 
acknowledged
176
.  
The usefulness of peer review 
The usefulness of peer-review is a debated area within publishing. Peer-review has 
long been used as a way to assess quality and accuracy of a paper, and for journals
77
, 
although even fraudulent papers have made it through the peer review system
177;178
 
and there is no evidence that peer-review is improving quality
77;179
.  BioMed Central, 
the science, technology and medicine publisher, operates an open peer review model. 
This together with their open access to research model, attempts to link together 
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research, pre-publication information with peer review
180
. The  organisation Sense 
About Science state that peer-review is essential to assess scientific quality 
181
.  
 To improve transparency of peer review, attempts at open peer review, e.g. via 
electronic means on websites were tried but  failed
182
. Peer review has also been 
argued to be crude
178
. Peer review, although not perfect, is stated as our best option 
for the moment of ensuring quality of papers
183
 although this is disagreed by 
others
69
.  An issue with peer-review is that it‟s incredibly slow and there has been 
recent debate over reviewers remaining anonymous, when in fact conflict of interest 
may affect the peer review process
184
. 
Quality standards of websites and online content 
There have been proposals for sets of rules (ethic codes) and quality criteria for 
medical websites, as a way to assure certain quality for them, more prestige for the 
compliant sites, and more trusted sites visitors. Some examples of ethics codes are: 
the Health on the Net Foundation (HON) Code of Conduct
185
, presented in 1997, and 
standards on managing information from NISO
186
. The Information Standard
187
 is a 
new certification scheme in England for health and social care information providers 
and producers which when approved can use an approval logo on information 
resources that can be recognised by users of that information. A slight concern with 
the Information Standard is that it is run on a commercial basis (there is a payment 
involved in signing up to the standard) and it is also reliant on the government policy 
approval process. If the government changes, the standard is under review. It may 
therefore not be supported long term. The JAMA benchmarks
188
 have been used to 
assess technical quality on websites
189
. It has been suggested that designing a 
website with technical quality indicators can help users establish content quality, e.g. 
accuracy of the information provided
189
.   
Quality of clinical trial registers/registries/databases/results databases 
There is general concern over the varied quality and consistency of registers
190
 and 
lack of leadership, data and monitoring
191
.  The quality of clinical trial registers is 
suffering due to incompleteness of records, missing records, missing critical 
information and non-compliance by researchers uploading information. It has also 
been stated that the industry looks like they are complying with new regulations on 
registered trials but actually hinders the release of too much information
190
. 
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These concerns mean that registers do not aid public access to clinical trials and their 
results because true access depends on the existence of links to reports or published 
papers within those databases
106
 and reliable information within the databases 
themselves.  Limitations placed on the availability of information result in the 
limited efficiency of registers
192
 and therefore we must question if registers aid the 
public at all
94
. Although efforts have been made to release clinical trial data for the 
public good, we have not identified what the public wants out of clinical trial 
registers
193
. According to research, patients only access registers less than five 
minutes and look for very specific information
193
.  
 
The WHO has drawn up a quality standard of required datasets for registries 
containing information about clinical trials and suggest that Clinical trial registries 
should report twenty datasets, WHO Trial Registration Data Sets or TRDS
194
 and 
registries that do not meet those standards are not included as approved primary 
registers on the ICTRP meta portal for registers
105
. However, Clinical trial registries 
must apply to be included and are not checked against this standard unless an 
application has been made. 
 
As part of this PhD a study in comparing the recommended 20 data TRDS with a 
selection of registers and an analysis of content will reveal any quality concern with 
clinical trial registers. 
2.8. Factors that affect dissemination 
There are many factors that affect dissemination of clinical trial information; 
legislations and regulation, publication guidelines, selection and publication bias, 
effective dissemination, pressures in the research environment and transparency 
issues.    
Transparency issues in dissemination 
In order for research to be transparent there must be trust in the research that has 
taken place. Transparency is affected by issues such as funding, behaviour that either 
increase or decrease trust, career progression, publication or selection bias etc. A 
selection bias of what information is chosen for dissemination is necessary as it 
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would be impossible to disseminate all information in a clinical trial and it would not 
be of interest to everyone anyway. The authorities who approve drug applications do 
not have the resources to read or publish all information provided. The product 
dossier produced early on is provided to the authorities containing what is thought 
the relevant information needed for approval of an intervention. There have been 
media coverage of cases where crucial clinical trial information was withheld from 
authorities
195-197
, which has had detrimental effects on clinical research and the 
companies concerned. We must remember that researchers have to deal with many 
protocols and clinical trials across many different countries and reports in different 
languages, which is a challenge to control
198
.  
Disclosure policies 
Research ethics guidelines have provided statements about sharing or reporting 
clinical trials, although not covering this in detail and no specifically about 
disclosing information to the public or about publishing. Several developments in the 
1990s and into 2000s have provided guidelines on structure and content of clinical 
study reports, checklists for reporting randomised controlled trials (RCTs). In 1994 
the first International Committee Medical Journal Editors (ICMJE) Uniform 
Requirements for manuscripts submitted to biomedical journals was published. 
These together with organisational policy on publication of research address issues 
that unfortunately have occurred in research.  
Publication guidelines 
Issues within the complex relationship between the pharmaceutical industry and peer 
reviewed journals led to the actions and initiatives to encourage best practice and 
eliminate unacceptable behaviour
199
. Unacceptable behaviour includes not declaring 
conflict of interest, not naming authors (ghost authorship) or paying non-authors to 
be listed as authors to attract readers (guest authorship), falsifying data or publication 
bias (such as selective reporting of some results). Even though publishers use peer 
review as an additional check of content of manuscripts, there was a need to provide 
stricter guidelines to authors on their submissions. Journals themselves have author 
guidelines to aid authors when submitting a paper for publication. But there are also 
other guidelines available within medical and clinical research that lay out best 
practice for publishing results. 
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Regulations 
International declarations, conventions, directives, and various national laws and 
rules regulate research ethics and researchers‟ ethics. But laws and directives do not 
usually specifically provide guidelines on how and what to disclose and publish 
apart from data to the national authorities relevant to the new drug application. 
Pressures 
There are several kinds of pressures that affect clinical research and the 
dissemination output as a result. There is evidence of research pressure to publish 
research findings, to advance one‟s career, but there are also geo-political pressures 
and commercial pressures.  
 
Researchers are under enormous pressure to publish their research findings. It is time 
consuming to write and get a paper published. In a study of time to publication for 
clinical trials, trials with positive results took four to five years to publication and 
trials with null or negative results took six to eight years to publication
200
. Recent 
findings from other studies shows that some trials never reach publication
201;202
  and 
according to Dwan et al. the total amount of studies published was less than 50% on 
average between 1998 and 2008
27
. It has been suggested that researchers sometimes 
do not publish research with insignificant results or negative results as they are not 
of interest to anyone or they [researchers] lack the time to publish
203
 and the 
pharmaceutical industry has been accused of publishing only positive results
204
.  A 
study also showed that time to publication is delayed if the results of the trial are 
presented at a scientific meeting
205
. It is clear that researchers are pressurised from 
an ethical point of view to report findings to the public, but also pressurised from a 
funding point of view with stakeholders‟ stock value being affected by sales.  The 
researcher needs full permission from the owners of that data, or the funders, to 
provide all this information. In some cases this could also mean lengthy informed 
consent exercises with patients whose data may be made available, sometimes after a 
trial took place, if data sharing had not already been made clear during the consent 
procedure. Company disclosure or publication policies may also indicate where to 
publish and what journals are the preferred places of publication. 
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Unfortunately, scientific misconduct and fraudulent cases in biomedical research 
have come to light
206-208
. Scientists were until recently considered more honest than 
ordinary citizens and were an elite and that they could regulate themselves
209;210
. 
Journals, authorities and clinical research organisations now have guidelines to 
monitor for misconduct and fraud
211
. 
 
Unfortunately not all trials can include all types of patients from different minorities 
and nationalities. We often have little information about how the intervention will 
react in the individual patient who is unique, it is impossible to group all patients 
into one category. There are pressures to provide data of trial results in children 
212
 in 
incapacitated adults
213
, those patients who are suffering from disease and need 
available drugs and in patients from ethnic minorities. There is also pressure for 
information to be provided to all (for free) and various initiatives exist providing 
information to developing countries
214
.  This thesis will highlight some factors that 
affect dissemination of clinical trial information and understanding these factors help 
towards providing a recommendation for improving transparency.  
2.9. Can we improve the transparency of disseminating clinical trial 
information? 
The requirement for improved transparency in the publication of clinical trial results 
began in the 1980s when Simes published his concerns for reporting bias within 
publications
215
. Since then several other concerns have been made public; 
underreporting, guest and ghost authorship, falsified data etc. In 1990 Chalmers 
stated his concerns for underreporting of clinical trials and claimed that this was 
scientific fraud
216
.  It has been argued that clinical trials funded by profit making 
organisations, such as industry, publish only positive results
27;76;217
 or that trials with 
positive results are published sooner than negative results
200
. However, arguments 
have been made in other studies that the journal only wants to publish results that 
will immediately change practice
218
.  For the sake of transparency it has been said 
that all results should be published, whether positive or not
216;219
.  
  
 It has also been highlighted that the use of key opinion leaders as guest-authors and 
promoters (of a particular product) to improve acceptability of new research results 
or in short to make a drug look good
175
. These opinion leaders are respected at 
Korjonen: Clinical Trial Information  65 
 
conferences as speakers, act as drug or therapeutic area experts and often publish in 
their area of expertise. A publication strategy conference highlighted that the main 
concerns in the publication of clinical trials are off-label promotion, false efficacy 
claims and kickbacks, where physicians are paid to appear as authors of papers or as 
key opinion leaders
220
. 
 
According to a statement by the Royal Society, scientists should consider the interest 
of the public when deciding when and how to communicate research results
221
, not 
their own commercial interests. In order to improve transparency and to further the 
understanding of clinical trials, scientists should provide implications of research to 
the public and ensure timely and appropriate communication of the results. A report 
warns of drawing attention to clinical trial results too early, as an awareness over a 
product before it reaches the market could have negative commercial impact
222
. The 
report also suggests that there should be a core communications team that already at 
the pre-clinical stage make plans for customised messages for the timing and varying 
information that needs to go out depending on the audience. 
 
Society is facing a crisis of trust
223
. According to sociologists and journalists there 
are signs of mistrust even at familiar institutions or individuals and consumer no 
longer trust business or products and patients no longer trust their doctors or 
hospitals. O‟Neill states that we live in a culture of suspicion of accountability and 
transparency
223
. However it will not improve our trust if we constantly expect 
individuals to declare their accountability or ask for proof that everything is to be 
trusted
223
. Several sources confirm that the public distrusts the pharmaceutical 
industry
193;224-227
.  In clinical trials, informed consent of the research subject is an 
important part of gaining trust. In the clinical setting trust is tied to the interpersonal 
caring attributes of the provider and confidence in their competence
228
 and trust in 
someone depends on the circumstances
229
. Renn and Levine stated “Confidence 
denotes the subjective expectation of receiving trustworthy information from a 
person or an institution.”165  If what is received is not trustworthy, confidence will be 
replaced by uncertainty and create a climate of distrust.  In clinical research, the 
difference between a positive and negative climate has great impact in how the drug 
development process is managed, including communication of results.  
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The question of whether we can improve transparency and improve how clinical trial 
information is disseminated is one research question that this thesis will respond to. 
It has been argued that the clinical research community has failed to respond to the 
widespread distrust
225
 although there are clear signs that publishers, researchers, 
medical writers and the like are introducing efforts in improving reporting of clinical 
trials.  Reporting tools, guidelines
176
, Clinical trial registries
193;230
, data sharing, 
publication of all research findings and publication planning
220
 are components of 
improving research transparency.  
 
Chapter 6 pulls together recommendations based on the findings in this thesis on 
how clinical research can be made more transparent when it comes to dissemination 
information from clinical trials. 
2.10. Conclusion to Chapter 2 
This chapter described in detail the resource discovery process undertaken for this 
thesis. The literature review is organised around the research questions and 
summarises what is known about the topics and what was to be included in this 
thesis, specifically gaps that needed responding to. The review also provides 
information about controversies in the topics and definitions to terminology used in 
literature and in this thesis. I now move onto the research methodology for this study 
and the choice of studies to answer our research questions. 
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3. Chapter 3: Research methodology 
3.1. Introduction  
The purpose of this chapter is to describe the approach to the research, the design of 
the methodology and to discuss the methods and procedures employed for data 
collection and analysis. The chapter explains the reasons for a more qualitative rather 
than quantitative approach to the research design drawing information from both 
health informatics and clinical research as subject areas.  It will cover how the 
research was broken down into segments of smaller studies that were undertaken in 
order to reach the goal of having a comprehensive picture of how clinical trial 
information is disseminated It will also described the methodology of the studies 
undertaken and any problems encountered.   
Desk-Based Research  
A large amount of time was spent on literature searches and reviews in the beginning 
of the research process. It was part of the research process to revisit the research 
questions and objectives as the main issues and themes were revealed during the 
initial phase of reading literature and narrowing down the scope of the thesis. 
Approach to the research 
It was clear early on that this study would require an examination of a variety of 
aspects relevant to clinical trial dissemination.  The study had to be broken down 
into segments of smaller studies, and the results drawn together with the literature 
review to form a comprehensive picture of how clinical trial information is 
disseminated and to model it. From that a conclusion could be drawn on how 
dissemination could be improved. (See figure 4 for studies and data collection 
methods.) 
Validity of research 
Throughout planning the research for this thesis, ideas, methodology and research 
experiments were checked or discussed with experts.  All aspects of the research 
were discussed with my supervisor, Professor Ian Rowlands. Other experts that were 
consulted were: 
 Vanda Broughton, Department for Information Studies UCL 
 Nadine Lott, Regulatory Affairs, Merck-Serono Pharmaceuticals 
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 Ida Sim, Associate Professor in Residence Director, Center for Clinical and 
Translational Informatics, University of California San Fransisco 
 Elizabeth Wager, Chairperson COPE and Consultant at Sideview 
 Adam Jacobs, Director and Dianthus Medical Limited 
 Andrea Palluch, Medical Writer 
 Faiz Kermani, BioPharm International Clinical Trials Advisor 
 Sue Fitzpatrick, Education Manager Institute of Clinical Research 
 
Research Design  
The study adopted a mixed methods approach and used qualitative and quantitative 
techniques to examine the dissemination of clinical trial information. Using the two 
methods complemented each other
231
 and helped to understand dissemination 
practices and perceptions of the practices. Collecting diverse types of data and 
information using different methods provided this study with a broader 
understanding of the complexities of clinical trial information, dissemination and 
factors affecting dissemination.  
Data Collection Methods  
Both primary and secondary methods were used to gather data and information. 
Primary methods used include collecting data through experiments, talking to and 
surveying clinical research professionals and drawing on researcher‟s own 
experience from working in a pharmaceutical medical information department and 
later in a clinical research environment, whereby knowledge of the process of a 
clinical trial and key information generation and dissemination has been learnt. 
Secondary methods, data collected by others
232
, involved reading published and 
unpublished material relevant to clinical research found in the literature review.  
Quantitative methods 
The quantitative methods in this study involved collecting data in a survey and 
analysing the data with the Statistical Package for Social Sciences (SPSS) as well as 
minor data sets from smaller studies using Excel. Excel was also used for the 
creation of useful tables, graphs and figures with SPSS analysed data. The findings 
in the quantitative analyses were used to compare or complement findings of 
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qualitative methods. When I have presented research findings and data in this thesis, 
I have specified in the figures if I am showing numbers (n=) or percentage (%). 
Qualitative methods 
The qualitative methods used in this study were applied to more accurately describe 
how clinical trial information is disseminated and interpret choice of dissemination 
by those who work with clinical trial information and those who disseminate it. This 
thesis predominately consists of qualitative methods as the research questions are 
such that it would be difficult to design research methodology that explains the 
dissemination of clinical trial information with quantitative data alone.  
3.1. Research ethics permission 
Most research for this thesis involved collection of study data not involving human 
participants, therefore not requiring ethics approval. 
The survey of clinical research professionals involved collecting data from human 
participants. I sought ethics approval from the UCL Research Ethics Committee, 
who responded that permission is not required as I did not intend to identify the 
participants and it was a survey based on behaviour. The UCL ethics approval 
exemption part d therefore applied
vii
. The UCL research ethics standards comply 
with the Framework for Research Ethics
viii
. 
 
 
 
 
 
                                                 
 
vii Research involving the use of educational tests (cognitive, diagnostic, aptitude, achievement), 
survey procedures, interview procedures or observation of public behaviour that is not exempt 
under paragraph (c) of this section, if the human participants are elected or appointed public 
officials or candidates for public office http://ethics.grad.ucl.ac.uk/exemptions.php   [Accessed: 
16 January 2012] 
viii  http://www.esrc.ac.uk/about-esrc/information/research-ethics.aspx [Accessed 16 January 2012] 
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3.2. A mixed methods approach to the research 
 
 
Figure 4: Overview of research design and data collection methods plus geographic coverage 
 
• Using a variety of resources and material 
Literature review 
• Drawing on own experience 
• Results of research studies  Model of clinical research 
process 
• Quantitative data from survey - SPSS for 
analysis - EU Survey of clinical research 
professionals 
• Online information about clinical trials - UK 
• Observation and data collection 
• Bibliometrics study into journals - global 
Internet search experiments 
• Comparative study of various guidelines 
and policies - global Evaluate organisational 
publication policies and 
guidelines 
• Comparative study with quantitative and 
qualitative techniques - UK clinical trials 
featured within a global register 
 
Evaluate CTRs on the Internet 
• Qualitative evaluation of different methods 
• Qualitative evaluation of factors 
Critical analysis of 
dissemination methods & 
factors that affect 
dissemination 
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3.3. A model approach  
There are many written documents describing the regulatory authorities‟ approval 
process for a new intervention undergoing research and subsequent launch onto the 
market
233
. However, no one as far as this researcher is aware no one has modelled 
the clinical research process highlighting important points in the clinical research 
process where key information is produced and the type of output it takes. 
Constructing a conceptual graphical model of the clinical research process and the 
information generated throughout it could act as a road map for discussions 
concerning the aspects of making information available. The model constructed is 
outlines activities and output. The scope of the model is the information generation 
from the beginning of the research process, through the clinical trial phases to the 
post-marketing phase of studies that may take place once the intervention is already 
on the market.  The model shows both publicly and confidential information that is 
generated. The model is tested in part 2 of this thesis where the methods used for 
dissemination are examined and the factors that affect dissemination. The model will 
also form the basis for our final recommendation of how dissemination of clinical 
trial information can be improved and become more effective. (See figure 7 for 
model or appendix A for enlarged view.) 
3.4. Survey of clinical research professionals 
A survey (Appendix G) aimed at clinical research professionals who work with 
clinical trials was designed to ask them (1) about their knowledge and understanding 
of clinical trial dissemination activities and relevant regulations and policy and (2) 
about actual practice and timing of different dissemination activities, e.g. the release 
of clinical trial data, clinical trial registration, posting of results etc. At the time of 
the survey, WHO had called for the voluntary registration of all clinical trials
234
, and 
even though registration of clinical trials had been made mandatory in the state of 
Maine in the USA
235
 it is not a legal requirement anywhere else. It was uncertain if 
clinical trials were registered and if so where, and how results of clinical trials were 
disseminated and specifically more information about what clinical research 
professionals know about their own organisations, e.g. if they have a publication 
policy and if so what is the policy on disclosure? Do they post results on their own 
websites? 
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The survey questions were drawn up firstly based on information and data needed to 
respond to the research questions for this doctoral thesis. The survey questions were 
discussed and tested with two experienced clinical research professionals and 
medical writers, Liz Wager of Sideview and Adam Jacobs of Dianthus Medical 
Limited. The survey questions can be found in Appendix G (p.253). 
Population of the Study  
A study in the dissemination of clinical trial information has to take into account 
those who work with clinical trial information to establish what they know about the 
dissemination of clinical trial information including clinical trial registration. 
Persons involved in the creation and management of clinical trial information 
constitute many types of individuals like authors (those reporting on clinical trials), 
managers of clinical trials, clinical trial site staff, statisticians, research staff etc. 
These individuals are based in different organisations like national health services, 
pharmaceutical companies, research companies, academic institutions etc. Generally 
each organisation has a different set up in what roles are involved in the different 
parts of disseminating clinical trial information. Departments such as regulatory 
affairs collate the final product dossier of a new medicine and notify the regulatory 
authorities, the marketing department use the data to draft promotional material and 
the medical department use the research findings as evidence to provide to healthcare 
professionals requiring evidence as base for treatment.  
Sampling and Sampling Strategies  
One of the difficulties of this study was to reach the right people in a variety of 
organisations. The respondents were selected using purposive sampling, e.g. a 
predefined group. Purposive sampling was used to detect clinical trial information 
dissemination within a wide range of affiliations and across departments with 
individuals working in different roles. Individuals belonging to particular 
membership bodies were chosen because they are likely to have some knowledge of 
reporting in clinical trials which enabled detailed exploration of the dissemination of 
clinical trial information. However the actual sample population is unknown. 
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Sample Size  
The survey was announced and distributed by the Institute of Clinical Research 
(ICR), European Medical Writer‟s Association (EMWA) and the Pharmaceutical 
Information & Pharmacovigilance Association (PIPA). It ran between 20 August 
2007 and 7 October 2007. These organisations had a total membership of 7,113 of 
which only a small number would find the survey relevant to their work and 
therefore be the target audience of this survey.  The survey had 938 hits, 159 partial 
responses and 309 complete responses.   
 
Three filters were set before analysing numbers (see figure x). Incomplete responses 
(n=159) were removed. A limit was also set to responses from the EU as there were 
only 40 responses outside the EU. The regulatory environment is quite different in 
other areas outside the EU. Drawing conclusions of actual practice of clinical trial 
registration would be difficult without considering the regulatory environment.  A 
filtering question was also asked in the survey of whether the survey was relevant to 
the respondent‟s work. The point of this filter was to remove individuals (n=171) 
who may not had sufficient experience or knowledge of trial registration and 
dissemination. This left 98 survey responses for analysis. 
 
Figure 5: Flowchart of responses to survey (n=98) 
Data collection and instruments 
The survey was deployed using Zoomerang online (see Appendix G for survey).  
Online surveys are low cost, easy to deploy as well as easy to collect data from. It 
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was not feasible to send out print questionnaires to such a large amount of people. 
Zoomerang was chosen as it was the survey tool used in-house in the researcher‟s 
organisation and made design and deployment easier. 
 
Data analysis was done using SPSS as described earlier in the section on 
„Quantitative methods‟. Data was then exported into Excel for creating tables, 
figures and charts. 
Limitations and problems encountered 
The Internet gives the opportunity to conduct surveys more efficiently and 
effectively than traditional print methods. However, using only a web-based survey 
does create risks, in particular the self-selection of respondents, which may result in 
a sample that does not represent the targeted population and we must also assume 
that not everyone has access to a computer or the web which could reduce the 
potential sample
236;237
.  Another difficulty with web-based survey is the difficulty in 
calculating a response rate.  
 
Even though the design of the survey was checked with experienced clinical research 
professionals, some of the terminology within questions was ambiguous. Clinical 
trial registration is relatively new and the terminology (as explained earlier) is not 
used consistently by the clinical research community. For example, a question on 
„releasing research results early‟ can mean different things, e.g. release prior to 
publication in a journal or releasing results before the end of a clinical trial. 
Assumptions cannot be made on what respondents assumed it meant and so 
interpretation must be cautious. However, a follow-on question asked respondents to 
describe how research results were released early meaning prior to end of trial, 
providing some responses that can be interpreted.  
 
Another after-thought is the complexity of the survey. Since the questions ranged 
from clinical trial registration to disseminating clinical trial results, it may have 
benefited from being a briefer survey followed by in-depth selective face-to-face 
interviews. The appendix to this thesis contains the published paper of the survey 
results (Appendix I), the survey questionnaire (Appendix G) and a poster with 
findings (Appendix H). 
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3.5. Online information about diabetes clinical trials – an evaluation of 
website results from a Google search 
We know that the Internet is increasingly used when trying to find medical 
information. The aim of this study was to „mystery-shop‟ to try to find clinical trials 
for diabetes in the UK and examine the types of websites, the reading level of the 
content and date the website was reviewed (if dates were given). The result will 
reveal the types of information about clinical trials that is disseminated on the web 
by using one of the most commonly used search engines. 
Data collection and instruments 
Using Google, I limited our search
ix
 to diabetes clinical trials as with our other 
studies in this thesis. I also limited the search to the UK. The search terms: diabetes 
clinical trial (not using boolean operators or “”). The first twenty websites listed 
from Google were selected for examination. The decision to only analyse the first 20 
results was because the average searcher rarely go beyond the first page of returned 
results
238
.  
Limitations and problems encountered 
This type of search is only a snapshot in time as more content is added to the web 
and indexed by search engines every day. The results examined were true for the 
date the search took place and if repeated regularly will produce a different result. 
Nevertheless, it was an interesting exercise providing an idea into how information is 
scattered across a variety of online resources and fits the objectives of this thesis. 
3.6. Evaluate existing publication/disclosure policies of organisations  
The decision as to how clinical trial information is disseminated or to what extent 
data from clinical trials are released, are covered in publication and/or disclosure 
policies of organisations, institutions and journals. For this thesis, I will refer to them 
all as publication guidelines. There are three sets of publication guidelines that this 
thesis refers to. First there are the guidelines issued by authorities or authoritative 
sources, e.g. ICH GCP (good clinical practice) guidelines
167
 or  ICH E3
239
 is a 
guideline regarding formatting and reporting of research to authorities. Second there 
                                                 
 
ix Search conducted 19 July 2008  
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are guidelines drawn up by journal publishers or research groups, e.g. the ICMJE 
guidelines
176
 or the GPP guidelines
240
. The ICMJE guidelines are comprehensive 
with regards to reporting and writing up research. Both these types of guidelines aim 
to provide recommendations to clinical researchers on reporting clinical trial results 
and findings to the authorities and the public including the scientific audience. The 
third type of guidelines are organisations‟ internal guidelines, e.g. guidelines for 
researchers within a pharmaceutical company or an institutional statement of 
disclosure of research results. The Pharmaceutical Research and Manufacturers of 
America (PhRMA) issued their principles of disclosure
241
 of clinical trials, based on 
the ICMJE uniform requirements advising their members (pharmaceutical 
companies) to adopt the principles or adapt them into their own policies.  
 
For this thesis, I investigated these three types of guidelines in two studies to 
establish their content of coverage and recommendations for dissemination of 
clinical trials. 
Study 1: Pharmaceutical companies’ guidelines  
The first study was a comparative analysis of ten large and small pharmaceutical 
companies‟ publication guidelinesx, comparing the content of them to the 
recommended ICMJE requirements
176
. In the survey of clinical research 
professionals, questions regarding publication guidelines within organisations as 
well as external guidelines were asked and responses useful for comparison in this 
analysis.  
 
Each year a list is published of the top 50 pharmaceutical companies in the world is 
published
242
. From this list five large and five small (based on number of 
prescription drug sales) companies were randomly selected for this study. Initially it 
was investigated whether or not the companies had a disclosure policy or not (Table 
2).  Policies were found on companies‟ websites and if they were not found, the 
company was contacted by email to request a copy of their policy. 
                                                 
 
x
 The policies were downloaded or read online between May and July 2007.  
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Table 2: Companies selected for analysis and whether they had a public policy on disclosure 
 
Company Public policy of 
disclosure 
Five large companies Yes No 
P1. Pfizer   
P2. GSK   
P3. Novartis   
P4. AstraZeneca   
P5. Sanofi-Aventis   
Five small companies   
P6. Merck Pharmaceuticals (KgaA)   
P7. Eli Lillyxi   
P8. Roche   
P9. Amgen International   
P10. Ipsen Ltd.   
Data collection and instruments 
The ICMJE provides a uniform list of requirements of a manuscript submitted to one 
of its member journals. In this study, these requirements were used for comparison 
against the publication or disclosure policies. Publication guidelines were compared 
against the headings of the ICMJE requirements (Table 3) to establish if they have 
incorporated the uniform requirements within their guidelines. 
  
                                                 
 
xi
 Eli Lilly has a policy on the conduct of clinical trials which includes some disclosure information 
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Table 3: ICMJE uniform requirement headings used for comparison  
 
Using external contractors for drafting publication 
Conflict of interest 
Obligation to communicate negative results 
Obligation to register clinical trials Phase I-IV 
Preparing manuscript for publishing 
Registration of Phase I studies 
Commitment to communication of results 
Acknowledges official guidelines (e.g.PhRMA/ICMJE) 
Posting results on a public database 
Admits commercial sensitivity 
Identifies database where registering trials 
Gives timeline when results will be released 
Discusses interim or preliminary results 
Talks about publication of results 
Internal review of abstracts/scripts 
Discusses delayed publication 
Sharing of protocol with journal editors 
Authorship of publications 
Peer review 
Communicating outside peer-review journal 
Information analysis also extended to: title of policy, year of publication, availability 
on the web, full text of policy publicly available and the coverage of the policy. 
A coding scale was used for scoring the findings: 
0=no coverage,  
1=some mention  
2=yes covered 
 
Each publication guideline then had a total score, providing an insight into its 
coverage.   
Study 2: Authority guidelines and clinical trial specific guidelines (publishers or 
research groups) 
This second study into guidelines aimed to create a chronological timeline of the 
release of guidelines that have affected the dissemination of clinical trial 
information. The timeline supports this thesis argument that there is change in how 
clinical trial information is disseminated and helps to answer the research question 
about what factors affect what is disseminated.   
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Data collection and instruments 
The information to produce the timeline in Figure 20 (p.154) came from a review of 
literature which provided the dates and titles of relevant guidelines. The timeline 
identifies the different guidelines with colour-coding. It also includes important 
events (black) in clinical research. Each guideline was read and summarised to 
provide a brief background into how they may affect clinical trial dissemination. 
The survey of clinical research professionals also asked individuals to identify 
guidelines that they are aware of, which ones that they use and the usefulness of the 
guidelines.  These findings are supplemented by literature searches. The findings 
may help identify some of the issues that exist in clinical trial dissemination. 
Limitations and problems encountered 
The results of the survey (section 1.19) also provide a small insight into which 
guidelines are known by clinical research professionals. The survey asked users to 
evaluate guidelines usefulness which is a question asking for their personal opinion. 
It is not evidence enough of a guidelines‟ usefulness to only refer to opinions of a 
sample. There would be more clout if there was evidence of which guideline(s) were 
officially adopted by organisations. Very little such information exists, although 
there is some evidence provided by the authors of the GPP
240
 and ICMJE 
guidelines
176
, as they formally publish lists of organisations which have approved 
their guidelines on their websites. 
 
With regards to organisational guidelines, it may be that organisations did not model 
their guidelines against the ICMJE principles. However, these guidelines were 
chosen in this study as most peer-reviewed journals that publish clinical trial results 
expect papers submitted for publication to adhere to these principles. Therefore the 
assumption was taken that organisations would cover the same topics within their 
guidelines as those of the ICMJE.  
 
Not all pharmaceutical companies have publication guidelines, or these are not made 
available to the public. Two of the ten companies studied here did not have public 
policies. They were removed from further study. One company had a policy on the 
conduct of clinical trials, which included disclosure, and this one was included in the 
study. 
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3.7. Critical analysis of the methods used to disseminate clinical trial 
information 
The methods used to disseminate clinical trial information are many. A key 
observation in this thesis, which is argued throughout, is that clinical trial 
information and data are scattered around various resources, mainly online (Figure 
6). Of interest in this thesis is how dissemination is changing with the invention of 
new tools on the Internet and new developments in publishing. How have these new 
developments affected the way in which research is disseminated and are the 
methods fit for purpose?   
Figure 6: Scatter of clinical trial information 
 
•Books 
•Journals, print or open access 
•Promotional/educational material by pharmaceutical companies or health professionals 
•Advertising on the radio, on TV, in magazines 
•News services, e.g. BBC, newspapers  
Media or Print 
•Portals/Databases/Pipeline sources , e.g. Medscape, Medline, NHS Direct, Doctors.net 
•EBM sites, e.g. Cochrane Reviews, Clinical Evidence 
•Online shops/pharmacies 
•Product websites, e.g. a drug promotional or information site 
•Clinical trial registers (CTRs), e.g. Clinicaltrials.gov 
•Search engines, e.g. Google, Yahoo 
•Open access journals, e.g. PLOS, Trials, BMJ open archive 
•Advertising/Banners, e.g. by pharmaceutical companies or pharmacies 
•eMail lists/newsletters 
Internet or e-methods 
•Physician 
•Friends/colleagues 
•Health service, e.g. nurse, pharmacist, dentist 
•Discussion forums on the web with personal experiences 
People 
•Library, eg public, hospital or organisational 
•Patient organisation, e.g. The Stroke Association, Diabetes UK 
•Research council, e.g. MRC, Wellcome Trust 
•Pharmaceutical companies 
•Repositories, e.g. university or PubMed Central 
Organisations 
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To establish if methods used to disseminate are fit for purpose, an evaluation of 
traditional methods and new or recently developed methods took place. With 
traditional methods, I mean those methods used prior to the Internet, e.g. peer-
reviewed journals, conference meetings etc. With new methods I mean those that 
have developed in the electronic era with the help of the Internet, e.g. clinical trial 
registries, online tools such as blogs and websites etc. 
3.8. An evaluation of methods used for dissemination 
Individual but related studies took place to evaluate different dissemination methods. 
The research objectives were: 
1. An examination of the journal as a suitable tool for disseminating clinical 
trial results, a bibliometrics study to establish what journals are core clinical 
trial journals and what information the abstracts of published papers contain. 
2. An examination of electronic alternatives to traditional dissemination 
methods. 
3. An examination of clinical trial registers; their quality and content 
 
Responses in the survey of clinical research professionals are used to compare with 
findings of the above analysis.  
Study 1- Part 1:  Journal as a tool of dissemination: A bibliometrics study -
Bradford’s law applied to Scopus search 
The literature review showed that some bibliometrics studies have taken place into 
specific disease areas or a specific journal, but not into the obesity and diabetes 
therapy areas. The first aim of this bibliometrics study was to establish what journals 
cover the subject of obesity and diabetes clinical trials; the number and the titles of 
core journals to get the most relevant articles in the field. I have already established 
that clinical trial information is scattered around a variety of resources and journals. 
This study may show which and how many journals covered by a bibliographic 
database will supply a certain percentage of journals relevant for a specific topic. It 
will also tell us what type of journals are the core set that cover information about 
clinical trials in the area of obesity and diabetes.  
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Bradford’s law of scattering comprises one law of bibliometrics. In knowing the 
core journals that cover our subject, it may help to understand the type of journals 
that cover our topic and to see if the core set is large or small. It‟s important to 
remember that the Bradford nucleus or core of journals continues to develop as a 
topic matures, if the graph that is generated is mostly linear, the topic is still in a 
stage of development. A Groos drop, the Bradford curve is an S-shape and droops at 
the end, could indicate of an incomplete nature of the bibliography examined
243
, but 
Braga states that a Groos drop could indicate the maturity of the subject area
244
. 
Data collection and instruments 
Bradford’s law was applied on the results from a search on the database Scopus to 
establish core journals. Scopus was selected as it provides a useful citation tracker 
tool, one which does not exist within PubMed. The search terms were: humans, 
obesity, diabetes, 2008. 
  
In order for Bradford’s law to work in this study, the search had a limited time span 
(articles from year 2008 only), the subject is well-defined (clinical trials, obesity, 
diabetes) and the bibliography must be complete, although it has been stated that a 
complete bibliography is difficult to achieve
245
. Scopus is a relatively comprehensive 
database listing medical and scientific articles. 
Study 1 – Part 2: Journal as a tool of dissemination: Eigenfactor score applied 
to PubMed search  
In this part of the study the objectives were to examine the types of journals that 
publish the most clinical trials in the area of obesity and diabetes, and if those that 
publish the most clinical trials have the highest impact factor. The objective was also 
to examine the abstracts of published papers to establish usefulness, was sufficient 
information provided about the clinical trial in the abstract, e.g. type of trial, IMPs 
used, methodology, main findings, clinical trial registration number, declaration of 
funding etc. 
 
The Eigenfactor Article Influence Score calculates measures the relative importance 
of the journal on a per-article basis. It is the journal's Eigenfactor score divided by 
the fraction of articles published by the journal. That fraction is normalized so that 
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the sum total of articles from all journals is 1. The mean Article Influence Score is 
1.00. A score greater than 1.00 indicates that each article in the journal has above-
average influence. A score less than 1.00 indicates that each article in the journal has 
below-average influence. 
Data collection and instruments 
A PubMed search was conducted on 14 June 2009 using the search terms: obesity 
and diabetes. Filters were set to „clinical trials‟, „humans‟, and „2008‟.  There were 
80 citations that matched this search. The abstracts and journals published in were 
analysed for the following information: publisher, the impact factor, the Eigenfactor 
Article Influence Score (referred to as Eigenfactor score from hereon), country of 
author(s), transparency of sponsor and funding, if clinical trial registration number 
was given, evidence of type of study published and the language of the article. This 
search did not use a Bradford analysis but used the impact factor and Eigenfactor 
score (found in the Science Journal Citation Reports from Thomson Reuters
xii
) 
instead and it was an interesting comparison between the Bradford analysis on 
Scopus and the Eigenfactor score from PubMed result to establish if the same 
journals came up as core journals. 
Limitations and problems encountered 
I cannot be sure of how authors select publications to submit their clinical trial paper. 
By examining impact factors I cannot determine the choice of journal. I cannot 
therefore draw conclusions on suitability of a journal as a method of disseminating 
clinical trial results on behalf of the author.  
 
Journals use different abstracting methods and do not necessarily use an IMRAD
xiii
 
structured abstract making it difficult to quickly find relevant parts of the abstract for 
analysis. 
 
                                                 
 
xiihttp://thomsonreuters.com/products_services/science/science_products/scholarly_research_anal
ysis/research_evaluation/journal_citation_reports [Accessed 26 Jul 2009] 
 
xiii
 IMRAD stands for Introduction, Methods, Results And Discussion  
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Using two different methods in analysing journals to establish a core journal set 
proved interesting. It is known that the impact factor can be manipulated and that 
journals that publish reviews and summaries tend to have higher impact factor due to 
higher citations than journals that publish original research.  However, journal value 
is more than just its impact. Coleman suggests that journal value is multidimensional 
and citations alone which drive impact factors do not capture other value factors 
such as costs and benefits, e.g. the scientific value must be developed in a fuller 
model
246
. Furthermore, impact factors cannot be used for other methods of 
publishing, and there is a need to develop a model of showing scientific value in 
other types of publication activities. Similarly, the Eigenfactor score aims to measure 
influence. However, influence is more than citing articles and the rank of a journal.  
Study 2: Examination of electronic alternatives as dissemination methods 
The objective was to establish what the electronic alternatives are compared to 
publishing in a journal and in particular find out if blogs or other social tools were 
used to announce clinical trial results.  
Data collection and instruments 
As an online search experience, Google was used with the search terms: clinical 
trials AND results and a limit set to year 2008. There were 4,290,000 results 
matching this search.  Looking at the results, it was difficult to establish what type of 
online page or document it was, unless the URL specifies so in its path name, e.g. 
using words like blog, press release, publications etc. Therefore clicking on links 
was required to establish what type it was. The overwhelming result count means 
that only links that seemed suitable were visited and recorded. 
Limitations and problems encountered 
Many alternative methods to disseminate clinical trial information are available 
using the Internet.  It is evident that by using an Internet search engine we can 
discover clinical trial results, however, it is time consuming and difficult to conduct 
a search that will bring back relevant articles as search engines do not yet allow for 
more sophisticated searching. The different types of web pages that exist also make 
it difficult to determine ownership, quality, publication date, authorship and 
relevancy of content. 
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It was not obvious when reading blogs and random web pages that came up through 
the Google search who the owners were and if they were researchers or representing 
research institutions.  It is known that researchers use blogs or other kinds of web 
presence to be transparent about their research in particular to those funding it
53
. 
There is some evidence that researchers are also using new social tools such as 
Twitter, to list research, papers and researchers
247
. 
  
The research does not show if dissemination has changed over a specific time period. 
That type of research is difficult to conduct as some electronic tools online do not 
have date stamps on when information was uploaded. 
Study 3: Evaluation of clinical trial registries on the Internet  
Clinical trial registries are repositories of data and information about current and 
closed clinical trials and sometimes also the results of the trials (abstract and 
references of published papers). The aim of the register is for the sponsor of a 
clinical trial to record information about clinical trials, which improves transparency 
and allows users to search for information about clinical trials. There are many 
clinical trial registries in existence, with different content, structure and 
functionality. Clinical trial registries are a link between the clinical trial, the formally 
published results, the authorities and the public.  
 
As publishers now recommend
176
 that clinical trials are registered before publication 
of results in a journal, it was important to review this type of dissemination method 
of clinical trial information. For this thesis an evaluation of ten different clinical trial 
registries took place during a time of sudden increased interest in clinical trial 
registries. There was a sudden growth in registers coming to the market and their 
purpose was debated in published literature. My research also took place before 
Clinicaltrial.gov became the largest register in use and recognised as the default 
register for clinical trials and before the WHO launched the ICTRP metaregister, a 
combined register, of other existing clinical trial registries
105
 allowing for cross-
searching. The focus of the research was to establish the functionality of the clinical 
trial registries and assess the quality of the content.  
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Data collection and instruments  
To make the study manageable, these research questions were set: 
 What clinical trial registries are relevant for this study when you want to find 
open clinical trials in type 2 diabetes and obesity in the UK? 
 According to the evaluation tool114 used, does the register provide suitable 
functionality and tools to enable the user to find information? 
 Does the register meet the criteria of the WHO by providing information in 
the WHO recommended 20 datasets (TRDS) (Table 4)? 
Table 4: The WHO 20 minimal dataset (TRDS) 
 
WHO 20 minimal dataset 
1. Primary Register and Trial ID # 
2. Date of Registration in Primary Register 
3. Secondary ID#s 
4. Source(s) of Monetary or Material Support 
5. Primary Sponsor 
6. Secondary Sponsor(s) 
7. Contact for Public Queries 
8. Contact for Scientific Queries 
9. Public Title 
10. Scientific Title 
11. Countries of Recruitment 
12. Health Condition(s) or Problem(s) Studied 
13. Intervention(s) 
14. Key Inclusion and Exclusion Criteria 
15. Study Type  
16. Date of First Enrollment 
17. Target Sample Size 
18. Recruitment Status 
19. Primary Outcome(s) 
20. Key Secondary Outcomes 
 
The study began by compiling a list of clinical trial registers by using a four step 
process to identify and select for review web sites that offer clinical trial search 
tools. 
 
Step 1:  Sites recommended by diabetes related organisations  
Step 2:  Online search using Google to expand the site list. Most Internet searchers 
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start with a search engine and Google is the most widely used search engine 
Step 3:  A Medline search 
Step 4:  Information from experts in the area, e.g. lists or published information. 
 
Eligible resources 
Resources had to contain information about diabetes clinical trials available in the 
UK. Websites reviewed are not limited to those based in the UK but must contain 
information about diabetes trials in the UK. Sites were excluded if they did not allow 
the user to search or at least display information about current (ongoing or open and 
recruiting) trials. 
Search conducted to find relevant clinical trial registries 
A search was conducted
xiv
 in Medline, on Google and on known diabetes websites 
and supplemented with clinical trial registries known to researcher. In Medline, the 
search terms used were: “clinical trial” AND “diabetes” AND (“database” OR 
“register”) without result. New terms were: “diabetes” and “database” with the limits 
“2006-8” and “UK” yielded 11 results. On Google, the search terms were “clinical” 
“trial” “database” “diabetes”, and pages from the UK radio button was selected, were 
used in Google yielding a total of 137,000 websites. Site links on the first two pages 
of the Google findings for each search were considered as users rarely go beyond the 
first page of returned results
238
.  Organisations that promote diabetes care that were 
consulted for further clinical trial registries were Diabetes UK, Diabetes.org.uk, 
Diabetes Action and Juvenile Diabetes Research Foundation International. 
 
In total 11 clinical trial registries were considered relevant to the study.  
Table 5: List of Clinical trial registries relevant to searching for diabetes clinical trials 
                                                 
 
xiv The search took place 7 July 2008 
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Note: ISRCTN, MRCT and UKCTR (now called UKCTG) are available to search within the Current 
Controlled Trials register. Please also note that CRMInteract ceased to exist 31 Dec 2009. 
 
Tool to compare clinical trial registries: Range, content and quality markers 
There are no validated tools to evaluate content and form of Internet information. 
The JAMA benchmarks quality rating scale
188
 or the DISCERN Instrument
248
 were 
not suitable for this study as it was not an evaluation of websites but specific 
databases on websites. For this study I based our content evaluation  tool on one 
used by Atkinson et al. in the search for clinical trials
114
. The tool developed by them 
reviews functionality and features of websites with clinical trials looking for: 
 Basic search tool 
 Advanced search tool 
 Registration options 
 Presentation of results 
 Additional site content. 
Limitations and problems encountered 
It is not difficult to find clinical trial registries by searching Google, however it is 
difficult to know suitability of a register without visiting it and attempting a search 
first.  Some of the clinical trial registries suffered from technical problems, e.g. 
search not working as it should. Many clinical trial registries had rudimentary search 
engines and different terminology was used making it difficult to make a search 
similar in all clinical trial registries. Sometimes it was impossible to know if a study 
was still open or closed. Other difficulties were that sometimes the country could not 
be selected when searching.  
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This study is also a snapshot in time but shows an interesting picture of registers at a 
time when their growth and development was at its infancy. It is difficult to judge 
the quality of registers from different organisations with different agendas, level of 
funding and management time invested. It was still a valuable exercise in identifying 
recommendations for registers to be fit for purpose in chapter 6. 
3.9. Discover factors that affect dissemination 
The objective was to discover the factors that affect dissemination, e.g. what 
determined which method was chosen for dissemination, why were other methods 
not chosen, what was disseminated and why? By understanding the forces that affect 
dissemination, it will allow us to address the potential issues in drawing up 
recommendations for future dissemination. 
Data collection and instruments 
Two methods were used to help discover the factors affecting dissemination. A 
literature review into existing research or claims made about the dissemination 
process is supplemented with comments made by clinical research professionals in 
the survey described earlier. 
Limitations and problems encountered 
Much of the literature reviewed contains personal comments and emotional 
statements, sometimes very negative comments against the publishing and 
pharmaceutical industry. To what extent these comments are based on scientific truth 
is difficult to determine. Another research method for this topic could have been to 
select a sample of clinical trials recently published and approach the authors asking 
specific questions about their dissemination activities and behaviour and researching 
their organisations‟ policies on dissemination. However, for this thesis there was not 
enough time to conduct a more comprehensive study. 
3.10. Conclusion to Chapter 3 
This chapter summarised the research methods adopted to address the research 
questions and objectives set for this thesis. Many studies were small scale, but 
necessary to get an insight into the dissemination process of clinical research 
professionals: the traditional methods and new methods that have been developed 
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mainly with the help of the Internet, factors that affect dissemination and the fitness 
of purpose of the methods used for dissemination.  The chapter describes the 
objectives of each study, the data collection methods used and limitations 
encountered with each study. The research findings of these studies and the literature 
review are discussed in chapter 4 and 5 with recommendations presented in chapter 
6. 
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PART 1 
 
4. Chapter 4: Modelling clinical trial information  
 
4.1. Introduction 
Chapter 4 is the first chapter in which I will try to make sense of clinical trial 
information and explain the complexity of information within the clinical research 
process. Chapter 4 and 5 are arranged around the themes as introduced in the 
Literature review chapter (Chapter 2) and in order to respond to the research 
questions. This chapter will define clinical trial information. The findings presented 
here responds to the first research objective to model the clinical trial process and 
what type of information is generated throughout the clinical trial. The conceptual 
model of information generation and dissemination is presented as a backbone to 
discussing clinical research, regulations and the information that is produced in the 
various phases of clinical trials. There is special emphasis placed on discussing 
research data, the evidence of a clinical trial, and issues around raw data, sharing of 
data and ownership. This is followed by a brief introduction into the heavily 
regulated clinical trial industry which impacts on information dissemination as will 
be seen in later chapters.  I draw on references introduced in the literature review and 
new references not previously discussed will be introduced to compare with findings 
of research done for this thesis and to add to the discussion.  
4.2. What is clinical trial information? 
Clinical research answers research questions into the efficacy and safety of 
medicines. A promising compound is selected to go through phases of research 
(clinical trials) to establish its behaviour. A clinical trial is the gold standard into the 
discovery of new medicines and devices, testing their efficacies before being 
marketed. The results from trials, research data, are analysed and interpreted and if 
successful form the basis for new drug applications.  Throughout the drug 
development a large amount of clinical trial information is generated in the different 
processes that a compound or entity is put through. That clinical trial data consists of 
complex information and data that are connected to one another. This generated 
information is adapted or repurposed for various use and some publicly released in a 
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number of ways, although it is unknown how much research information is publicly 
released.  
 
Clinical trial information can be broken down into four components of information 
generated: 
1. Information about the clinical trial, e.g. name of entity, type of trial, number 
of patients, research questions, funding etc. 
2. Information sought during a clinical trial, e.g. efficacy data, dosage 
information, side-effects etc.  
3. The final results of a clinical trial, the data. 
4. The interpretation of the research process and data and their output, e.g. the 
written summary of a trial, a published paper, the evidence of efficacy and 
safety etc. 
 
These components, and surrounding issues, will be explained in more detail in this 
chapter and are key to discussion throughout this thesis. When this thesis refers to 
clinical trial information it includes all these components of information. 
4.3. A conceptual model of the clinical research process and information 
generation 
For this thesis, a graphical model has been constructed (figure 7, or see appendix A 
for larger scale) as a road map to understand the phases of clinical research and 
output of information generated during the different points of the lifecycle of a new 
intervention. The model is showing the path of a typical intervention, but of course 
the model can vary considerably depending on things that affect research, e.g.  
research aims, type of intervention and events etc.  The model consists of a pre-
clinical phase (a) and the clinical phases (b). The clinical phase section is split into a 
number of types of phases, phases 1 – 3, all which seek out to answer specific 
questions about an entity. The arrow represents the clinical research process starting 
at year 0 with the selection of an entity that shows potential. The end of the arrow 
represents the end of research, e.g. the launch of a new medicine on the market and 
the end of the research lifecycle. It is unlikely to be an „end‟ as often research 
continues but for illustrative purposes I mark an end when an intervention is 
approved for sales on the market. It can take on average 12 years and cost around 
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$1billion to bring a new medicine to the market, although due to economic pressures 
the time can now be as low as seven years due to the pressure to generate revenue to 
bring more entities through development
249
 as well as priorities to finding suitable 
interventions to pressing diseases. 
 
In this thesis I refer to „information generation‟ where during the various phases of 
clinical research information about the entity is discovered and when output becomes 
evidence of how the research took place, the research findings, data etc., which is 
then disseminated and published in various ways. 
4.4. Model walk-through 
As an entity continues through the phases, more information is generated, indicated 
with the thickening of the arrow. Along the way, there is some key information 
output, shown by yellow diamonds on the arrow. There are also decisive moments 
between the phases of whether or not to continue developing the entity, a decision of 
go/no go that depends on research findings so far, continuous funding, opportunities 
to recruit subjects for trials and so on. Phases may also overlap and there may be 
more than one clinical trial in each phase. 
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Figure 7: Constructing a conceptual model of information generation and dissemination for a new 
intervention undergoing clinical research   
(Available in larger scale in appendix A.) 
 
 
The pre-clinical phase – understanding disease 
 
Figure 8: Pre-clinical phase: ‘entity x’ at 0 years  - (1)Target product profile produced 
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In the pre-clinical phase (Figure 2), the first step in drug development is to find a 
promising entity. This requires an understanding of disease, pharmacology and using 
computer technology and chemistry. Numerous entities are tested and computer 
modelling helps establish what entity shows promising signs. Why a particular entity 
is selected for development depends on economic, political and other agendas. It is 
likely that the entity chosen fits in with the existing drug portfolio or it may be sold 
off to another company who will develop it further. It will need to generate a 
financial profit and be worth investing time and effort for a final product. There may 
also be cultural-political pressures to develop drugs, e.g. a drug for a disease 
affecting a large population, e.g. HIV, or an unexpected breakout of a disease, e.g. 
flu. 
 
Early in vivo tests are carried out in living animals, usually rodents, to demonstrate 
the safety of a suggested medicine. In vitro tests, using cells and tissues in an 
artificial environment, are also done to assess safety and effectiveness of an 
intervention. Computer models are also used and can in some cases replace in-vivo 
and in-vitro tests. The drug regulatory authorities (or competent authorities) require 
certain safety tests to take place before humans are exposed to a new entity.  
Information that is generated during the pre-clinical phase includes toxicology and 
safety information. This information generates a „target product profile‟(marked with 
diamond 1). This information is used to support a submission of a clinical trial 
application (CTA) (in the US this is called an Investigational New Drug (IND) 
application). Usually before a submission is prepared, the sponsor company (a 
pharmaceutical company or research organisation) holds discussions with the 
competent authorities to discuss the potential of the new entity. No information 
about the entity is publicly disseminated at this stage. 
Information about the clinical trial itself 
Each clinical trial has to be approved by an ethics committee and by the competent 
authority in the country of which the trial will take place, and by the EMA if it is a 
trial taking place in the EU. When a Clinical Trial Application (CTA) is made, 
certain amount of information has to be provided about the clinical trial for an 
assessment of whether the clinical trial should go ahead and the design of the trial is 
Korjonen: Clinical Trial Information  96 
 
ethically sound. Information has to be provided on the name of the entity to be 
studied, what the research objectives and aims are, how many patients will be 
studied, what type of trial it will be, how the trial will be managed, where it will take 
place and so on. If any of these pieces of information change at any point before or 
during the clinical trial, an amendment must be applied for and approved. The 
procedure for applying for a clinical trial and an amendment are highly regulated. 
This information is stored in databases and can be accessed by any competent 
authority which needs to access it. Some of this information may also be released in 
public clinical trial register. Registration usually takes place before subject 
recruitment for a clinical trial begins.  
The clinical phases – testing in humans 
 
Figure 9: Clinical phase: information heavy phases – (2) Investigator brochure (3) Clinical Trial 
Application (CTA) (4) The dossier 
 
Phase 1 in healthy volunteers 
The sponsor company will seek out investigators (researchers) and investigator sites 
that are suitable to carry out trials in healthy volunteers. There has been much 
discussion around the use of healthy volunteers with ethical questions being raised 
surrounding the type of volunteer, e.g. healthy males. There have been calls to 
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extend trials in Phase I to women, children and the elderly. Investigator brochures 
are produced providing background information about the entity and information 
about the clinical trial and the objectives. The clinical trial may be registered in a 
public register to attract trial subjects and investigators. The phase 1 studies are 
looking for tolerability and pharmacology of the drug.  
 
During the trial, all data are fed back to the sponsor company who analyse them and 
report any possible adverse events information. The results of the trial are sometimes 
posted on a public results database within 12 months post-trial, according to 
guidelines
250
.  There is actually no regulation in the EU forcing sponsor companies 
to register clinical trials in the public domain, but there are guidelines recommending 
to do so
97;250;251
. Results are sometimes released before the end of the trial, e.g. at a 
conference during a presentation, sometimes with great media speculation on the 
success or failure of the drug. (I discuss dissemination of clinical trial information 
fully in chapter 5.) 
 
The success of the drug in phase 1 will determine whether or not it will continue into 
Phase 2. In fact this question of go or no go is asked after each phase. This is the 
most volatile aspect of a trial, as a no go means the research is abandoned and 
information generated so far may not be disseminated in any way apart from what is 
submitted to authorities in end of trial documentation. The sponsor company is likely 
to begin planning the publication strategy when drafting the protocol for the next 
phase, and it‟s suggested that planning should begin early, but even the planning 
process is currently actively debated in the clinical research environment
220
.  
Usually, the research questions and aims in the original clinical trial protocol form 
the basis of the structure for the final paper reporting on the trial once a trial has 
ended.  
Phase 2 in a small number of patients who suffer from the condition 
For each clinical trial a separate protocol and CTA must be filed and approved by the 
ethics committees and regulatory authorities. (The first CTA application is marked 
with diamond 3 on Figure 3, although it will be a regular occurrence between phase 
2 and 4, including possible amendments to the protocol.) The role of the ethics 
committee is to review the drug development procedures of any ethical issues that 
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may arise from any of the activities. A clinical trial must demonstrate that the 
anticipated benefits justify any risks. 
 
In phase 2, the entity is tested in a few hundred patients who suffer from the 
condition the new drug is intended to treat. The aim is to identify the optimum dose, 
method of delivery and to reconfirm patient safety. Patients are monitored and 
assessed frequently. Many drug trials fail at this stage when a drug proves ineffective 
or has unwanted side-effects. 
 
Conference abstracts and posters are presented whilst clinical trials are ongoing. The 
media report from conferences and disseminate wider than the intended research 
community, results sometimes covered in the popular press. Papers may be 
published on the results, but unfortunately some „failed‟ trials are never 
published
252;253
. With failed trials we mean trials that failed to show successful 
results, expected results or even trials that may have ended for some reason, e.g. 
safety concerns. I discuss dissemination methods and factors that affect 
dissemination in chapter 5.  
Phase 3 in larger patient population 
During phase 3 information about the effects of the drug on organs and efficacy are 
monitored. This is the final step before regulatory approval for a new drug.  
Researchers aim to confirm findings from phase 2 trials in a larger patient population 
and continue to study safety data. These studies can last two to 10 years and involve 
thousands of individuals across many sites and countries. Approximately 10% of 
drugs fail in phase 3 trials. 
 
Data from phase 2 and phase 3 trials are compiled into the „product dossier‟. (This is 
marked by diamond 4 on Figure 3.) The Summary of Product Characteristics 
(SmPC) is an executive summary of the evidence of the intervention that has been 
verified in clinical trials and Patient Information Leaflets (PILs), providing a 
summary of evidence in a format that is easy to understand in inserted into  
packaging, labelling for packaging are all produced and submitted with the dossier to 
the regulatory authorities to obtain a marketing authorisation. The application 
contains information on chemical makeup, manufacturing process, pharmacology, 
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toxicology, human pharmacokinetics, results from clinical trials and all the proposed 
inserts and labelling.  
 
In accordance with the Directive 2004/27/EC
254
, the EMA publishes information 
online, including summaries of clinical trials, on products assessed by the Committee 
for Medicinal Products for Human Use (CHMP). Any positive opinion given by the 
CHMP is published in the first instance as a Summary of Opinion. More detailed 
information is published later, following the granting of a Marketing Authorisation 
by the European Commission as a European Public Assessment Report (EPAR)
255
. 
The MHRA also publishes this Public Assessment Report (PAR) in the UK 
online
256
. In both cases the reports are prepared by medical writers and commercially 
sensitive information or confidential information is removed. The sponsor company 
has the opportunity to comment on the report before it‟s published. The information 
is available to the public and contains a summary written in an easy to understand 
language for the public. This summary, SmPC, PIL and packaging information is 
provided in all EU languages. The time scales vary depending on which authority is 
dealing with the application, but in the EU this usually takes up to 60 days but may 
include lengthy discussions and questions between the authority and sponsor 
company.  
Phase 3b, comparator or pharmacoeconomic studies and phase 4 or 
postmarketing studies 
Sponsor companies may also choose to conduct further studies such as 
pharmacoeconomic, comparative, new strengths and formulations. Additional 
information, and evidence, in particularly published information generated can 
provide beneficial in improving marketing efforts, in providing cost data to decision-
makers and to extend market authorisation for other strengths. Formulary decisions 
made on behalf of national health services in the UK require suitably strong evidence 
of the medical as well as cost benefits of a new drug. If a drug fails to be approved 
by treatment and national formulary decision-making bodies, such as National 
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Institute of Clinical Excellence (NICE)
xv
, it can have economic repercussions on the 
sponsor company who will not be able to get their drug prescribed. 
 
Market authorisation can be rejected by the authorities. The sponsor company will be 
provided with reasons why and information that could be provided for re-approval. 
This could mean conducting additional trials, such as a Phase 4 post-marketing study 
to examine risks and benefits of a new medicine in a population, or to assess long 
term effects of drug exposure, or evaluate the effects in paediatric patients (Figure 
4).  
Product launch after market authorisation 
 
Figure 10: Launch of drug: post marketing studies – (5) Active promotional period 
 
The intervention is officially launched once it has had successful market 
authorisation by the relevant competent authority. In the EU, the regulation of 
medicines is harmonised, where submission for market authorisation can be done to 
the EMA and makes it valid across the European Economic Area (EEA). There are 
                                                 
 
xv As this PhD is written, NICE is under review under the new coalition government and NICE 
guidelines may not have as strong an input on prescribing as GPs take control of own budgets 
whilst PCTs are phased out by 2013.  
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still some national procedures for some interventions, which must be checked with 
each national competent authority directly.  
 
The information in the product dossier is used when preparing a promotional plan or 
submission to a prescribing authority (diamond 5 in Figure 10). A company can 
produce literature, advertising and questions and answers that may be received by 
prescribers or other health professionals. Promotional material can include reprints 
of published papers, „detail aids‟ which is a product profile brochure, and other 
materials to help with presentations or submissions to formulary decision makers, 
e.g. NICE. In the UK, the Association of the British Pharmaceutical Industry (ABPI) 
Code of Practice guidelines
257
 restrict what kind of promotions the pharmaceutical 
industry is entitled to. At the time of writing this, the code has strict guidelines on 
marketing and promotions which are designed to protect the health professional and 
the public of irresponsible marketing. There is now less of a requirement to use a 
sales force to sell products in the field because authorities such as NICE are making 
health technology assessments and write recommended treatment guidelines that are 
used by the health services.  Individual sales pitches have been eradicated. Currently 
the sponsor company invests more time in formulary submissions and in educating 
health professionals, although this may change as health services are under regular 
review and due to other forces. 
4.5. Validation of the model 
The model in its current shape has not been validated in detail but three colleagues
xvi
 
provided useful feedback which led to the model evolving into this third version. All 
models have limitations
34;35
.  The main emphasis on this model is to show the 
information produced throughout the various phases of research. More in-depth 
activities, such as type of communication activity or activities of participants could 
be included but would also make the model more complex.  It is not easy to test a 
model in its entirety as different participants of the clinical research process may 
have a different perspective on the process that they are involved with. This model is 
                                                 
 
xvi Sue Fitzpatrick, Education Manager Institute of Clinical Research; Nadine Lott, Regulatory 
Submissions Manager, Merck Serono; Andrea Palluch, Independent Medical Writer. 
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a diagram of the overall process of clinical research and it may be useful for others to 
consider diagrams of sub-activities.  A model such as this one can contribute to 
examining many aspects of the clinical research process, by creating a model of sun-
activities in each section and adding additional resources and participants required. 
This way we can measure: 
 Time spent on activities 
 Number of participants required 
 Costs of each activity and a total cost 
 Quality of information output 
 Type of information output and whether public or confidential 
 Roles of individuals etc. 
The thesis will now move on to discuss the specific components that make up the 
information within the model. 
4.6. Clinical trial data – the raw material and evidence 
A large amount of data are generated during clinical trials. Data are raw materials of 
information and are evidence of the research that has taken place. There is a lot of 
discussion around research data, in particular around sharing the data, making them 
publicly available and if all data should be published. Clinical trials generate data 
showing the efficacy of an intervention in a particular population, for a particular 
treatment.  These data are analysed and some used as evidence to back up a claim, or 
respond to a research question made when disseminating the results of a clinical 
trial. Without data, we cannot make a claim that an intervention is effective in a 
treatment.  As data are the raw material of research information, they need to be 
accurate enough for their purpose, they must be relevant to a decision, they must be 
timely, accessible and digestible
258
.  
Raw data – before they are processed  
Raw data are the primary output of any research before anyone has made the data 
usable or retrievable
259
. Data are vital to evaluate research results, reconstruct the 
events and processes leading to them
260
. Lyon
20
 described the scholarly knowledge 
cycle and the creation of data. Original data, such as numerical data are created in 
experiments or surveys in a clinical study.  Additional processes may follow such as 
selection of an initial data subset with repetition of experiments or re-analysis and 
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possibly manipulation or editing of images or models creating modified datasets. 
Data are raw materials derived from research information and may never fully 
analysed by the researchers who generate them
261
.  
Sharing of data – benefits and methods 
There is an ethical and scientific goal of sharing research data, in particular in 
clinical research, with the objective of accelerating dissemination of trial data 
making the results available sooner and enabling patients to benefit
262
. The goal to 
facilitate access to information culminated in the invention of the clinical trial 
registries which allow for sharing of data and other clinical trial information.  
Sharing data is useful for different kinds of groups and for differing reasons: 
 those who are looking for clinical trials to partake in, to find out if the 
research results look promising (in case they suffer from an illness and are 
looking for treatments)  
 those who have participated in a trial, to satisfy that their contribution to 
research was recorded 
 for clinicians, researchers and anyone else who have an interest in clinical 
trial data to keep themselves up to date, to enable them to treat patients with 
the latest evidence at hand, to know what pharmaceuticals are up and coming 
etc. 
 Those who wish to continue research building on existing data. 
 
By sharing data we can also avoid research duplication and science can move faster 
by building on existing research that has been shared. By sharing data, the data will 
be re-analysed
263
 which can improve concentration into specific research 
questions
264
.  Auffray argued that there are large amounts of unused datasets 
available in laboratories and much of these data remain unused although they may be 
useful in other contexts
265
.  There is also potential for experts adding more data and 
annotations to previous datasets
263
 and developing knowledge this way between 
academics and industrial partners creating open access repositories or „data 
warehouses‟265. Data must be shared to avoid unnecessary duplication of research. In 
fact Lyon argues that other researchers and students in higher education will want 
more access to research data in particular as the life sciences is becoming more data-
rich and because future e-science will be more data-intensive and collaborative
20
. 
Korjonen: Clinical Trial Information  104 
 
Researchers are expecting to access published output and research 
261;266
. Journals 
and other organisations are also expecting data to be shared 
263
. There are some 
publishers that insist that all data are published online for access
265
.  
 
Lyon states that the availability of original data will raise standards associated with 
the publication of research as the review of accuracy of data will be more 
transparent, access to research will increase the speed of dissemination of research 
activity allowing data to be re-used and original data of published work will be 
available to those undertaking learning activities
20
.  
 
Many agree that clinical trial data should be available to the public, including to the 
research participants of studies, as the information, including for the safety of public 
will improve the reputation of the industry for their transparency efforts
267;268
. When 
disclosing research results to those participating in a study, it is important to take 
into account the possible negative effect the results may have if the results were 
undesirable, or not effective
267
. A study
24
 showed that participants of clinical trials 
usually want to know the outcome of the study but 33% misunderstand the meaning 
of results or were unsure of their significance.  Awareness of the results was through 
the media (29%), by post (26%), via a healthcare provider 19%). More participants 
learned about the results through the mail than through a healthcare provider.  
Another study
269
 shows that research results are rarely communicated in a timely or 
effective manner. Most participants found out study results via the phone (73.1%) 
when they prefer a personal contact.  
 
There is agreement in general however that sharing of data is not always possible: 
time constraints in formatting data, lack of standards, where to release or publish 
data, concerns over debate arising over data analysis, e.g. that re-analysis may 
impact on future research, informed consent issues over acquired data and 
intellectual property issues, e.g. the sponsor does not want data released as it may 
affect patent 
106;264;270
 or ownership questions
271
. There are also issues such as patient 
privacy
20;271
, where data protection and copyright apply.  Raw data from clinical 
studies are often thousands of pages long causing space problems, such as within 
print journals that cannot publish all data or the non-existence of institutional 
Korjonen: Clinical Trial Information  105 
 
repositories to store data. Fortunately the online environment has made storage 
possibilities nearly endless, in particular with cloud computing.  
 
The pharmaceutical industry has been seen to be against the public release of product 
information prior to the product has been approved by the authorities
251;264;270;270
. 
The main concern is around intellectual property of confidential information and 
there is also the opinion that a lot of the information generated, e.g. results, are not 
suitable for the lay public to read anyway.  In a survey conducted in Oct 2007 as part 
of this PhD
xvii
, respondents stated that they did not disseminate unfavourable results 
for several reasons; it was not company policy to do so, they felt there was no need 
to disseminate unfavourable results, they thought that results may harm the 
organisation‟s reputation and peer-reviewed journals had rejected publishing the 
results (more information about this survey in chapter 6). 
Methods of sharing data  
Since the invention of clinical trial registries, data from clinical trials are posted on 
results databases and there are guidelines suggesting they should be published within 
12 - 24 months of study completion
250
. Only half of published papers make their data 
publicly available on the Internet
20
 and these data are scattered across many 
websites, not retrievable from one place (more on scatter in chapter 5). There are 
also arguments that if data are raw, incomplete or not considered „useful‟ by those 
who own them, then there is no point in sharing data
20;258
.   
 
ClinicalStudyResults.com
141
, led by the Pharmaceutical Research and 
Manufacturers of America (PhRMA), argue that there is no point sharing data that is 
meaningless to those who read it, and this includes data from Phase I, and some 
Phase II trials, as well as raw data. Evidence, if only as data, encourages a false sense 
of scientific accuracy and objectivity
258
. Therefore study summaries are published 
and shared on clinical trial registries, rather than raw data, although there may be 
developments on this in the future. 
                                                 
 
xvii The perception and practice of publishing clinical trial results survey was conducted between Aug-
Oct 2007 and details of the survey are in chapter 6.  
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A recent US law states that all clinical trial data will be publicly available within 12 
months of the end of a clinical trial
272
. The ICMJE journal editors
176
 suggest that all 
trials published in their journals (any trials around the world) should release the 
results in clinical trial registries or results databases within 24 months of the end of 
the trial if it has not already been published in a peer reviewed journal by that date.   
The submission to the register should be in the form of a short abstract which will 
not be considered pre-publication
273
 which concerns journal editors. Journals do not 
like publishing original papers already published elsewhere (duplication).  If the 
authors/sponsors submit detailed results to the results databases, this could be 
considered as publication by the ICMJE editors and submitted articles could be 
rejected based on this.  This suggests that those that have to comply by US law will 
post results as required and those trials not conducted for the US market can choose 
to follow the ICMJE guidelines. The next few years will see much unpredictable 
change of these regulations and guidelines.  
 
Examples of repositories are the GenBank
274
 and the National Institute of Diabetes 
and Digestive and Kidney Diseases (NIDDK)
275
, a catalogue for samples, DNA and 
genetic materials and a number of registries, e.g. Clinicaltrials.gov. Associated 
problems with repositories can be identifying what data are original and what may be 
manipulated data
276
.  Other problems are the search mechanism, poor structure and 
variance in quality and format (discussed in chapter 5). 
 
The eBank UK project
277
 which ran between 2003-7 aimed to develop an 
information architecture for providing access to electronic resources in the UK, 
linking research data with other derived information. The project harvested metadata 
about research data from institutional repositories. The role of institutional 
repositories is for researchers to deposit, disseminate and preserve data. Several 
projects
278-280
 that looked at the concerns of depositing data show that academics are 
reluctant to share data due to intellectual property, quality and cultural issues.  
Ownership or stewardship of data 
Challenges in the field of repositories include issues of data preparation, curation, 
storage and preservation of data
18
. Repositories still lack the technical and 
institutional framework to support data sharing. 
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Because of the reluctance of researchers to share data in the past there have been 
examples of where we have been unable to attribute research to specific researchers, 
as there is  a lack of evidence of who the originator of data was. The data banks or 
repositories are an obvious solution to this as they can help with confirming 
ownership and/or originator, removing doubt of who should be acknowledged. 
 
Scofield suggested we replace the word ownership with stewardship as ownership of 
data may mean hoarding of data and that the person owning the data is responsible 
for the quality of it, which is not good for an organisation
281
. As an example, 
Scofield mentions company sales data that may be owned by an employee, not 
allowing other colleagues to access and manipulate the data. The consequence may 
be having several different versions of the data and in different formats.  
Stewardship means that someone is responsible for checking data, for its accuracy 
therefore ensuring that the quality is maintained
281
. 
 
According to recent report, policy on effective stewardship is needed for key players 
involved with research data
282
. The key players are researchers, libraries, publishers, 
research sponsors, university and research institutions
282
. According to the report, the 
five principles of stewardship are: roles; standards and quality assurance; access, 
usage and credit; benefits and cost-effectiveness and; preservation and sustainability. 
4.7. Why do we need clinical trial information? 
The evidence from the clinical trials, e.g. information generated, is used to prove 
efficacy of a product in treating a disease. In evidence-based medicine (EBM), health 
practitioners use the best available evidence to make treatment decisions. Data on 
their own may not be useful without interpretation and subject knowledge.  The best 
available evidence together with treatment expertise is what makes the practice of 
evidence-based medicine possible
19
.  Full research information behind the data is 
needed together with the data, showing why the research was done, the aims and 
outcomes. The ability of other scientists to validate each other‟s theories is what 
confirms validity of research
21
.  The data and the scientific validity of trials, such as 
the ability to repeat the trial and peer review of such trials, are key aspects to 
ensuring EBM. We must be aware, however, that there cannot be clinical trials for 
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every type of patient, therefore we have populations in which we don‟t know how an 
intervention will behave. Therefore information from trials cannot by itself 
determine efficacy in a patient. It must be combined with expertise.  
 
The information that is generated in a clinical trial is not always what we need to 
know in order to change practice 
283;284
. There is an information gap between what is 
needed to know and what is actually produced in a clinical trial.  Without access to 
current best evidence, a patient (who we are all at some point in our lives) is at risk 
because of out of date practice by health practitioners
19
. EBM should identify the 
best treatment, e.g. efficient and appropriate, to maximise the quality and quantity of 
life for a patient.  Clinical trials, generating information about treatment, improve 
medical practice but some of the barriers to practicing EBM are the poor access to 
information about trials as well as the volume and complexity of trials taking 
place
25;26
.  
4.8. A basic overview of clinical trial regulations 
It is important to provide a basic overview of the regulations surrounding clinical 
trials, as they have an impact on how clinical trial information is disseminated, not 
necessarily obvious this early on in the thesis but it will be clearer in the next chapter 
where I discuss factors that affect dissemination. The clinical research industry is 
strictly regulated by authorities, with directives and legislation for clinical trials
285
 
and for good clinical practice
286
 in the EU regulated by the EMA. Other regions, 
outside the EU, have their own regulations and guidelines, so international research 
and related activities such as marketing are controlled by the authorities in other 
countries, e.g. the Food and Drug Administration (FDA) in the USA.  There is other 
legislation that may apply in drug development such as manufacturing and quality 
assurance. Furthermore, the industry is heavily referring to several guidelines related 
to clinical research. The International Conference on Harmonisation of technical 
requirements for registration of pharmaceuticals for human use (ICH)
1
 brings 
together the European, American and Japanese regions to harmonise guidelines and 
requirements for clinical trials to avoid duplication of unnecessary research.  ICH 
has guidelines in four categories: quality topics (Q), safety topics (S), efficacy topics 
(E) and multidisciplinary topics (M) (Table 1). 
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Table 6: ICH guidelines topics 1 
Q 
"Quality" Topics, i.e., 
those relating to 
chemical and 
pharmaceutical 
Quality Assurance 
(Stability Testing, 
Impurity Testing, etc.) 
S 
"Safety" Topics, i.e., 
those relating to in 
vitro and in vivo pre-
clinical studies 
(Carcinogenicity 
Testing, Genotoxicity 
Testing, etc.) 
E 
"Efficacy" Topics, i.e., 
those relating to 
clinical studies in 
human subject (Dose 
Response Studies, 
Good Clinical 
Practices, etc.) 
M 
"Multidisciplinary" 
Topics, i.e., cross-
cutting Topics which 
do not fit uniquely into 
one of the above 
categories (MedDRA, 
ESTRI, M3, CTD, M5) 
 
 
In clinical trials, the 'E' topics are particularly important, relating to the process of 
conducting research and the use of the human subject. The 'E6' Good Clinical 
Practice guideline
167
 is the gold standard in clinical research.   
 
The Declaration of Helsinki
287, referred to as „the Declaration‟, first adopted by the 
World Medical Association (WMA) in 1964, is a statement of ethical principles 
relevant to the conduct of research involving humans or their data or material. These 
principles have been re-examined and updated several times, most recently in 
November 2008. One issue with the Declaration which has caused much debate is 
that the 1996 version of the Declaration is referred to in the EU Directives and in UK 
statutory instruments, which is against the advice of the WMA. The FDA refers to 
the 1998 Declaration.  This ongoing debate has recently led to the US FDA rejecting 
the use of the Declaration of Helsinki in April 2008
288
. The 2000 (with a 
commentary added in 2004) Declaration stated that industry should conduct trials 
with placebo with extra care, as it was considered unethical to refuse subjects access 
to treatment. Industry prefer testing against placebo because equivalence studies 
(drug against drug) are very expensive and time consuming, and it is easier to show 
that a drug is better than placebo than with existing therapies. Another issue with the 
Declaration has been that it was written by the WMA for physicians. Many people 
involved with clinical trials are not physicians and it is questioned whether or not the 
Declaration applies to all those involved in the research or only physicians. A recent 
WMA consultation promoted these issues for discussion.  
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Other events have shaped the changes in clinical research reporting (see figure 5) 
The CONSORT statement
289
 in 1996 was designed as a checklist to improve the 
conduct and reporting of Randomised Clinical Trials (RCTs).  In 1997 it became US 
legislation to register all trials involving “serious or life-threatening diseases” 
according to the FDA Modernization Act (FDAMA)
101
.  Clinicaltrials.gov, a clinical 
trial register, was set up by the US National Institutes of Health (through the NLM) 
as a requirement of this law. In 2003 a group of clinical research professionals and 
medical writers from around the world drafted the Good Publication Practice 
guidelines
290
, providing guidelines for authors and medical writers on how to report 
results when publishing clinical trials.  In 2004 GSK were fined for withholding 
clinical trial data from publication and to improve transparency set up the first 
commercial clinical trial registry on their website.  This controversial incident also 
sparked the International Committee of Medical Journal Editors (ICMJE) to publish 
the first ICMJE statement
251
 on registering clinical trials in a clinical trial registry as 
a pre-requisite of publishing a paper in an ICMJE journal. The pharmaceutical 
industry made recommendations via the Joint Position Paper
250
 in 2005, between 
IFPMA, EFPIA, JPMA and PhRMA trade associations that all their members should 
adhere to transparency standards.  The position paper agreed that all clinical trials 
should be registered (apart from exploratory studies, e.g. Phase I) and that results for 
all clinical trials (apart from Phase I again) should be made available within 12 
months of study completion. In 2008 this has been changed to include Phase I 
trials
291
. 
 
In 2005 in the US the Fair Access to Clinical Trials (FACT) Act
292
  was proposed 
suggesting the disclosure of results , but it never became law.  In the same year the 
state Maine in the US issued legislation
235
 that all trials carried out in Maine should 
publicly disclose information about clinical trials that are or have been approved by 
the FDA.  
 
It is unnecessary to list all regulations but bear in mind these main developments and 
other events that have had an impact on dissemination and which are determinants in 
how dissemination is changing. 
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4.9. Conclusion to Chapter 4 
Part 1 aimed to characterise and evaluate clinical trial information and the 
dissemination of that information. It answered the first research question „what is 
clinical trial information‟. It introduced the conceptual model which identifies the 
development lifecycle of a new intervention and outlines what key information is 
produced in clinical trials. A lot of information is produced throughout processes of 
clinical research and information is complex.  I have identified four components of 
information, generated in clinical trials, information about a clinical trial, 
information sought in a clinical trial about the intervention, results from clinical 
trials and the interpretation of findings. The information is interconnected and we 
need all these pieces of information as evidence behind a new intervention in order 
to practice EBM. If we do not have all the pieces, we may not know the relevance of 
a clinical trial in a particular patient population, and we may not be able to replicate 
a trial or compare it to another one.   
 
There are large amounts of clinical trial data, and with related information these can 
cover several thousand pages. This information is the raw materials of research 
which is never fully analysed or made available to others. Sharing data has been 
proven to be useful to several groups and for different purposes. We avoid research 
duplication, allow further research of existing data and there is a new expectation 
that data can be shared in repositories made available online. Sharing of data can 
improve research interpretation accuracy through peer review of data. Sharing of 
data is labour intensive and without standards in formatting, the interpretation of data 
can be very difficult. There are other issues affecting sharing such as informed 
consent, data protection, intellectual property issues and others. 
 
I briefly introduced clinical trial registries. There are ongoing discussions around 
what data should be shared, the value of sharing data and their format, e.g. 
summaries of clinical trials are easier to digest than raw data, and such raw data may 
harm if not interpreted accurately. Repositories can also act as a way to confirm 
ownership of research projects and protect research findings and allow stewardship 
of data to protect their quality. 
 
Korjonen: Clinical Trial Information  112 
 
The chapter introduced events, regulations, guidelines and legislation. There are 
many new initiatives in clinical research to make the process more transparent, e.g. 
registering in a clinical trial registry before the trial commences and provide some 
detailed information, e.g.  about the aims of the trial.  This chapter has summarised 
that information is disseminated, and reported or published in various ways, before 
and after clinical trials have ended. Next, part 2 will test the model by identifying the 
dissemination methods used, consider their effectiveness and what factors affect 
dissemination. 
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PART 2 
 
5. Chapter 5: Current state of dissemination and publication of clinical trials  
5.1. Introduction 
 
As we have seen in the Part 1, a lot of information is generated in clinical trials and 
the outcome of clinical trials form the foundation for evidence-based medicine. The 
goal of clinical research is improve health delivery. In order to improve health 
delivery reports of clinical trials needs to influence its audience and this can only 
happen if all research is disseminated. Reports of clinical trials are difficult to find 
and in some cases do not exist in the public domain. In order to improve health 
delivery practice this gap between research and health delivery must be addressed. 
This chapter reports the findings of the research looking at the methods of 
dissemination and factors that affect dissemination.  
 
Part 2 will test the constructed model from the last chapter by identifying the 
dissemination methods used, consider their effectiveness and what factors affect 
dissemination. The findings presented in part 2 are responses to the research 
questions what range of methods are used to disseminate clinical trial information, 
what factors affect how clinical trial information is disseminated, including attitudes 
and practices of dissemination and how effective a particular method is for 
dissemination. To respond to these questions research objectives included: through 
search experiments assess where clinical trial information is scattered, and how it 
was found, followed by critical analyses of the methods used for dissemination and 
the factors affecting dissemination. The responses to the survey of clinical research 
professionals were also analysed to understand practices of dissemination but also 
attitudes of clinical research professionals towards dissemination.  Through an 
analysis of publication policies and survey responses we will know more about 
factors that affect dissemination and this is compared to information found in 
literature reviews. The responses to this research questions will put the model to test 
in order to identify how we can make the information from the research process 
more transparent. 
Korjonen: Clinical Trial Information  114 
 
5.2. True access to clinical trial results 
According to Wood
106
 there are three types resources that meet the criteria of 
providing true access to clinical trial results, e.g. links to reports and published 
papers: PubMed or other bibliographic databases with indexes of publications, FDA 
analyses and documents on the FDA website (in Europe we would rely on our 
research ethics committees or EMA posting such documents) and existing industry 
databases such as the GSK results website
140
 or the PhRMA results database
141
.  
 
I will review the scatter of clinical trial information across many resources next in 
this chapter. 
5.3. Scatter of clinical trial information 
 
Information is disorganised and health professionals cannot find it when they need 
it
72
.  At the beginning of this research a research objective was to establish the 
methods used to disseminate clinical trial information and confirm the extent of the 
scatter of clinical trial information across many resources.  It was also suggested that 
a lot of information would exist online and a large part of research included 
investigating this possibility. 
 
As the model of clinical research information shows us (Figure 11 and Appendix A), 
a lot of information is generated throughout the research process some which remain 
confidential and will never be publicly released. Information can exist in print and 
electronic copy. 
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Figure 11: Clinical research process information generation and output 
 
What methods of dissemination can be found searching Google? 
The model does not give us a comprehensive picture of all the methods used for 
dissemination. Eysenbach et al evaluated the usefulness of Internet searches to 
identify unpublished clinical trials
120
. They found unpublished studies on 
departmental and institutional websites, personal web-pages of academic researchers, 
conference proceedings, announcements, press releases, unreferenced papers and 
patient recruitment sites. They concluded that authors will leave “digital footprints” 
on the web from various parts of the research process. To find out what types of 
resources contain clinical trial information in diabetes, a simple Google search 
experiment
xviii
 took place first in 2008 and then again in 2010 to compare the 
findings. 
 
 
 
 
                                                 
 
xviii Search took place 19 July 2008 
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The search conducted in 2008 
  
The search was limited to diabetes
xix
 clinical trials in the UK. The search terms used 
were: diabetes clinical trial (not using boolean operators or “”). The aim was to 
identify types of digital content and whether the content directed the user to a 
clinical trial register or repository. The search brought back a large amount of 
websites (n=504). The first twenty websites were selected for analysis (Table 7) 
because it is known that users rarely go beyond the first page of returned results
238
. 
Table 7: 2008 Types of websites discovered when searching for diabetes clinical trial in the UK 
using Google (n=20) 
Type of site n= 
Jobs (vacant) 2 
Commercial (money making) 3 
Journal/Magazine 3 
Personal website (patient blog) 1 
Information resource (database/portal) 2 
PR/news 9 
Total 20 
 
Five resources were removed as proved duplicates leaving 15 resources for analysis.  
 
The following information was gathered about each site: 
 Institution or organisation behind the site 
 Format (e.g. document, portal, journal) 
 Date of last review (if provided) 
 Reading level grade (SMOG) 
 Does the site list or attempt to forward the user to clinical trials, e.g. a 
repository/clinical trial register? 
 Focus of the website. 
 
                                                 
 
xix
 Continuing with the obesity/diabetes theme of the research 
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Table 8:  Types of resources found in Google search experiment 2008 
 
 
Reading levels (SMOG) 
A SMOG calculation of each site was performed
xx
 to reveal level of education 
expected to read and understand the content found in the search in 2008. The SMOG 
grades reveal that all sites that could be measured expect some American college 
level literacy
xxi
. Two evidence-based sites scored above 16 which expect university 
level literacy.  Not all resources were measurable if insufficient textual content was 
provided. 
 
The results from 2008 show that there is a mixture of websites that contain the words 
diabetes clinical trial, e.g. job vacancies, press releases, magazines, news sites etc. 
Only three sites referred the user directly to a site that contained information about 
clinical trials. This shows that it can be quite difficult for a user to search and find 
relevant websites, if they are looking for diabetes clinical trials. 
 
The search conducted in 2010 
The same search as the one in 2008 was conducted
xxii
  in 2010 limiting results to the 
                                                 
 
xx
 http://www.literacytrust.org.uk/campaign/SMOG.html 
 
xxi Since this calculation was performed, a UK equivalent SMOG calculator has been introduced: 
http://shop.niace.org.uk/readability.html  
xxii 11 September 2010  
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UK.  
Table 9:  Types of resources found in Google search experiment two years later (n=20) 
Insitution Format Link to clinical trials Type of site
Diabetes clinical trial unit HTML yes Organisational website
UKCRN diabetes clinical trials HTML yes Not for profit research
Diabetes Research Network HTML yes News story
Diabetes Research Networking HTML yes Patient information
NHS Choices HTML yes Patient information
Diabetes Research Network HTML yes Patient information
Veeda Clinical Research HTML no Commercial clinical research
Financial Times HTML no News story
Next Generation Pharmaceutical HTML no News story
Biocompatibles HTML no News story
British Geriatrics Society PPT no Presentation
Daily Mail HTML no News story
Juvenile Diabetes Research FoundationHTML yes Patient information
BMJ Evidence HTML no List of references
NHS Choices HTML yes Patient information
UKCRN  HTML no News story
Medical Research Council HTML no News story
Nottingham Clinical Trials HTML yes Patient information
Times Online HTML no News story
Trials Journal HTML no Journal
 
Table 10: 2010 Type of websites found in Google search 
Type of site n= 
 Presentation 1 
Journal/Magazine 1 
Organisational website 3 
Information resource (database/portal) 7 
PR/news/newspaper 8 
Total 20 
 
Comparing findings in 2008 with 2010 
Not surprisingly the results are very different from the search in 2008. Two years 
later, Google has become more sophisticated in its search mechanism and in general 
clinical trial registers have also become more prominent on the web. There were 
333,000 relevant web pages to the search compared to only 504 in 2008. This shows 
that the information available on the Internet about diabetes clinical trials is 
increasing rapidly. 
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When comparing the type of information that is found, the information found in 
2010 is much more geared towards providing public information about clinical trials, 
whether to patients or professionals, and the content brought back is much more 
relevant to what a user would expect to see when searching for diabetes clinical 
trials. When the search results were brought back, Google first of all provides a top 
level list of scholarly articles that are relevant as well as sponsored links at the top of 
the page and commercial links (advertisements) to the right. 
  
Nine websites in 2010 compared to only three in 2008 provide information or links 
to clinical trials that are recruiting, or a listing of clinical trials. 
5.4. Resources that provide information about clinical trials: a map 
A more comprehensive picture of the scatter of clinical trial information across 
various resources is shown in figure 12. This list, or map, has been compiled by me 
throughout a number of years working in the industry. This research has identified 
that a few of these stand out as being key resources for individuals looking for 
clinical trial information.  
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Figure 12: Map: Scatter of clinical trial information across a number of resources 
 
Looking at the resources in figure 12 we see a mix of formal and informal 
dissemination, or communication, methods. Journals and books are considered 
formal communication modes
293
. It is also known that new communication methods 
developed within the Internet are blurring the formal and informal methods. Young 
et al.. and Halliday argued that the distinction between raw data in grey literature 
and peer-reviewed articles can be difficult
52;294
 in particular in the digital 
environment where information presentation can make it look as though it is a 
formally published piece of work and from a trustworthy source. Without a 
definition; the quality, integrity and authentication of electronic scientific 
•Books 
•Journals, print or open access 
•Promotional/educational material by pharmaceutical companies or health professionals 
•Advertising on the radio, on TV, in magazines 
•News services, e.g. BBC, newspapers  
Media or Print 
•Portals/Databases/Pipeline sources , e.g. Medscape, Medline, NHS Direct, Doctors.net 
•EBM sites, e.g. Cochrane Reviews, Clinical Evidence 
•Online shops/pharmacies 
•Product websites, e.g. a drug promotional or information site 
•Clinical trial registers (CTRs), e.g. Clinicaltrials.gov 
•Search engines, e.g. Google, Yahoo 
•Open access journals, e.g. PLOS, Trials, BMJ open archive 
•Advertising/Banners, e.g. by pharmaceutical companies or pharmacies 
•eMail lists/newsletters 
Internet or e-methods 
•Physician 
•Friends/colleagues 
•Health service, e.g. nurse, pharmacist, dentist 
•Discussion forums on the web with personal experiences 
People 
•Library, eg public, hospital or organisational 
•Patient organisation, e.g. The Stroke Association, Diabetes UK 
•Research council, e.g. MRC, Wellcome Trust 
•Pharmaceutical companies 
•Repositories, e.g. university or PubMed Central 
Organisations 
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information will be difficult to determine
44
.  Examples of material that is published 
on the web include conference proceedings, preprints, theses and reports. It is clear 
to state that the electronic environment makes these resources more accessible and 
according to Halliday fulfil some of the functions of a scholarly publication more 
effectively for timely communication
52
.   
5.5. Current methods used in dissemination 
This section will cover the methods used for dissemination. This is different from 
resources that aggregate information and re-present it in another format, from an 
access point of view.  The clinical research professional decides on an appropriate 
method to disseminate suitable for his audience. Information of course subsequently 
ends up in other forms of resources, secondary sources, e.g. bibliographic databases 
such as Medline that provide abstracts which will not be covered here. There are 
some resources that fit into both categories, a primary method of dissemination and a 
secondary source, e.g. an aggregating resource, such as news services and pipeline 
information, which will be covered here.  
Journals that disseminate clinical trial information 
 
According to Griffin and O‟Grady70 scientific journals are a key source of 
information on medical research. Published papers are used as original reference 
sources in pharmacopoeia, advertisements and promotions
70
.  The journal has existed 
for hundreds of years as a tool to disseminate research findings and opinions and has 
been a key component of the scholarly communication process.  Original research 
data is usually presented at conferences and subsequently published in peer reviewed 
journals
152
, although we know that not all conference presented data is subsequently 
published
153;200;295
. Each year more than two million research articles are published 
in medical and scientific journals
69
. There are many journals, around 17,000 
biomedical journals in publication with 4,000 of these indexed on Medline
49
, of 
these around 114 journals specifically publish influential clinical trials
296
. It can be 
argued that there is a need for more journals as research areas are growing and 
separate themselves away to create their own topic areas.  
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Bibliometrics to establish core journals 
To establish which core journals are used for publishing clinical trials in obesity and 
diabetes, a bibliometric study took place using Bradford’s law243.  The Bradford 
distribution model shows how a subject‟s literature is distributed among journals, 
with a core and further scatter
14
. In knowing the core journals that cover our subject, 
it may help to understand the type of journals that cover our topic and to see if the 
core set is large or small. Data was analysed from Scopus. Using Scopus, a search 
was conducted for articles published in journals on the subject of clinical trials 
narrowed down to obesity and diabetes published in 2008 resulted in 557 articles 
covered on Scopus. This study was not looking at growth of literature in this topic 
area but aiming to establish the core set of journals published in and the 
characteristics of those journals. 
 
 
 
 
Figure 13: Bradford distribution of articles to journals in Scopus with five zones identified 
 
 
 
 
 
Korjonen: Clinical Trial Information  123 
 
Table 11: Data table from Bradford Analysis of core journals in obesity and diabetes clinical trials 
y-axis x-axis
Journals Articles Total Cumulative articles Cumulative journals Log journals
1 19 19 19 1 0.000
1 17 17 36 2 0.693
1 15 15 51 3 1.099
1 13 13 64 4 1.386
4 12 48 112 8 2.079
1 10 10 122 9 2.197
3 8 24 146 12 2.485
4 7 28 174 16 2.773
3 6 18 192 19 2.944
9 5 45 237 28 3.332
13 4 52 289 41 3.714
33 3 99 388 74 4.304
81 2 162 550 155 5.043
7 1 7 557 162 5.088  
 
 
Although there are a large amount of journals that publish the results of clinical trials 
in diabetes and obesity, a very small amount of core journals (n=8) account for 112 
articles (20%) of published clinical trials according to the Bradford analysis done for 
published clinical trials in obesity and diabetes found in the database Scopus (Figure 
13 and Table 11). We can see that 557 articles were published in 162 different kinds 
of journals. 
There is a pattern in numbers of journals: 8: 19: 41: 74: 155, meaning the Bradford 
multiplier is 2; the number of journals has to double to add another 100 articles. The 
analysis reveals a typical Bradford curve which suggests that it is a well developed 
field. Had the graph been linear the topic is still in development.  
 
Table 12: Five zones of journals identified 
 
Journals Articles % of refs
Zone 1 8 112 20.1
Zone 2 19 80 14.4
Zone 3 41 97 17.4
Zone 4 74 99 17.8
Zone 5 155 162 29.1  
 
The core journals (zone 1) that were identified in the Bradford analysis can be seen 
in table 13 below. 
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Table 13: Eight core journals (zone 1) identified in Scopus (112 cumulative articles) and impact 
factor 
Journal title Impact 
factor (IF)  
Diabetes 8.398 
Diabetes Care  7.349 
Diabetes Obesity and Metabolism  4.126 
Current Atherosclerosis Reports  1 
Current Diabetes Reports  1.56 
Clinical Cornerstone  Unknown 
Obesity  2.762 
Expert Review of Cardiovascular Therapy  2.991 
 
 
A second study examining the journal as a tool of dissemination was conducted in 
PubMed to compare with the findings of the Bradford analysis.     
 
The 80 abstracts found were published in 58 unique journal titles. Some journals 
were specialist in the cardiovascular, diabetes and lipids areas. Six journals 
published three or more of the abstracts (n=25, 43%) (Table 14) of which three are 
society or association journals and these have higher impact numbers than the 
commercial publishers‟ journals.   
Table 14: PubMed study of core journals that published ≥3 articles in the subject of diabetes and 
obesity clinical trials 
 
Articles 
(n=) 
Journal title Impact 
factor (IF)  
Eigenfactor 
metric 
influence 
score 
Publisher 
6 Diabetes Care 7.349 2.508 Am Diab Ass 
5 Obesity  2.762 0.845 Nature  
4 Diabetes  8.398 2.989 Am Diab Ass 
4 Diabetologia  6.418 2.180 Springer 
3 Am J Clin Nutr.  6.740 2.246 Am Soc for Nutrition 
3 Diabetes Res Clin Pract  1.888 0.572 Elsevier 
 
The Bradford analysis suggests that researchers publish the majority of their clinical 
trials in eight core journals, three of which were also identified in the PubMed 
analysis. I can therefore identify three journals as being core in publishing clinical 
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trials in obesity and diabetes: Diabetes Care, Obesity and Diabetes with impact 
factors 7.349, 2.762 and 8.398. These three journals are subject specific and not 
broad-based healthcare and they have differing impact factors, one low and two 
higher. Therefore these research findings confirm findings of McKibbon
92
 where 
healthcare disciplines such as nursing, internal medicine, general practice and mental 
health publish in small subsets of journals but do not concur with the finding that 
many important articles for all disciplines were published in broadbased health care 
journals. However, further analysis of the Scopus data in the latter zones (Table 13) 
may reveal more broad-based healthcare journals. This PhD study findings are more 
in line with the those of Falagas et al. who found that the majority of articles were 
not published in journals with the highest impact factor
82
 and Barbui et al. who 
found that high impact factor journals do not publish the highest quality RCTs
297
, 
where quality was measured by using the Jadad instrument
298
 and the Cochrane 
quality criterion and Costa et al. who reached the same conclusion looking at 
physical therapy clinical trials
80
. 
There are some limitations attached to these two studies. I selected Scopus initially, 
as Scopus provides useful citation tracker information and I performed the Bradford 
analysis based on this data. I then wanted to search PubMed, which I consider a 
more comprehensive bibliographic database, to see if the results were similar and to 
confirm my findings in the Scopus search. I chose not to run the Bradford analysis 
on the dataset from this search, but to use Excel to analyse the data.  I compared 
numbers of articles between journals (see Methodology). Comparing the two results, 
three journals came up in both searches as core for the topic. I used this as an 
confirmation of the results of the Bradford curve. 
Abstracts 
The study of the abstracts found in the PubMed search also identified some 
interesting details about published clinical trials. As has been discussed earlier, there 
is no agreement on terminology within clinical research. When searching for 
published literature containing information about clinical trials various different 
subjects headings are used to identify papers. In the Pub Med study out of the 80 
studies, 45 (56%) were key-worded as Randomised Controlled Clinical Trials. The 
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rest were marked up as clinical trials, multicenter trials or comparative studies and 
sometimes a combination of these terms. 
 
Sometimes the abstract is all that is read and it does not always contain all the 
necessary information
73;147;299;300
.  Abstracts should have comprehensive structure 
and metadata attached to make it easier to find and ready.  
 
The study of abstracts within this thesis revealed the lack of standardised content 
required in abstracts. ICMJE declared that the publication of an abstract of around 
500 words is not considered pre-publication
176
 and that such abstracts can be 
disseminated as the researcher wishes, but many journal abstract vary greatly in 
length and content. Other abstracts are often published at events where researchers 
present findings from clinical trials and these abstracts make their way to the press 
and other aggregated news sources who report on information provided to them. It is 
obvious that although some recommendations exist for the format and content of 
abstracts, e.g CONSORT
301
 or IMRAD structured
xxiii
, many journals and event 
organisers have their own guidelines for what should be in the abstract rather than 
using a set standard. A study reported that only 66% (160/243) articles reported a 
source of study funding 
69
.  Furthermore, papers that disclosed funding sources were 
of higher quality than those that did not, where quality was assessed based on journal 
circulation, impact factor, citation rate and journal acceptance rates. Funding should 
be considered when assessing the usefulness of an article 
69;302
.  It has been identified 
that abstracts often underreport in some aspects of a clinical trial
145;155;157;303
 but most 
abstracts analysed here provided useful information on methodology, results and 
conclusion of the trials.  
 
In the PubMed study, only four out of 80 (5%) abstracts listed clinical trial 
registration numbers. This makes it difficult for people reading abstracts knowing if 
the trial was registered or not. If trials are registered more information about the 
study can usually be found in the clinical trial registry, including data and other 
published papers. By providing the registration number we can also more quickly 
                                                 
 
xxiii
 IMRAD stands for Introduction, Methods, Results And Discussion  
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spot duplicated papers published about the same trial, or related articles with data 
from the same trial. Some of these published clinical trials may of course have taken 
place long before it was a requirement to register all trials, e.g. phase I and medical 
device trials, in which case a registration number may not exist, but then this should 
be noted. 
 
Abstracts should also report on all aspects of the trial
145
.  Some of the abstracts 
declared funding, but not all journals collect this information from authors and the 
information provided in the citation did not make it clear if a study was 
commercially sponsored or not. Declaring funding is an important aspect of making 
research transparent and would be helpful if provided in abstracts. 
Access to full text articles 
Access to full text journal articles has been a long debated issue in medicine with 
many institutions, organisations and other bodies getting involved in the 
discussion
71
. It is such a large issue that it would be impossible to discuss it in its 
entirety within this thesis. This thesis concerns itself with it by analysing decision-
making of methods used to disseminate clinical trial information. The decision-
making process may include access issues, e.g. access for developing countries, 
institutional guidelines determine choice etc. The open access movement
180
 as we 
refer to it as has made access to clinical trial information easier from a user point of 
view, but possibly more difficult for a researcher who may have to pay to publish. 
This move from „user paid‟ to „author paid‟ model has made journals more complex 
for users who have to find out if they have access to a paper or not at the point of 
access. In the analysis of the PubMed abstracts, only 28/80 (35%) articles offer free 
full text access.  Five (6%) articles did not carry a link to an electronic version or 
webpage of the journal and 47/80 (59%) articles asked for a subscription or pay 
online.  
Journal – fit for purpose? 
We assess fit for purpose in journals by looking at how quality is defined. The 
quality of journals is identified by articles that have higher citation rates and high 
impact factors, higher circulation and low acceptance rates
69
.  
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Journals improve the quality of research papers using three methods; instructions to 
authors, peer review and the editorial process 
77
. 
 
Improved publication guidelines and editorial standards within journals are attempts 
at improving the quality of papers published in journals. Journal editors have 
changed requirements for acceptance of manuscripts to include the transparency of 
authorship, e.g. declaring authors and acknowledging other contributors. This will 
lead to less cases of ghost-authorship and guest-authorship which has been said to 
harmful to the public and institutions and the paper cannot be trusted or accurately 
judged 
172;173
. 
 
The usefulness of peer-review is a debated area within publishing. Peer-review has 
long been used as a way to assess quality and accuracy of a paper although even 
fraudulent papers have made it through the peer review system
177;178
 and there is no 
evidence that peer-review is improving quality
77;179
.  Peer review, although not 
perfect, is the best option for the moment of ensuring quality of papers
183
 although 
this is disagreed by others
69
. An issue with peer-review is that it‟s incredibly slow 
and there has been recent debate over reviewers remaining anonymous, when in fact 
conflict of interest may affect the peer review process
184
. 
 
The journal model  with articles that are trying to please every type of reader with 
the same length articles not providing all information that may be required for those 
with needs for information is not working
74;98;304
 and it has been said that it is time 
that journals change their role in disseminating clinical trial results
74
. Articles are 
restrictive in nature; “confusing tables, use acronyms, sometimes lack 
methodological rigour, do not discuss findings in broader context and this is 
frustrating”73. Nevertheless, the journal is considered the second most important 
resource to some health professionals
305
. Journals are also important as evidence 
where published papers are required to form evidence, such as in assessments of new 
technology or treatment.  Journals try to be useful tools for health professionals in 
their practice but have little success in changing practice
49
 and journals have rarely 
been tested for their effectiveness in conveying information
306
. It has been suggested 
that the journal can be replaced by systematic reviews and institutional repositories 
that deposit papers written by scholars
294
.  
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Even in 1974 it was stated that the role of the journal is changing and that the 
publication speed is of vital importance to those conducting research
307
. Publishers 
of medical journals should explore co-operation so that findings of clinical trials 
could be shared, reducing the „scatter‟ of medical information, and journals should 
only publish well-conducted clinical trials providing the clinical bottom-lines
49
.  
Journals could publish summaries of pre-appraised evidence and evaluative research 
articles representing higher levels of evidence with potential to change practice
49
.  
In order to survive, publishers need to adapt to new formats and respond to the 
digital developments
183
. 
News services and pipeline information 
The news media plays an important role in which to make drug development 
information available quickly to a wider audience. The news media are an important 
source of information about medical research for the public and even some 
physicians
308;309
. The public and many physicians learn about new medical research 
through media rather than medical journals133;308.  The news distribution can have a 
positive or negative impact upon sponsor companies, the researcher or medicines 
themselves as well as journalists with benefits if the story is sensationalised
310
. An 
analysis of media coverage showed that pharmaceutical scandals can impact research 
efforts even when a study isn‟t linked to the scandal itself311. Therefore, media 
coverage of research can also set the agenda for future research.  
 
Prior to 1960 the press didn‟t report as widely on medicine138. However, over the last 
thirty years the public interest in medicine has changed
40
. The New York Times 
increased its coverage of medical articles by 250% between 1968 and 1978 and 
425% between 1969 and 1988
40
. Journal editors began to see that media coverage is 
valuable to attract attention and increase subscriptions, building brand recognition
139
.  
Providers such as NHS Choices, NHS Evidence and Bandolier (an independent 
journal) disseminate information around new treatments and disease specific 
research. 
 
Drug development information is a commodity and has for many decades been sold 
through subscription services such as drug pipeline resources, e.g. journals, abstracts 
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or electronic news feeds to the sectors that need drug information for a variety of 
reasons such as competitor scanning, current drug development and in the case of 
decision-making as evidence for efficacy.  Such resources have grown and are more 
freely available via news/pipeline websites or portals, e.g. Drug Discovery News
312
.  
Pharmaceutical industry pipeline sources can be searched for information about 
drugs in development but these sources contain non-standardised information and 
sometimes very little data making it difficult to search
103
. Pipeline sources are still 
used to find out about products undergoing development, these sometime contain 
information not available on a clinical trial registry. The main reason for this may be 
that there is pre-clinical information that exists prior to clinical trials. Pipeline 
sources are often subscription based although some exist free on the Internet. This 
type of information is expensive to produce and highly valued in particular for 
competitor information. 
 
The providers of such information often make income through other means such as 
publishing journals, sponsorship and advertising. Medical journals have been a 
primary source of medical information to the pipeline resources but also to news 
media. Clinical trial registries are now becoming an alternative resource for both 
those seeking the information and those making it their business distributing it.  
 
These days the market is flooded with press releases, sometimes deliberately vague 
or even misleading to get media attention
40
 and some do not provide sufficient 
information
308
. Data in newspapers are presented in such a way that the findings are 
exaggerated136;313 and according to Woloshin and Schwartz the journal press releases 
are prone to exaggeration
133
. Seven out of nine medical journals routinely issue press 
releases and only 23% (n=29/127) of the press releases included study limitation and 
65% (n=83/127) included results
133
. In a study
313
 of news stories reporting on 
research presented at scientific meetings, it was found that the news items often omit 
basic study facts, e.g. study results, study design and study size. Another study found 
that press releases report basic study details, usually preliminary findings presented 
at conferences, but often do not disclose study limitations
314
. It is suggested that 
press releases should put results into context, provide study limitations, reveal 
author‟s competing interests and provide absolute results133. Medical journals should 
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ensure quality of content of press releases as physicians and the public often find out 
about new medical research through the media
133-137
. 
 
The media report topical drug news with an impact on lifestyle rather than with 
medical implications and journals issue press releases that they know the journalists 
will be interested in
40;133;313
.  Bad news is more likely to be published in newspapers, 
and in particular women‟s health issues315.  However, a study316 of US reporters 
found that more than eight out of ten reporters have no training in interpreting health 
statistics and one third said that understanding health issues was „often‟ or „nearly 
always‟ difficult.   
 
Newspapers can generate false hope and unwarranted fears
310
. In 2002 the hormone 
replacement therapy (HRT) scare broke in the media of HRT increasing health risks. 
A study examined the newspaper reports on the topic and found that the stories 
published were accurate and reported consistently
317
. The media generally get their 
stories from press releases issued by sponsors and journal editors and the study 
highlighted the importance of planning strategies when communicating research 
results to the media, and in particular using reporting intermediaries to translate the 
science to plain language.  One important finding in the study was the lack of 
communication and guidance directed specifically at medical practitioners
317
. 
Advertising  
Advertising over-the-counter (OTC) drugs, e.g. painkillers, cold and flu treatments 
etc., in mass media reaches a large number of people. OTC adverts tend not to 
provide much information about the mechanism of action, details of clinical trials or 
information of educational value
318
. There is also some indication that 
advertisements in medical journals aimed at medical professionals make promotional 
claims that are not substantiated with references
319
.  Clinical trials are also advertised 
through media, in particular on the radio asking for volunteers for new treatments. 
 
Industry has long been blocked to advertise prescription drugs and claims to patients 
in the EU due to EU directive 2001/83/EC, echoed in the voluntary Code of 
Practice
257
 in the UK. There is a discussion to allow for more advertising and 
provision of information by the pharmaceutical industry to the public in the EU
320
. 
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Only the US and New Zealand allows direct to consumer advertising (DTCA) at this 
point in time.  
 
A link has been identified between published papers and drug promotion 
76;321
. It has 
been suggested that publishing papers is merely another method of promoting a 
particular drug, in particular if there is the opportunity to publish a supplement of 
inferior quality to parent journal
322
 which can be given to healthcare professionals in 
marketing efforts.  Some journals allow the placement of an advert in the same 
journal as the results article making marketing claims
323;324
.  
 
There are arguments for and against the industry providing advertising and 
information to the public. As we have seen, the industry holds a great deal of 
information and is able to offer useful information on its product to information-
hungry public. The European Commission has stated that there is a lot of varied 
quality information provided by relevant authorities throughout the EU and as the 
public turn to the Internet the information is not reliable and not always 
understandable
325
.  However, it has been argued that the information will not be 
objective. Those against the industry advertising to the public suggest two other 
options: an expansion of information offered by community pharmacists and more 
patient-to-patient information offered via a controlled website such as 
healthtalkonline.org
xxiv
 
; 326
, offering patient experiences combined with advice from 
health professionals. In 2008 the European Commission ran a consultation on DTCA 
with the result that a proposal has been submitted to the Parliament for decision to 
provide detailed guidance on what DTCA is allowed and identify types of 
information dissemination methods appropriate for member states, in particular 
provide a distinction between advertising and provision of information where this 
could be blurred. 
The physician-patient relationship 
People make treatment choices themselves
123;327
. Some personal published accounts 
exist that provide some insight into the behaviour of individuals looking for trial 
                                                 
 
xxiv http://www.healthtalkonline.org/ Previously known as DIPEx [Accessed 7 January 2012] 
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information
327;328
 for personal use or to pass on to someone that they know. It has 
been suggested that the primary source of information about clinical trials is the 
patient‟s physician121;122.  
 
Physicians are generally aware of existing clinical trials or may know which 
companies are conducting relevant clinical trial, should a patient ask. There is 
evidence to show that patients now turn to the Internet rather than a health 
professional
123
 for medical information, including treatment decisions. Patients also 
prefer conversing with a health professional via a portal or email
124
. In fact, a study 
shows that physicians feel uncomfortable speaking to patients about clinical 
trials
121;125
.  Each individual has its own unique information needs, which may 
complicate how well physicians are able to communicate information about clinical 
trials to them
121
.  As our map of information scatter shows (figure 12 in section 
1.45), and the result of our Google searches indicate (section 1.44), a lot of 
information about clinical trials can be found on the Internet and there are many 
websites that provide patient information on clinical trials.   
Pharmaceutical companies and provision of information 
Pharmaceutical companies through their medical information or scientific 
departments have the expertise of dealing with patient enquiries about their personal 
medical condition, although in the UK it is practice to refer such individuals to their 
physician as discussing personal medical conditions with patients is prohibited by 
the Code of Practice
257
.   It is possible however to provide the patient with a 
summary of product characteristics (SmPC) or patient information leaflet, although 
these are also available via the web, e.g. EudraPharm
329
 maintained by the EMA. 
Information to patients on clinical trials is rarely provided directly, but it is 
suggested to the patient that they discuss requirements with their doctor to whom 
information can be sent or patients are recommended to search for suitable trials on 
clinical trial registries. 
 
With the advent of the Internet, there was scope for pharmaceutical companies to 
provide more information to patients via a website.  An example of such a website is 
Amgen
330
.  Pharmaceutical companies use the Internet to set up product specific 
websites, where allowed, with sections separated for health care professionals and 
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for patients, and they also sponsor educational patient websites as well as some 
public health initiatives.  A current example of how the pharmaceutical industry 
helps with disease awareness activities is via sponsorship of the FAST stroke adverts 
in the media
331
. The adverts together with educational material offered by The Stroke 
Association are sponsored by GE Healthcare. GE Healthcare is a supplier of 
diagnostic imaging equipment used to detect stroke amongst other things. 
 
In 2007, the European Commission suggested that industry could have a greater role 
in provision of information to patients
325.  Although the term „advertising‟ isn‟t used 
in the plans, the Commission suggest that information should be objective.  The EU 
consultation launched in 2007 was met with both negative and positive comments, 
generally it was felt that the industry could not be expected to provide balanced or 
comprehensive information and that the information will be more in the form of 
advertising. A survey in the US on public perception of advertising showed that 
many individuals assume that information in advertising is checked by some 
agency
332
 which of course is not the case. However, we know that in the UK the 
Code of Practice provides guidelines with regards to product promotion including 
the Internet and provision of information to the public. There are of course 
difficulties in regulating information on the Internet with an abundance of product 
information of drugs and treatment in existence and accessible to all regardless of 
who they are and where they live.   
  
The pharmaceutical industry provides much information to physicians on new and 
existing drugs.  Information is delivered in different formats, e.g. mailings from 
pharmaceutical companies that go out to physicians
308
, educational events on 
therapeutic areas often in combination with a drug launch, visits from medical 
representatives who bring clinical papers and a detail aids, conference posters and 
presentations and promotional material providing some basic information on a drug. 
Much of this type of drug promotion has undergone change.  As drug prescribing 
was done less by individual physicians and more by organisations such as NICE, 
there is no need for a medical representative to sell product efficiency to a physician 
in order to get prescription. However, change of Government in England in 2010 has 
seen yet another change in responsibilities. Although NICE retains its role in 
assessing products and therapies and issue treatment and prevention guidelines, the 
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general practitioner through consortia has resumed the role of commissioning 
services within the practice from 2013.  
 
There has also been much discussion around pharmaceutical sponsorship of 
educational events
333;334
.  The discussion has led to PhRMA limiting pharmaceutical 
sponsorships and separating such funding decisions from marketing decisions
335
.  
This was followed in 2008 by Pfizer announcing it will no longer sponsor profitable 
third party companies running courses, but will continue to sponsor medical school, 
medical society and teaching hospital courses
336
. 
 
There is no doubt that the Internet and the invention of clinical trial registries have 
revolutionised the way in which information about clinical trials can be found.  The 
pharmaceutical industry provide clinical trial summaries on their websites and some 
companies have their own clinical trial registries, or databases, showing what current 
clinical trials are available and what the results were of previous trials which allows 
the physician and patient to discover suitable trials and potential treatments more 
easily
140
.  Still, in the EU there needs to be better and shared standards on what 
information, where and how, pharmaceutical companies are allowed to provide 
information publicly. 
Patient organisations and charities 
Patient organisations and charities are ideal places where details on patient and 
public information needs can be assessed and responded to. Medical research 
charities put great effort into improving public understanding of science, including 
clinical trials, and other charities provide information into public health, aiming to 
prevent disease but also inform regarding treatment. Many research charities and 
patient associations in the UK are members of the Association of Medical Research 
Charities (AMRC). The organisations inform on different scientific developments, 
provide patient information leaflets, publish blogs and involve the public in research 
activities. 
 
Without patient involvement in setting the research agenda, researchers could not be 
sure the research conducted is relevant to patients‟ needs337.  Unfortunately not all 
patient associations, or charities, are consulted on research projects. The European 
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Cancer Patient Coalition  (ECPC) has suggested a model of collaboration between 
industry, academia, patient groups and the European Health Commissioner
337
.  The 
UK „Best Research for Best Health‟ report also outline plans to involve patients 
groups in medical research
338
.  Many patient organisations, like Diabetes UK, fund 
research and also provide information to patients about clinical trials. In the UK the 
research networks supported by the National Institute for Health Research provide 
useful information about clinical trials to the public, e.g. the Diabetes Research 
Network website
339
. In the recent years a large amount of websites have been built 
aimed at the public to provide a wealth of information on health related issues, 
including clinical trials, e.g. NHS Choices
xxv
 and aimed at professionals, e.g. NHS 
Evidence
xxvi
. 
The library 
Patients use libraries to find medical information
340-342
. The public library is a trusted 
public institution where people go for information and could play an important role 
in the provision of health information
341
, in fact, partnerships between public 
libraries and the NHS exist
xxvii
.  For public librarians it is a challenge to organise and 
provide patrons with evaluated information
340;342;343
. Although researchers do not 
disseminate information with libraries in mind, information that they produce such 
as clinical summaries, patient information and healthcare professional information 
are disseminated via electronic libraries, portals, directories and evidence-base 
websites, which are undoubtedly found by library patrons and staff. 
 
In the UK the Clinical Knowledge Summaries (CKS) website
344
, formerly known as 
Prodigy, aims to provide some medical information on behalf of the then called 
National Library for Health, now called NHS Evidence. As can be seen here, there 
are rapid changes in ownership and titles and it can be difficult to remain up to date. 
It is not exactly clear how the public use these websites and whether they speak to 
their physician about information that they find by using their websites. 
                                                 
 
xxv http://www.nhs.uk/Conditions/Clinical-trials/Pages/Introduction.aspx  
xxvi http://www.library.nhs.uk/KnowledgeManagement/page.aspx?pagename=CONCLINTR  
xxvii http://www.yorksandhumber.nhs.uk/news.php?id=282 [Accessed 19 January 2012] 
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Many hospitals have a medical library or education centre that supports the health 
professionals who work there but also have an active involvement of providing 
information to patients and help with collating information
345
. In England the NHS 
Evidence website also attempts to bring together relevant information for 
professionals.  Trials of patient kiosks
346
 in health surgeries and hospitals provide 
patient information through electronic means although these are not standard in all 
surgeries. In the US, information is also being embedded in the electronic patient 
record that can be downloaded by the patient
347
. There have also been trials of 
telemedicine where information is disseminated via TVs or mobile devices. 
Information dissemination via mobile devices is on the rise as it is the method most 
easily available at reasonably low cost to the user. 
 
The James Lind Library, an online library, was set up to improve public and 
professional knowledge on fair tests of treatments in healthcare. It has a unique 
library into the history of clinical trials and provides documents and research via the 
website
348
. 
 
Unfortunately little published information exists specifying the types of questions 
patrons have when visiting libraries. Although, it is likely that patients ask for 
information on clinical trials as many patient organisations provide information on 
their websites about clinical trials, indicating that it is a frequently asked question. 
The Internet – information about clinical trials online 
The Internet helps resource discovery and can be used to publicly disseminate 
clinical trial information. The challenge lies in trusting information posted on the 
Internet. Information technologies are ideal tools for disseminating information but 
“they dislocate our ordinary ways of judging one another‟s claims and deciding 
where to place our trust”223. The Internet houses a growing number of diverse 
resources related to clinical trials that can be accessed by anyone. With the 
proliferation of health information on the Internet it is likely that the public, as well 
has health professionals, try to find information about clinical trials on the Internet. It 
is thought that 79 percent of Internet users have actively searched online for 
information of a health topic
129
. It is estimated that 12.34 million health-related 
searches are conducted worldwide every day on the web
130
. In 2004, 23 percent of 
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Internet users have searched for experimental treatments or medicines compared to 
18 percent in 2002
129
. Online access to information about the availability of clinical 
trials creates an expectation that the information will be comprehensive, because the 
web is not restricting content or forces formats like journals do.  There has also been 
an expectation of improved subject recruitment into trials with more online 
information available 
110
.  
 
There needs to be more research into where on the Internet patients go to find 
information about health, medicines or treatment and what kind of information that 
they download. The study for this thesis into what resources can be found when 
searching Google shows that patient information, news and clinical trial portals 
appear high on the results list. We know that website data and statistics show 
increased visitors numbers, e.g. in 2009 Clinicaltrials.gov has 40 million page views 
per month with 50,000 visitors daily
xxviii
, and there are also increased visitors to free 
online databases like PubMed.  Between Jun 2007 and Feb 2009 interactive searches 
on PubMed jumped from 54,663,426 to 67,406,898
xxix
.  It is likely that there is a 
steady increase as individuals have more readily access to computers but we do not 
know who these individuals are and their reasons for going online.   
 
A study tried to establish how often patients of a rheumatology clinic search for 
health information on the Internet
123
. Thirty-seven respondents (27%) out of 138 
patients had used the Internet for medical information in the past year. 83 percent 
had found useful information, 54 percent found information that they had not 
previously known and 31 percent preferred using the Internet to their doctor or nurse 
for information (see also the doctor-patient relationship p.129).  
 
Physicians use the Internet to find medical information too. According to one study 
physicians access targeted sites rather than search engines
131
, e.g. research databases, 
medical journals and portals. Other research shows that physicians are increasing 
their use of the Internet to find clinical information and news
349
. 
                                                 
 
xxviii  http://clinicaltrials.gov/ct2/info/about [4 April 2009] 
xxix http://www.ncbi.nlm.nih.gov/About/tools/restable_stat_pubmeddata.html  [6 Apr 2009]  
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Even though a review
132
 of the information-seeking behaviour of physicians 
spanning over ten years 1996-2006 shows that physicians refer to colleagues and 
hard-copy evidence when seeking information in general and it is likely that 
physicians also turn to the web when looking for clinical trials. Eysenbach has 
suggested that the Internet is useful in particular when looking for unpublished or 
ongoing clinical trials
120
. 
 
An objective for this PhD was to identify the online „alternatives‟, as opposed to the 
traditional methods of dissemination such as journal articles, that are used to 
disseminate clinical trial information.  My Google search showed that information 
about clinical trials on the Internet is increasing rapidly and with more information 
made public. In particular it is interesting to see the use of more informal methods 
and some web 2.0 „social tools‟, e.g. blogs, discussion forums etc. are being used for 
disseminating clinical trial information (table 15).  
Table 15: Types of methods used for disseminating clinical trial results on the Internet 
Academic personal pages
Blogs with unidentified owners
Conference proceedings
CTRs
Discussion forums
News blogs
Newsletters posted on websites
Personal blogs from sufferers
Portals for trade magazines
Pre-publication press releases
Pre-publication reports
Result summaries on pharmaceutical websites
Slides from presentations  
 
5.6. Current practice of dissemination of clinical trial information: a survey 
Data from a survey of clinical research professionals provide an insight into the 
current practice of dissemination of information and also gives us a snapshot into 
their knowledge of regulations and tools to assist with dissemination. I draw upon 
the responses to the survey questions to compare with our literature review findings. 
The 98 respondents to the survey work predominately in the pharmaceutical industry 
or contract research organisations, but there were also respondents working for the 
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national health service, in not-for-profit/academic research and as contractors.  The 
respondents live in the EU. The job roles of those responding were varied (table 16). 
Table 16: Job role of respondents in survey (n=98) 
 
Job role  n= 
Other 9 
Medical writer 11 
Medic/Scientist/Researcher 11 
Product manager 1 
Clinical Research Associate (CRA)/ 
Project manager 
16 
Clinical Research/Clinical manager/Director 37 
Statistician/Data manager 2 
Regulatory/Quality 2 
Nurse/Pharmacist 2 
Admin/support role 4 
Operations/process 3 
  98 
 
The survey of clinical research professionals asked respondents to identify various 
methods that they used for disseminating clinical trial results (table 17). 
Table 17: Survey data: Dissemination methods for clinical trial results (respondents n=98) 
 
Method n= 
 Blog/wiki 1 
 Online discussion groups 2 
 Repository  5 
 Newspapers/magazines  6 
 Advertising 9 
 Website (external) 13 
 Reprints of journal articles 18 
 Open access journal 19 
 Promotional material  19 
 Standard letter sent out to physicians 25 
 Meetings/conferences exhibition 40 
 Press release 41 
 Website (own) 42 
 One of the top five medical journals  45 
 Conference presentation 61 
 Conference abstract/poster 73 
 Other peer-reviewed journal  80 
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The responses show the most common methods used for disseminating clinical trial 
results are through a peer-reviewed journal, through conferences and via websites.  
Although it also shows that researchers are using online alternatives to disseminate 
information, such as blogs, websites and through discussion forums. 
5.7. Online tools – clinical trial registries 
Computer-based clinical trial registries improve information flow
98
 and registrations 
have increased nearly 420% from year 2005 to 2009 in Clinicaltrials.gov
xxx
.  Several 
studies have analysed websites containing information about cancer clinical trials
110-
114
.  Some of these websites provide tools, e.g. a database or clinical trial registers 
that can be searched for information about clinical trials.  
 
Atkinson et al. studied cancer clinical trial search tools online to establish how easy 
it was to use these tools available to the public
114
. The outcome of this study was that 
online search tools do not adequately facilitate providing information about the 
clinical trial process and there was great variety between different tools.  Till et al. 
conducted an exploratory evaluation of online resources for Canadian cancer 
trials
110
. The outcome of the study was a statement that online sources should strive 
to make access to clinical trials simpler and reliable. 
 
In 2002, Manheimer
103
 examined the completeness and accessibility of ongoing drug 
trials for prostate or colon cancer in the UK. He concluded that existing clinical trial 
registries were not meeting existing user needs as many ongoing drug trials were not 
listed. A examination by Monaco and Krills
112
 of cancer centres websites concluded 
that websites that provided information about cancer clinical trials were providing 
limited content and the reading level of the information was at college level. Another 
study in 2007 evaluated online resources for cancer clinical trials
113
. This study 
found that the resources varied greatly regarding information provided and called for 
an improvement to content, design and presentation of clinical trials. A further 
                                                 
 
xxx
 In October 2005 Clinicaltrials.gov contained 13,153 registrations and in February 
2009 it contained 68,223 clinical trials
xxx
. 
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content analysis into cancer clinical trial search tools in 2008 also found that 
functionality and content varied greatly
114
.   
5.8. Clinical trial registers – study of functionality and content 
No similar studies of functionality and content of diabetes and obesity clinical trial 
registries have been published and therefore a study into this area could establish if 
the issues are comparable across registers containing information and diabetes and 
obesity clinical trials. This research wanted to confirm if similar findings apply to 
clinical trial registries containing information about open or ongoing clinical trials 
available in the UK. The evaluative study of the content and functionality of clinical 
trial registries took place with eleven eligible clinical trial registries.  
 
In order to measure functionality and quality of content, two measures were used: 1) 
a tool evaluating functionality and 2) a list of recommended datasets to evaluate 
quality of content. There are no validated tools to evaluate content and format of 
Internet information.  This study used a website feature tool used by Atkinson et al. 
in the search for cancer clinical trials
114
. The tool reviews functionalities and features 
of websites for the following features being available: 
 Basic search tool 
 Advanced search tool 
 Registration options 
 Presentation of results 
 Additional site content. 
 
The World Health Organization has recommended that 20 WHO datasets are 
provided at the time of registering a clinical trial in a clinical trial registry
350
 and 
these fields were used as a comparative standard for quality of content in a clinical 
trial registry in this study. 
 
The outcome of the evaluative study shows that the clinical trial registries varied 
considerably in what features and functionality they offered to the user..  
 
To summarise the key findings; some clinical trial registries provided minimal tools 
to aid the searcher in discovering information (see research data in appendix B). 
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 Ten out of 11 registers offered a search tool, but only three out of 11 offered 
an advanced search tool.  
 Two out of 11 registers required the user to register on the site prior to 
searching.  
 The sites that offered advanced search functionality provided many search 
field options, e.g. terms, phase, condition, study type, dates of registration 
etc. Even the sites that offered very basic search tools tended to provide a list 
of search terms or keywords to use.  
 
Obviously functionality of a site is dependent on the software in place and level of 
funding available to the register owners. Technical difficulties affected some 
registers and many of them did not offer any help with searching. 
 
The same keywords were used in each directory search: 'diabetes' AND 'obesity' 
AND 'United Kingdom'. The expectation was that the results list would display 
studies and the status of those studies, so that open or recruiting studies could be 
selected. This was not always the case, sometimes it was impossible to know if a 
study was still open or already closed. Other difficulties presented themselves, such 
as selecting a country. When comparing results, the different registers did not 
contain the same clinical trial content. This suggests that the content policy of a 
register needs to be declared on the site to the user.  
 
The result display varied amongst the registers. Two of the sites provided the results 
as narrative rather than in data sets; CenterWatch and MedTrials. These two sites 
aimed at recruiting subjects for trials, rather than providing structured output of 
information. 
 
Using the World Health Organization twenty recommended TRDS as a comparator, 
table 18 (and appendix C) shows what data was found when searching across the 
registers. The table also shows how many diabetes and obesity clinical trials were 
found in the UK, and the number varies greatly between registers. The CenterWatch 
register, MedTrials and ClinicalConnection had a zero result, therefore not 
comparable to the TRDS and excluded. The three Current Controlled Trials 
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registries had similar output so have been grouped as one in this table, leaving six 
registries that were analysed for fields and content. 
 
If a clinical trial registry had a matching TRDS field, and if content was available in 
the results, they received a „tick‟. If no data was provided, even if the field was there, 
the register did not receive a tick. The numbers of ticks were calculated at the end. 
Using this method to assess quality of content, the register with the higher number of 
ticks therefore offer better output of information than those with lower ticks and can 
be considered to offer better quality content.  
Table 18: Comparison of the WHO TRDS and register data fields and review of content provided 
within registers  
(Larger image in appendix C) 
 
 
 
The Clinical Trials.gov and IFPMA clinical trial registries show appropriate data 
fields in line with WHO recommendations and accurate data within the fields which 
suggests they are of higher quality than any of the other registers. The WHO ICTRP 
platform was still at early development during this study, and this may explain the 
lack of data in some of the data fields. The poorest performance was from 
CMRInteract which failed to provide some of the basic information such as 
registration date, funding, inclusion criteria and the title of a clinical trial. However, 
CMRInteract ceased to exist after 31 Dec 2009, some time after this study took 
place. 
Many clinical trial registries in this study did have similar data fields as that of the 
recommended WHO TRDS. Quite disappointingly, some registers were lacking 
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checks and review as fields had been left blank or mandatory fields contain 
inaccurate information. In a field requesting the name of the study drug, some other 
word had been provided and fields for contact names and telephone numbers were 
blank.  
 
The WHO ICTRP’s register received a low score against its own criteria in this 
study. However, the ICTRP is meta-register searching across a network of registers. 
Therefore we can assume that if data fields or data are missing from the results of a 
search in the ICTRP, then it is because the data field or data do not exist in the 
original register from which ICTRP aggregates its information.  
 
This evaluative study, which is a snapshot in a time of fast development for registers, 
shows that some registers‟ technical capabilities are crude and with regards to 
content many fields were left blank and some fields carried irrelevant information, 
perhaps the details were not known or they did not want to provide it (for 
confidential reasons). Some key information was sometimes missing, such as contact 
information, drug name and the name of the study. Results and type of information 
offered varied from site to site and it was difficult to interpret the data provided. This 
finding is in line with similar studies
112;114
. The study by the Cochrane 
Collaboration in 2011 also confirms that information in published reports of RCTs is 
not the same as that provided in the protocol or the entry in a clinical trial registry
115
. 
 
The absence of a comprehensive standardised registers creates problems for 
clinicians and patients seeking information about clinical trials
103
.  Research also 
shows that trial registration does not ensure the timely availability of accurate trial 
results
351-354
 because records remain incomplete and are not updated with 
information even after publication of results and they need to be able to provide 
information at the point of care. 
 
The results of the recent studies of websites have been that finding search tools was 
easy, but using the tools was more complex and many sites also used difficult 
medical and research terminology
114
. It was suggested by several 
investigators
110;111;114
 that developers of search tools should get input from patients 
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to simplify and enhance search options and to share tools with clinicians and health 
professionals on how best to integrate these tools into the health care encounter
113;114
. 
 
The US activist group Public Citizen conducted a study of registers in 2007
190
. The 
study included 22 registers of which four were publicly accessible and the rest 
private websites. They found that the privately run registers lacked consistent design 
and were of varied quality.  It was also felt that these registers were an attempt by 
the pharmaceutical industry to be seen to comply with new guidelines on trial 
legislation but in fact hinder the release of too much information. Another concern 
has been that registers lack data on trial leadership and contact information and are 
not monitored to ensure completion of mandatory fields.
191
 
 
There are now developments to link the most used register, Clincialtrials.gov, with 
results databases from the FDA, NLM and NIH websites. This is because of section 
801 in the Food and Drug Administration Act enacted in September 2007
272
 which 
mandated the expansion of Clinicaltrials.gov to include results information of trials.  
 
There is a move to make the Clinicaltrials.gov website the comprehensive source of 
trial information. In a three year development plan starting in 2009, the website will 
develop a comprehensive results database that may or may not be combined with the 
registration database. The complexities in creating a clinical trials register including 
registration and results information, are that there are a wide range of trial designs 
making it difficult to match their information up with fields, and the information 
within the database is not peer-reviewed, interpreted or explained
106
.  A register 
complements existing methods of disseminate and releasing results on such 
databases are not considered pre-publication of data complying with publishers‟ 
requirement of only publishing original research. 
 
Perhaps strange to the public, the legalities surrounding the Clinicaltrials.gov 
database were set by legislation in the US and only applies to clinical trials taking 
place under the FDA authority, e.g. for the US market. Nevertheless, studies from 
around the world are registered on the Clinicaltrials.gov database, which has 
developed into the largest clinical trial registry in existence. The difficulty is in 
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imposing US legalities on trials conducted in the EU for the EU region. The EU has 
no similar legal requirements for trial registration and posting of results. 
5.9. Usage of clinical trial registries – survey results 
The survey of clinical research professionals for this study hoped to find out what 
registries were used for registration and posting of results. 
 
Results databases were set up for results to be posted and some are separate from 
clinical trial registries. Some example results databases are: clinicalstudyresults.org 
by PhRMA, lillytrials.com by Lilly, ctr.gsk.co.uk by GlaxoSmithKline (GSK).  
 
When survey respondents were asked if the last clinical trial was registered the 
response was that 60% (n=59) said yes it was registered, but 24% (n=24) did not 
register the trial and 15% (n=15) did not know.  71% (n=37) registered the clinical 
trial on clinicaltrial.gov with the remainder registering their trials on other registries. 
When asked if the sponsor of the clinical trial have their own registry available 
online, 22% (n=22) said yes and 60% (n=59) said no. The remainder did not know. 
 
It was also not common practice for the sponsor to post results on their website 56% 
(n=55) although 31% (n=30) of respondents stated that the sponsor did. 
5.10. Social media and networks 
Online information and networking tools are reshaping research but we do not really 
know to what extent these are used for disseminating clinical trial information or if 
they are likely to replace what we think of as traditional methods of dissemination, 
e.g. the journal. Scientists use emails, blogs, Twitter, wikis and social networks 
when collaborating and sharing information. Research into this kind of scholarly 
activity is taking place and there have been references to how social media is 
changing scholarly communication
355
. 
 
A recent survey showed that researchers believe social applications will have a major 
influence on the future of research 
356
, although it identified that there needs to be 
work on quality indications, validation of users and credibility is needed to attract 
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researchers. Another survey of scientists show that since the shift of the millennium, 
email is being used for research related tasks and is central to scientific work
357
.  
 
Research in the US shows that the usage of medical data online by physicians will 
increase 
358
. According to their research, physicians visit pharmaceutical websites, 
use e-detailing and the younger physicians post content online. There is a growth in 
usage of mobile devices and content such as news and journal content is downloaded 
by physicians 
358
 and the researchers conclude that the portable‟ on demand‟ content 
model is likely to replace traditional resources. 
5.11. Reports by the regulatory authorities 
Interventions that are tested in trials are submitted for approval with  European 
Public Assessment Reports (EPARs) giving an overview of the clinical trial. EPARs 
are important additional sources of information about a clinical trial, in particular as 
only 35% of all RCTs between 1999 and 2005 of approved new medicines were 
published 
359
. The EPARs can be found online from the EMA in the EU. Some drug 
companies present the clinical study reports on their websites, however there is no 
evidence that this detailed report (usually 30 pages or more) is the best format for the 
public
94
.  
5.12. Choice of dissemination method and factors affecting 
dissemination? 
 
As we have seen in the previous section there are many different methods available 
to disseminate clinical trial information.  What determines where information is 
disseminated? This was a very important question to examine as the answer to this 
question will help with making recommendations at the end of this thesis. A further 
question was about what clinical trial information is disseminated. The two question 
fit together as it was part of the investigation to examine if what was disseminated 
affected where it was disseminated.   
 
Research for this PhD discovered many initiatives and events that have shaped the 
way in which clinical trial information is disseminated. As discussed earlier, clinical 
trial regulations are complex and requirements vary in different countries. 
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Researchers have to deal with protocols and information from clinical trials that are 
taking place in many different countries and with reporting in different languages, a 
challenge to control
198
. They also have to deal with different regulatory 
requirements. The regulatory framework in which researchers work have an impact 
on dissemination. Other initiatives have included publication guidelines, which set 
standards of what should be disclosed and how to address reporting and 
dissemination.  
 
An interesting discovery in this research was the role of pressure and its effect on 
dissemination. Several types of pressure could be identified ranging from economic 
to geo-political.  There are forces at play affecting dissemination and the choice of a 
particular dissemination method. A number of factors through various studies that 
will be discussed covered in this section (Table 19). A factor which has impacted on 
dissemination and shaped the current practice of dissemination is transparency, a 
need to declare everything from funding to methods to results. Linked to 
transparency but also to behaviour of individuals within the research environment 
are the concepts of trust and confidence.  
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Table 19: Factors that affect dissemination and choice of method 
 
Factor Description 
Legislation and regulation   Requirement to register trials 
 Requirement to report on outcome 
 Research regulations 
Publication guidelines  Journal or research group guidelines 
 Industry/authority guidelines 
 Internal disclosure guidelines 
Transparency  Selection and publication bias  
 Career progression 
 Funding 
 Trust 
 Behaviour 
 Fraud 
Effective dissemination  Quality 
 Timing 
 Time to publish 
 Target audience 
Pressures in the environment  Economic: funding, sales/performance, 
cost 
 Geopolitical: ethics, global trials, 
regulations 
 Social: individual opinion 
5.13. Awareness of legislation and regulatory framework behind 
dissemination 
The clinical research environment is heavily regulated with a number of processes 
and guidelines in place to support the clinical trial activity. The EU has its own 
directives that outline how clinical research should be conducted, but there is very 
little guidance on how the information generated should be disseminated. Guidelines 
have instead come from other sources, such as ICH E3
239
 which provides guidance 
on reporting to authorities with specific details on reporting safety information. The 
WMA Declaration of Helsinki (2008)
360
 provides some vague instruction to register 
the clinical trial and to share study outcomes with those who partook in the trial. The 
clinical research environment has still not agreed to accept the 2008 declaration, 
many still referring to the one dated 2004 and the FDA in the US has completed 
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abandoned the Declaration
288
. ICMJE
176
 and the WHO
194
 have provided more 
comprehensive guidance on publication in journals and clinical trial registration.  
 
The respondents in the survey for clinical research professionals were asked to rate 
their understanding of current practice of registering and disseminating clinical trial 
information to which 85% (n=83) felt that they were reasonably or mildly confident 
in their understanding of these practices. 9% (n=9) individuals stated that they were 
not at all confident. When examining this further, the least confident individuals 
worked in the national health service and pharmaceutical industry.  Data did not 
show any trend towards a particular role being the least confident as most individuals 
felt that they had some confidence. 
 
Many new initiatives during the 1990s relate to ethical guidelines or legislation and 
in the 2000s we see the emergence of publication guidelines (Table 20). 
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Table 20: Timeline of the various guidelines and important events relevant to transparency 
 
Year Event 
2010* GPP2 
2008 Declaration of Helsinki (update) 
2007* ICMJE statement (update) 
2007 WHO ICTRP (launch) 
2006* Council of Science Editors guidelines 
2005* EMWA guidelines 
2005* WAME guidelines 
2005 EU GCP Directive 
2005* Ottawa Declaration II 
2004 EU CT Directive 
2004* Ottawa Declaration I 
2004 First Clinical Trial Registry (GSK) 
2004* ICMJE statement 
2003* Good Publication Practice (GPP) 
1999* COPE guidelines 
1997 Clinicaltrials.gov set up 
1997 FDA Modernisation Act 
1996 ICH E3 
1996* CONSORT 
1996 ICH GCP (E6) 
1996 Declaration of Helsinki 
1994* AMWA 
1989 ICH conceived 
1964 Declaration of Helsinki (first published) 
 
Key 
 Clinical research ethical guidelines 
* Publication guidelines 
 Other events 
 
5.14. Publication guidelines 
International declarations, conventions, directives, and various national laws and 
rules regulate research ethics and researchers‟ ethics. But laws and directives do not 
usually specifically provide guidelines on how and what to disclose and publish 
apart from data to the national authorities relevant to the new drug application. 
The issue of declaring all clinical trial data has been debated for a long time with a 
wish to eliminate unacceptable behaviour and encourage best practice
57;199;361-363
. 
 
Unacceptable behaviour includes not declaring conflict of interest, not naming 
authors (ghost authorship) or paying non-authors to be listed as authors to attract 
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readers (guest authorship) and falsifying data or publication bias (such as selective 
reporting of some results). It started with Chalmers declaring that underreporting 
research data is scientific misconduct
216 
and nearly twenty years later he claimed 
selection bias should be outlawed
364
.
 
 
 
This research has identified and refers to three types of publication guidelines. 
 
 Clinical research ethical guidelines, e.g. ICH E3 reporting guidelines  
 Publication or reporting guidelines, e.g. by journals or research bodies  
 Organisational internal disclosure guidelines, e.g. those by sponsor companies 
 
A comprehensive list of guidelines with further information referred to in this 
research is given in Appendix D. 
 
Looking at Table 21, we can see that the first clinical research ethic guideline is the 
Declaration of Helsinki in 1964 concerned with patient safety and that clinical trials 
should be conducted ethically. Table 21 (below) gives an overview of main events 
that have shaped publication guidelines and the path to transparency.  
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Table 21: Events that have shaped the evolution of publication guidelines 
 
1997 FDAMA Law, Section 113 (USA)  A Clinical Trials Data Bank should contain the following 
information: (1) Information about Federally and privately 
funded clinical trials for experimental treatments (drug and 
biological products) for patients with serious or life-threatening 
diseases or conditions, (2) a description of the purpose of each 
experimental drug, (3) patient eligibility criteria, (4) a description 
of the location of clinical trial sites, and (5) a point of contact for 
patients wanting to enroll in the trial, all in a form that could be 
readily understood by the public.  
2004 GSK sued for withholding 
negative data from paroxetine 
trials  
As a consequence of the event where GSK were found guilty for 
not disclosing results from paroxetine trials, GSK set up the first 
pharmaceutical clinical trials register online where all results are 
publicly disclosed.  
2004 Ottawa statements I & II  The Statement outlines the fundamental principles for trial 
registration (Part I), operational aspects of the protocol 
registration (Part II, in progress) and of results reporting (Part 
III). Part III  has been drafted and is under consultation. 
2005 WHO calls for registration of all 
trials (worldwide)  
The WHO held several consultations in 2004 on trial registration.  
In Jan 2005 the WHO started a project to set standards and 
advocate for compliance. The WHO launched a portal as a meta 
register of clinical trial registries in 2007. 
2007 Enhancing drug safety and 
innovation act: register all new 
trials and disclose all trial results 
(USA)  
This is a bill in the United States to amend the Public Health 
Service Act and the Federal Food, Drug and Cosmetics Act to 
improve drug safety.  This is the first stage of the legislative 
process where the bill is considered in the committee. 
2007 FACT: register new trials and 
disclose trial results of studies 
with serious and life-threatening 
diseases (USA)  
The Fair Access to Clinical Trials Act (FACT) of 2005 asks for a 
databank of clinical trials registered accessible to patients and 
healthcare professionals for information related to ongoing 
clinical studies as well as a results database with results of all 
publicly and privately funded clinical trials regardless of 
outcomes. Introduced Feb 2006 S.470 or FACT Act would 
require the FDA to expand on the clinicaltrials.gov database to 
incorporate the above features.  
2007 Maine Regulations (USA)  
 
February 2007: The rule defines the obligations of manufacturers 
and labellers of prescription drugs and biological products to 
publicly disclose websites information about clinical trials that 
are or have been FDA-approved for marketing and are or have 
been dispensed, administered, delivered or promoted in Maine. 
The final rule further clarifies the required content, timing and 
location of these disclosures, and indicates for which clinical 
trials this information is required.  
 
The first „original‟ publication guideline is the one produced by the American 
Medical Writers Agency (AMWA) in 1994 although AMWA has had a Code of 
Ethics for all its members dating back to 1940
365
.  1997 is a landmark for clinical 
trials as this is the year the US FDA Modernisation Act states that clinical trials must 
be registered in a databank which resulted in the invention of the clinicaltrials.gov 
register. This sparked the production of publication guidelines by the Committee on 
Publications Ethics (COPE)
366
 in 1999, the Good Publication Practice (GPP)
290
 in 
2003 and the statement made by the International Committee of Medical Journal 
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Editors (ICMJE)
251
 in 2004.  Another landmark event in 2004, probably the event 
that highlighted several issues and concerns with clinical trial reporting, Glaxo 
SmithKline (GSK) was found guilty for not disclosing results from Paroxetine 
clinical trials. GSK declared at the court trial that they would set up a clinical trial 
registry where all their trials and the results of trials would be posted
140
. As a 
consequence of this event in 2004, PhRMA made recommendations to its members, 
the pharmaceutical industry in the USA, to communicate clinical trial results 
publicly via a peer-reviewed journal, abstract submission, oral presentation or other 
means 
367
.  In November 2004 the World Health Organization (WHO) called for 
members to establish a platform to link clinical trial registers to ensure a single point 
of access and identification of clinical trials. The ICTRP was set up in August 2005 
linking primary registers. The Ottawa Statement in 2005 recommended that 
registration and the release of clinical trial information are necessary to fulfil ethical 
obligations in research. The Declaration of Helsinki was updated in 2008 with 
“Every clinical trial must be registered in a publicly accessible database before 
recruitment of the first subject”360. Several other guidelines were published thereafter 
and are regularly revisited for updates. 
5.15. Responses from survey of clinical research professionals 
In the survey of clinical research professionals, it was established that awareness of 
publication guidelines written by various research bodies is quite low (Table 22 and 
Figure 14). 
 
The most used guidelines by respondents are the ICMJE 41.8% (n=41), CONSORT 
28.6% (n=28) and GPP 24.5% (n=24) guidelines. 
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Table 22: Awareness and use of publication guidelines n=98 
 
 Not aware of 
it 
Aware of it 
but haven't 
used it 
Have used it 
ICMJE Count 23 34 41 
% 23.5% 34.7% 41.8% 
GPP Count 41 33 24 
% 41.8% 33.7% 24.5% 
CONSORT Count 54 16 28 
% 55.1% 16.3% 28.6% 
WAME Count 73 21 4 
% 74.5% 21.4% 4.1% 
COPE Count 84 12 2 
% 85.7% 12.2% 2.0% 
CSE Count 85 12 1 
% 86.7% 12.2% 1.0% 
PhRMA Count 55 23 20 
% 56.1% 23.5% 20.4% 
EMWA Count 69 22 7 
% 70.4% 22.4% 7.1% 
AMWA Count 82 11 5 
% 83.7% 11.2% 5.1% 
 
 
 
Figure 14: Awareness and use of guidelines % of respondents in a survey 
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Respondents were also asked to rate usefulness of guidelines where the ICMJE 
(n=33), CONSORT (n=30) and the GPP (n=23) were reported as the most „useful‟ to 
„very useful‟ guidelines (Figure 15). 
 
 
Figure 15: Guidelines used and their usefulness % by respondents in a survey 
When asked if the organisation, in which the respondent works, has a publication 
policy, 72% (n=71) responded that they do. Rather worryingly, 10% (n=10) did not 
even know (Table 23). It is surprising that 17% (n=17) state that they do not have a 
publication policy.  
Table 23: Publication policy within organisations n=98 
 
  n= % 
Yes 71 72.45 
No 17 17.35 
Don't know 10 10.20 
  98 100 
 
When cross referencing the availability of publication policy against organisation it 
was established that those organisations that had a publication policy were 
pharmaceutical, clinical research or device companies (75.4% (n=61)) as well as 
academic/not-for-profit organisations (88.9% (n=8)). Those that did not have 
policies were individuals working as contractors (58.3% (n=7)) and 8 pharmaceutical 
companies (13.1%). 
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5.16. Pharmaceutical disclosure policies 
During the GSK trial and the recommendation by PhRMA for industry disclosure 
guidelines, many pharmaceutical companies drafted and published their own 
guidelines to cover what information they will disclose about clinical trials. 
 
To establish to what extent the policies cover the issues identified for disclosure, the 
ICMJE uniform requirement headings were used for comparison with 
pharmaceutical disclosure policies selected for analysis
xxxi
(Table 24). Ten policies 
were randomly selected from ten pharmaceutical companies, of which five were 
larger (by sales) and five smaller
242
. 
 
Table 24: Publication or disclosure policies of pharmaceutical companies in the study 
Company Year of policy
1. Pfizer 2002
2. GSK 2003
3. Novartis 2005
4. AstraZeneca Not provided
5. Sanofi-Aventis N/A
6. Merck harmaceuticals (KgaA) 2005
7. Eli Lilly 2005
8. Roche 2005
9. Amgen International 2005
10. Ipsen Ltd. N/A  
 
Note: Sanofi-Aventis and Ipsen Ltd. do not have public policies of disclosure. Eli Lilly’s policy covers 
the broader conduct of trials. 
 
 
 
 
 
 
                                                 
 
xxxi Analysed between May and July 2007 
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Table 25: Comparing pharmaceutical disclosure policies against ICMJE Uniform Requirements 
headings for quality of content 
Pfizer GSK Novartis Astra-Zeneca Merck KgaA Eli Lilly Roche Amgen
Coverage
Using external contractors for drafting publication 2 0 0 2 2 0 0 0
Conflict of interest 0 0 0 2 0 0 0 0
Obligation to communicate negative results 2 2 1 0 0 2 2 2
Obligation to register clinical trials Phase II-IV 2 0 2 2 0 2 2 2
Preparing manuscript for publishing 0 2 0 2 0 0 0 0
Registration of Phase I studies 1 0 0 0 0 0 1 1
Commitment to communication of results 2 2 2 2 2 2 2 2
Acknowledges official guidelines 2 2 2 2 2 2 0 2
Posting results on a public database 1 0 2 2 0 2 2 2
Admits commercial sensitivity 2 0 0 0 0 0 1 0
Identifies database where registering trials 2 0 2 0 0 2 2 2
Gives timeline when results will be released 2 0 2 0 0 2 2 2
Discusses interim or preliminary results 0 1 0 0 0 0 0 0
Talks about publication of results 2 2 2 2 2 1 2 2
Internal review of abstracts/scripts 2 2 0 0 2 0 0 0
Discusses delayed publication 2 0 0 0 2 0 2 0
Sharing of protocol with journal editors 2 0 0 2 0 0 0 0
Authorship of publications 2 2 2 2 2 0 0 0
Peer review 0 2 0 0 0 0 0 0
Communicating outside peer-review journal 0 1 0 0 0 0 2 2
Total 28 18 17 20 14 15 20 19
 
This table is also available in Appendix E. 
 
Rating scale used for comparison 
  0 No coverage 
1 Some coverage 
2 Comprehensive coverage 
 
Table 26: Scores of analysis of disclosure policies against the ICMJE criteria 
 
Company Points scored 
Pfizer 28 
AZ 20 
Roche 20 
Amgen 19 
GSK 18 
Novartis 17 
Eli Lilly 15 
Merck KGaA 14 
 
Using a scoring system to analyse the quality of the content points were awarded on 
coverage of headings identified by the ICMJE. Out of a possible score of 40, the 
eight guidelines analysed performed poorly. Specifically some policies stated that 
they will not provide commercially sensitive information, e.g. name of 
investigational product, title of the study or how many subjects are in trials. Some of 
them also said they do not release interim results and will only share results once the 
study has ended. Some policies stated that non-publication will occur if a study has 
ended prematurely, if there is insufficient data or if the data are invalid. Some 
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companies are happy to publish results sooner than study end if the data are 
medically important. 
 
It seems that during the analysis of the content disclosure policies with that of the 
ICJME publication guideline, the content of those policies do not provide 
comprehensive guidance to clinical research professionals or possibly internal 
policies conflict with publishers‟ guidelines. This suggests that professionals writing 
papers or planning communication/dissemination activities may be experiencing 
pressure or difficulty when determining what to disseminate.  It was surprising that 
professionals were not always aware of external publication guidelines and also did 
not rate them very useful. 
5.17. Selection and publication bias 
Selection and publication bias refers to a decision to select information that will be 
published. This has traditionally encompassed publishing in a journal although we 
can extend this argument to a method of dissemination that is accessible by the 
public. It is recognised that medical journals in particular publish content that is 
affected by a form of bias
368
.  However, we know that information disseminated on 
the Internet will be biased, affected by things such as owner of the website, the 
editor/author and their own opinion and any other influences that may affect the 
content
130
.  It has been argued that researchers need more comprehensive guidelines 
to aid them in the reporting of results to avoid any kind of bias
369
, although we know 
there are several comprehensive guidelines available to researchers (as seen in the 
previous section) we also know that they are aware of some of them but not others.  
 
There are different types of selection bias, e.g. the selection of which studies to 
publish based on their results. It has been shown that studies without statistical 
significance (negative results) are less likely to be published
217;218;370
 and that profit-
making organisations only publish positive results
27;76;217
. There is also a selection 
bias on which data are selected for publication, withholding some data, e.g. some do 
not agree that data from Phase I trials are worth publishing
295
 or that some outcome 
data are not published
27
. Scientific misconduct such as fraudulent research claims 
207;371-373
 may be unfortunate outcomes of pressures for various reasons. Pressure to 
publish or end of funding means that the researcher may take shortcuts 
211
. There is 
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also a selection bias which affects in which journal results are published, where 
journal prestige affects choice
374
.  There is also current debate around editorial bias, 
to which extend the publisher rejects studies for publication
204;218;375
.  
 
Examining bias is difficult through a survey. However, in the survey of clinical 
research professionals, one question asked respondents if in a recent trial showing 
unfavourable (negative) results, the results were disseminated in any way (Figure 
16).  
 
35% (n=35) said that they disseminated the results in a peer-reviewed journal. Only 
14% (n=14) said that they did not disseminate them at all. 
 
 
Figure 16: Dissemination of clinical trial results that were unfavourable/negative (n=) 
 
Five respondents identified the reason for not disseminating unfavourable results as 
not being company policy to do so. However, they also identified that the journal to 
which they submitted the results rejected the publication (n=3) and admitted that 
releasing such data may harm the company reputation (n=4). Only 16 survey 
respondents provided an answer. 
 
It must be argued that a selection bias of what is disseminated is necessary, as it 
would be impossible to disseminate all the clinical trial information generated, as we 
have seen a very large amount of information is generated in clinical research. It is 
unlikely that all that information would be of interest to anyone and we know that 
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raw research data is not necessarily that useful without interpretation or research 
design information
376
.  But perhaps an argument is that as long as that information is 
publicly available at request, even if not disseminated, it would improve 
transparency. To improve transparency, all results should be published whether 
positive or not 
201;216;219
.  Underreporting or not reporting at all is recognised as 
research misconduct, and in particular as this can lead to seriously misleading 
recommendations for clinical practice and new research 
216
. 
5.18. Does impact factor play a role in selection of journal when 
disseminating clinical trial information? 
 
The impact factor has been used as a method to establish the impact a journal has on 
the community it serves.  It has been suggested that impact factor plays a role in 
which journal a researcher decides to publish in as it authors seek to profit from 
publication
81
.  It has also been suggested that journals are nothing but marketing 
tools where the authors publish for their own professional benefit in journals that 
impress
76
 and that journals foster the careers of researchers377. It is likely that authors 
select what journal to publish in based on impact factor, publication time span 
between submission and print of article and to improve their scientific merit
81;378-380
.  
If an author publishes frequently, the likelihood is that there will be a high volume of 
self-citations, contributing to a higher impact factor for the journal
81
. It has been 
argued that journal publishers reject authors that do not publish frequently for this 
reason
81
. Cynics have said that authors of scientific papers publish to get their own 
name in print and to serve their own needs, rather than a reader‟s381 and it has been 
stated that science, not marketing, should guide us in writing scientific papers
382
.   
 
The impact factor has become our way of measuring not only a journal‟s worth, e.g. 
quality, but also researchers‟ activity. The impact factor has become a way to 
measure a journal‟s, and a paper‟s,  scientific worth although it has been argued that 
the number of citations as a quality measure is questionable 
383;384
. The impact factor 
of a journal may have a role in decision making on where an article is 
submitted
374;378
. It is possible that research published in a top medical journal with 
high impact factor will be trusted more than the research published in a less well-
known publication
206
 and that authors who want their research to be identified as 
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evidence of good quality choose to publish in high quality research journals
53;69
. The 
sponsors of clinical trials need to sustain drug development and need funding for 
this
249
 and publishing is usually part of a funding application.  Although, Coleman 
states that journal attraction power, consumption power and author associativity
246
 
are indicators of journal value rather than impact factor and he suggests that the 
scientific value of a journal must be developed in a fuller model. Impact factors also 
cannot be extended to other dissemination activities outside publishing and so the 
model must show scientific value of other activities too. 
 
For this thesis, the analysis of the journals that publish the majority of clinical trials 
in diabetes and obesity (section 1.46) does not suggest that impact factor plays a role 
in selection of journal for publication of a clinical trial as I would have expected to 
see the majority of papers published in journals with top impact factors. It seems, at 
least in the discipline of obesity and diabetes that clinical trials are published in three 
journals that are subject specific. Societies and institutions have released statements 
to say that the choice of journal where primary research results are published is not 
relevant, as long as certain criteria are met by the researcher: that the results are 
made publicly available within three months of publishing and that the publication 
will be stored in an electronic repository after publication
271;385;386
. 
5.19. How effective are the methods chosen? 
“Dissemination activities seek to strengthen awareness and enhance the impact of 
research findings amongst relevant target audiences”49 and dissemination aims to 
influence policy makers or force decision-making, which creates a change in 
behaviour in the recipient
48
.  
 
By effectiveness in this thesis I am examining the methods used to disseminate and 
if they are fit for purpose for clinical trial information. The following section 
discusses fit for purpose and how effective the current dissemination methods are. 
Influencing decision-making 
The reason for dissemination is to actively spread information to a defined target 
group and to do so effectively that information has to be taken up in implementation, 
to influence decision-making. I have already looked at factors that affect 
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dissemination of clinical trial results, e.g. influences including political and 
economic pressures, existing policies, administrative feasibility, timing and bias.  
  
According to Duggan and Banwell
56
 these influential factors can be broken down 
into internal and external by provider of the information and by recipient (table 27). 
Table 27: Factors influencing effective dissemination 
Provider Recipient 
Internal External External Internal 
Effectiveness 
measures 
Cultural constraints Perceived 
relevance of the 
information 
Recognition of 
need for new 
knowledge 
Change in 
behaviour 
Socio-economic 
factors 
Interaction with 
information 
Information 
seeking style 
Change in attitude Other sources Participant 
enrolment in the 
strategy 
Awareness of 
information 
sources 
Change in 
knowledge 
Reinforcement of 
existing knowledge 
Environment Willingness to 
change as a result 
of new information 
Cost Research based 
information 
 Information 
literacy skills 
Evaluation Method chosen for 
delivery 
 Access to resource 
Time for research 
& delivery 
Tools for 
influencing 
  
Italics=additional factors identified by this research not included by Duggan and 
Banwell 
 
According to Duggan and Banwell, not one factor is crucial for effective 
dissemination
56
, but that there is a combination of factors that is important.  This 
thesis has identified a further four factors (in table 27 in italics). 
 Tools used for influencing, e.g. opinion leaders or social tools such as 
websites, Twitter, blogs. In public health there is evidence of where social 
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marketing campaigns involving social tools are used to change public health 
behaviour, e.g. reduce obesity
387
.  
 The environment in which the recipient is receiving the information, e.g. 
under a stressful situation or very little time to absorb the information
388
. 
 The recipient‟s information literacy skills also affect absorption of 
disseminated information, e.g. searching for information using various tools 
and the interpretation of the content and context of information
130
. 
 Access to the information, e.g. access to full text or Internet access in 
particular for healthcare providers
214
.  
  
Scientific evidence is only one aspect of information that influences policymaking, 
as can be seen in how NICE make technological assessments of interventions in 
England
389
.  It is not only the efficacy of the drug that matters, it is also the economic 
evidence and how it fits into other treatments that are on offer. Also, sometimes 
there is not sufficient evidence for a particular drug, decisions must be made based 
on incomplete evidence and sometimes quickly
390
. Sometimes new information may 
be adopted on the proviso that further information will be forthcoming, e.g. further 
research data. Research results and information have limited time in the limelight 
and often it is not known when an update will be made available, so there is a very 
short time in which to impress and influence. The information disseminated is likely 
to be more successful if the information was founded upon existing research and 
therefore reinforces the recipient‟s existing knowledge56. 
 
New treatment recommendation is often slow in uptake. In the 1970s and 1980s 
several randomised trials into a particular condition which suggested change in 
treatment practice were not adopted until nearly 20 years later by one of the Royal 
Colleges in the UK
391
. Certainly, NICE makes evidence-based treatment decisions 
on behalf of the National Health Service, e.g. what drugs are recommended in what 
treatment. However, NICE relies on access to the right type of evidence for new 
interventions and treatment suggestions in order to make a ruling on application in 
practice.  
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Barriers that may affect dissemination are existing assumptions, e.g. about the 
audience, and the need for homophilous communication
56;392
. There are identified 
barriers to effective communication, either cultural, e.g. existing ideals or emotions, 
or socio-economic, such as education and status
56
.  Environmental barriers  have 
been ignored, e.g. the environment in which the information is received can cause 
stress or not be ideal as identified by Wilson
388
. Most physicians have less than 15 
minutes to discuss diagnosis and treatment with a patient, in which the doctor is the 
only source of information for the patient
388
. Interruptions or lack of time can be 
significant barriers of time, e.g. a press conference, or a discussion that takes place in 
intense situations with little time. 
Influencing through effective dissemination 
To effectively disseminate information means to distribute into implementation
49
. 
There are several challenges in effectively disseminating findings from health 
research, with several stakeholders to satisfy: health professionals, policy makers, 
current and future consumers. Effective dissemination is also an interactive exchange 
between researchers and those that the information is intending to influence
48
 .  
 
It can take many years for research results to be disseminated, by which time the 
information is not relevant or when information is needed quickly, the speed of 
delivery may impact practice. The timing of the delivery is also important. If 
research is not delivered timely at the point of need, it may no longer be useful. 
According to Coomarasamy et al., clinical medical journals are not effective in 
motivating practitioners to change practice mainly because what is published is not 
valid or relevant with patient care
49
. It is also possible that clinical trial results are 
not reaching practicing physicians.  In 1979 a paper in JAMA highlighted a survey 
of primary care physicians‟ awareness of an important diabetic retinopathy study393. 
The results showed that only 33% of physicians had treated their patients correctly 
according to new study results published 18 months earlier. Two other papers in 
1981 stated that clinically significant research results that were published did not 
reach the practicing physician
394;395
.  These days, the publication of clinical trial 
results can have a “rapid and dramatic effect on treatment patterns”396-399. In 2004 
the Women‟s Health Initiative (WHI) trial was stopped early due to evidence that 
harm is associated with hormone replacement therapy in postmenopausal women, 
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which caused widespread panic amongst HRT users. It is also the case that 
researchers are more likely to find out about medical research through the popular 
press 
400
. However, there is evidence of where publications have taken many years to 
be incorporated into clinical practice or where new evidence has not made any 
change to existing practice
401;402
.  An example of where research was disseminated 
quickly, is the Million Women Study
403
. In this study, it was discovered during the 
clinical trial that HRT caused an alarming rise in severe long-term side effects. The 
results were published rapidly in various ways: by press release and in a peer-
reviewed journal, causing a sudden reduction in the prescription of HRT. 
 
One key paper
401
 aimed to examine the dissemination plan of a major clinical trial 
which had the potential immediate applicability in public health, the ALLHAT‟s 
trial. The study concluded that there is a need for a comprehensive plan to influence 
prescribing practices and that this planning should be part of the planning for the 
clinical trial.  
 
What are the implications of research in practice? In order to improve transparency 
and to further the understanding of clinical trials, scientists should provide 
implications of research to the public and ensure timely and appropriate 
communication of the results. There is an identified need for evaluation into 
dissemination and implementation strategies to estimate efficiency
62
.  There is also a 
concern over communicating research results too early. A report warns of drawing 
attention to clinical trial results too early, as an awareness over a product before it 
reaches the market could have negative commercial impact
222
.  The target audience 
must see a relevance of the material to them and be able to interact with the 
information
56
.  
 
Research from Thomson Pharma revealed that GlaxoSmithKline (GSK)‟s publishing 
practices between June and August 2006 made more impact than any other 
pharmaceutical company. They published nearly 80 articles of which 32% created an 
impact on the attitudes or product knowledge of prescribing physicians
404
. 
 
It has been established that the journals are still considered important by physicians 
in obtaining information
305
, although professional meetings and conferences are 
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considered more important and colleagues come closely after journals. 
Dissemination of trial results should be intensive
401
 and in order to impact practice 
behaviour efforts apart from journal publication should take into account drug 
promotions, recommendation from colleagues, guidelines, and use multiple methods 
such as detailing by opinion leaders, community based methods, provide patient 
guidelines etc.
405;406
.  
 
Dissemination activities should seek to “strengthen awareness and enhance the 
impact of research findings” amongst target audiences407. Medical journals could 
improve influence in practice by reducing the number of journals in existence and by 
journal articles being published in the right journal for their content
49
. To avoid the 
danger of practice-changing to results released at conferences or pre-submission, it 
has been suggested that more journals should publish rapid review and publication of 
those trials that are likely to change practice, and that publication should not be 
delayed
396
. 
 
The web is a breeding-ground for new ideas, products and services. Websites are set 
up, change and disappear frequently. We can quickly search and read material on the 
web, much quicker than we can digest it
408
, and it is much easier to come across 
misinformation on the web with the speed in which we use it. To deal with 
misinformation on the web Calvert suggested two solutions: that publishers control 
information flow as they have the experience of this in print formats and that we 
improve information literacy in individuals. 
 
Blogs are influential forms of web publication and communication and some blogs 
have media impact and are of commercial value
409. Blogs are “new forms of 
mainstream communication” to publish and exchange information and to establish 
networks
410
. According to data gathered between 2003-4, blog readership in the US 
increased 58%
411
. However, according to a lifestyle survey done in the US, blog 
readership did not increase during 2005
412
. We need more data on the use of blogs 
for those searching for information on the web. 
 
According to Shirky
413, blogs are expected to follow a „powerlaw‟ distribution 
whereby a small group of popular blogs have the highest readership. With time, 
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distribution becomes uneven so that popular blogs will become more popular, and 
blogs with less audience will reduce further in readership. The blog‟s „value‟ is 
determined by multiple factors: the „look and feel‟, e.g. how information is 
presented, the organisation of it, and also the extras a blog can offer, e.g. 
commentary, polls or other interactive features
409
. These factors and the accessibility 
of blogs affects the potential of the spread of the blog
414;415
. Another important value 
factor is the existing community of a blog; e.g. blog friends or links, which shows a 
trust in a blog
409
. 
 
According to research by Giordano et al., an oral presentation at a US oncology 
conference in 1998 increased the use of taxanes in breast cancer patients before the 
study was published and also before the drug was approved for this disease by the 
Food and Drug Administration
396
. Research results are often presented at 
conferences in advance of publication, and even though they are not subject to 
independent peer-review, the results are widely disseminated
396
.  
 
We are aware that presentations of research at conferences may be limited with 
information and outcomes may in fact change between the initial protocol and final 
publication of results
155;416;417
, and conference abstracts and posters could be 
presented throughout the phases of a trial. 
 
Concerns raised by Giordano et al., is that rapid changes in practice based on early 
results can be premature
396
 and the authors suggest that there should be caution 
exercised and awareness of the power of these meetings to publicise their agenda, 
using press releases to attract attention. Giordano et al. encourages conference 
organisers and participants to share data from studies presented with as much 
information as possible for health professionals to study before making practice 
decisions
396
.  A study on taxanes communicated at a conference concluded that there 
were insufficient data to recommend taxanes for the treatment of breast cancer and 
yet it did change practice. Giordano et al., provides three reasons as to why the 
practice changed. The first reason is that this particular study received intensive and 
positive media coverage.  The second reason is that the pharmaceutical company 
representatives were disseminating the results to oncologists. A third reason was the 
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type of study: an established research group, a multicenter randomized trial would 
have added trust. 
 
Conference presentations are often included in technology assessment reviews 
(TARs), which lead to treatment recommendations, where the presentations provide 
information that has not yet been published. In a study of presentations and abstracts 
used in TARs they found that the quality of reporting was poor failing to describe 
methods of randomisation or blinding of allocation, there were also discrepancies in 
reporting of results
155
.  
 
Continuous medical education (CME) events often communicate the latest research 
and recommendations.  Research shows that dissemination activities have little effect 
if used on their own
405
 although two systematic reviews found that CME events have 
some impact on practice behaviour
418;419
. This has been disputed in later research 
arguing that previous reviews were flawed with poor evidence
420
. Even the use of 
key opinion leaders in changing practice has been disputed
421
.  
 
However it seems that a combination of dissemination activities has greater success. 
The ALLHAT study used persuasive messages by opinion leaders delivered face-to-
face and intended to use professional societies, formularies and patients to intervene 
in practice
401
. The study stated that difficulties in organising opinion leaders, e.g. 
their availability, early on in a trial, before the results of the trials are known, is very 
expensive. The study authors suggested that the use of professional associations and 
public health networks would be useful for wide dissemination activities. Another 
difficulty is designing the right model of implementing the persuasive messages for 
the target practitioners. These strategies require long implementation times of six to 
twelve months in advance. The cost of the dissemination project in the ALLHAT 
trial was $3.7 million in 2007, which was 4% of the clinical trial budget
401
. 
 
It‟s the role of translational research to ensure that scientific knowledge is extracted 
from research and translated into use for patients by health care professionals
422
. One 
of the difficulties with translational research is ensuring the new knowledge is 
disseminated and affect everyday clinical practice
422
.  Woolf argues that there must 
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be more investment into working out how to ensure that research is translated into 
practice and should be funded by those sponsoring the research. 
 
An issue also identified by authors is the objectivity of information disseminated, in 
particular information delivered in the interest of pharmaceutical companies
401
 and 
the role of money in the dissemination of knowledge in the form of paying ghost-
authors and it was suggested that academic centres ensure guidelines exist when 
dealing with commercial studies
283
.  
 
In 2006 an incident at Northwick Park Hospital in London where a phase I trial went 
wrong left six men with multiple organ failure. Not only a shock to the public, but 
also to industry, this type of incident is highly unusual. The drug had been through 
several pre-clinical and animal tests without any sign of causing the types of events 
as was seen in the trial. The Medicines and Healthcare products Regulatory Agency 
(MHRA) and Ethics Committee had approved the trial protocol.  Over many days 
the media was full of anti-industry commentaries. 
 
In 2004 GlaxoSmithKline (GSK) was found guilty for not disclosing serious side 
effects of the drug paroxetine: suicidal thoughts in children and adolescents. GSK 
has been sued by more than 5,000 U.S. citizens since the incident.  
 
In October (2008) Pfizer was found guilty of marketing Celebrex, a cox-2 inhibitor, 
failing to disclose possible serious cardiovascular side-effects such as blood clots, 
heart attacks and stroke. They also falsely marketed Bextra, a drug for arthritis, by 
advertising the drug for use in non-approved uses, namely for pain. Pfizer conducted 
the trials in dental patients and published the results in a dental journal in 2002. The 
article and large marketing efforts increased sales. They had to withdraw the drug in 
2005 for safety concerns, in particular cardiovascular problems. In the case of 
Bextra, this was an important historic event where private litigation can hold 
pharmaceutical companies accountable in a case where the industry regulators have 
failed to spot scientific misconduct. There is no wonder that the media will cover 
these stories in detail and that public trust in clinical trials and industry fails.  
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5.20. Trust and confidence in clinical research 
Society is facing a crisis of trust
223
. According to sociologists and journalists there 
are signs of mistrust even at familiar institutions or individuals and consumer no 
longer trust business or products and patients no longer trust their doctors or 
hospitals. “Trust has to be placed without guarantees”223. If we are let down or we let 
someone else down, relationships based on trust are damaged. Therefore we place 
great emphasis on preventing fraud or deception to deter mistrust; through law, code 
of practices, examiners, passwords etc. The evidence of mistrust are for example 
demonstrations, results of opinion polls or the written opinion of someone, we don‟t 
have much choice in placing our trust in our day-to-day activities such as drinking 
tap water, taking medicines or using certain products but O‟Neill states that we live 
in a culture of suspicion of accountability and transparency. However it will not 
improve our trust if we constantly expect individuals to declare their accountability 
or ask for proof that everything is to be trusted
223
.  
 
Trust is relevant to clinical trial information in several ways. In the clinical setting 
trust is tied to the interpersonal caring attributes of the provider and confidence in 
their competence
228
 and trust in someone depends on the circumstances
229
. In clinical 
trials, informed consent is an important part of gaining the trust of a volunteer in a 
clinical trial, do they understand the  process of the clinical trial, including personal 
risks? The goals of the research and the institution conducting the research need to 
be believed in, and the public need to feel that they can place their trust in them. 
Trust could easily be called into question if people felt that their confidence was not 
being kept and if they felt that medical information was being used for commercial 
gain
169
.  A recent study shows that patient‟s confidence in their physician would 
improve if the physician disclosed relationships with pharmaceutical companies and 
other competing interests
170
.  
 
Trust can be hampered by evidence of bias or conflict of interest, lack of 
transparency and quality, pressures, ethics and geographic location. The scatter of 
information, the evolution of the Internet and the information skills needed to find 
and interpret information means it can be difficult for an individual to distinguish 
between accurate information and marketing claims or even inaccurate information. 
When reading an article, the goal is to balance strengths and flaws found and 
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establish an independent thought of whether the message is true
423
. Are the results 
believable and valid, do they represent the truth?  
 
In clinical research the aim is to disseminate the results of a clinical trial in order to 
influence, e.g. by providing the right information at the right time for the right 
audience. Trust is an important issue that must be considered by those who are 
communication information. The difference between a positive and negative climate 
of trust can have great impact in a clinical trial, including recruitment of subjects for 
trials, marketing products and in sales.  
5.21. Model of trust 
In order to understand how trust/distrust forms, a figure from online banking 
research has been adapted to fit the dissemination of clinical trial information 
(Figure 17) to illustrate issues I have discussed in this thesis, including the 
behaviours of trust shown in Table 1 (p. 57). 
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Figure 17: Framework of how trust or distrust forms throughout dissemination – adapted from 
‘five levels of trust’ in online banking166 
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In brief, factors throughout dissemination can affect the trust of the audience. I have 
discussed factors that affect dissemination in this thesis and they early on affect the 
researcher and research process, and the dissemination process. The choice of 
dissemination method can also affect trust, e.g. if communicating via a website 
compared to via a peer-reviewed journal will affect trust in the audience of that 
information, as some of these methods may be accompanied by peer review or other 
rigorous quality checks, e.g. a publication guideline. It may also be affected by 
previous knowledge or trust in that dissemination method or the author because of 
their institution or experience.  Behaviours affecting trust were discussed in the 
literature review.  There may also be factors that affect the dissemination process 
during the dissemination stage, how influential the information is that is 
disseminated and the way in which the information spreads.   
 
The audience now has to decide if they trust the content. Ambiguity, uncertainty and 
suspicion will lead the author and the institution into a climate of distrust and doubt.  
Conviction, assurance and certainty will lead the author and the institution into a 
climate of trust and credibility.  In a positive climate, more trust is invested in 
institutions, which improves the way in which the public behaves towards an 
institution or their opinions of it.  In a negative climate, trust is removed from 
institutions, causing a climate of distrust and this creates concerns within institutions.  
 
Although simplified here, the results of this research shows that trust surrounds the 
dissemination of clinical trial information throughout the clinical research process 
and the way in which trust or distrust forms should be included when planning a 
dissemination strategy. 
 
5.22. Conclusion to Chapter 5 
The findings presented in part 2 are responses to the research questions what range 
of methods are used to disseminate clinical trial information, what factors affect how 
clinical trial information is disseminated, including attitudes and practices of 
dissemination and how effective a particular method is for dissemination. These 
research questions aimed to test the model constructed and presented in part 1.  The 
chapter began by describing the scatter of information across many resources. The 
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„mystery shopper‟ search using Google showed that information about clinical trials 
is increasingly appearing on the Internet. It identified three core journals that publish 
clinical trial information from trials in obesity and diabetes which show that research 
is not just published in top medical journals, e.g. those with high impact factors. The 
research identified that abstracts and media services underreport aspects of clinical 
trials.  Information about clinical trials can also be found in advertising, promotional 
literature, via patient organisations and charities.  The electronic opportunities have 
greatly improved dissemination of clinical trial information. The Internet helps 
resource discovery and health information on the Internet is growing. In particular, 
clinical trial registries are publicly available but research shows that the content is 
limited and there is a need for an improvement in the design and presentation of 
information.  There are many factors that affect dissemination of clinical trial 
information. There are many regulatory requirements as well as institutional policies 
for reporting on clinical trials. A growth in publication guidelines has improved the 
publication process of clinical trials but my research shows that there is a lack of 
awareness of these guidelines and many of them are not considered useful. 
Effectiveness of a dissemination method is based on the impact of research findings 
on the relevant target audience and research shows that there is a need to understand 
dissemination theory as well as the framework for how trust and distrust form when 
planning dissemination strategies. It is also clear that we need a new definition of 
„publishing‟ to suit the new emerging electronic culture of sharing research.  Chapter 
6 will pull together the findings from Part 1 and Part 2 to make recommendations on 
how we can improve the dissemination of clinical trial information and present an 
optimal model of effective dissemination in order to make clinical research more 
transparent. 
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6. Chapter 6: Recommendations for how the dissemination of clinical trial 
information could be improved and more transparent 
 
6.1. Introduction 
In this chapter, the main findings are drawn together with reference to relevant 
literature and the findings in the studies for this PhD.  The goal of the research was 
split into two parts: (1) to characterise and evaluate clinical trial information and the 
dissemination of that information by constructing a conceptual model structuring the 
processes of information generation and (2) to test the model constructed by 
identifying the dissemination methods used, consider their effectiveness and what 
factors affect dissemination. 
 
This chapter responds to the final research question pulling together 
recommendations for how the dissemination process of clinical trial information can 
be improved and made more transparent. It is not an easy task to make 
recommendations which impacts on many aspects of communication, some which 
have existed for hundreds of years, others only a few years. It is difficult to predict 
the future. There are rapid changes within the information environment with many 
new opportunities that exist communicating via the Internet. Hybrid publishing 
models are emerging combining communication and publishing methods.  Many 
improvements have already been made in making the research process more 
transparent, which is promising. But there is still a need to identify a framework 
which can go some way towards improving the dissemination of clinical trial 
information. Within the framework suggested here there is a model outlining the 
clinical research process and the need for planning communications throughout the 
process. 
 
Three themes have been identified to outline the framework of recommendation: 
regulations and standards, communication planning and organisation of clinical trial 
information. The optimal model of effective dissemination will then be presented to 
outline the ideal methods used for disseminating clinical trial information. The 
model of the clinical research process will be re-introduced to include the optimal 
dissemination methods. The chapter ends with a suggested new definition for what it 
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means to publish, to incorporate the many new methods of disseminating 
information that were discovered during this research. 
 
6.2. Framework for improving the dissemination of clinical trial information 
The recommendations made in this chapter are aimed at the clinical research 
community, the organisations and authorities who are involved with clinical trials 
such as publishers, clinical trial register managers, intervention approval agencies 
and anyone else with an interest in clinical research process.  The framework is 
intended to provide some guidance into building on existing improvements made to 
the communication and dissemination process, highlighting development areas that 
need attention.  
 
The following areas have been highlighted throughout the research as potential 
improvements that can be made: 
 
 Communication planning as part of the clinical trial process 
 Legislation and harmonised regulation around the registration and dissemination 
of clinical trial information 
 Increased dissemination online in structured formats using metadata to improve 
accessibility and additional links between related resources 
 Clinical trial registers to become the key repositories of all clinical trial data and 
links to other relevant registers and published material in journals 
 Data management role – custodian of clinical trial data and information 
 Introduction of standards around clinical trial data 
 Journals should adapt to the electronic era and work closely with clinical trial 
registers, linking to data and research protocols 
 The role of the journal is to organise published peer-reviewed information and 
should concentrate on providing content that helps implementing research into 
practice 
 A new definition of what it means to publish will include the different 
dissemination methods: informal communication, deposited data and information 
in registers and repositories, communication at scholarly conferences and in 
abstracts, websites and formal publication 
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 Scholarly publication is linked to the public good and transparency of research, 
not to career progression and funding. 
 
These can be further broken down into three themes: 
1. Legal requirement of reporting 
2. Communication planning 
3. Organisation of clinical trial information 
 
These are idealistic recommendations to provide long-term guidance and steer the 
dissemination process of clinical trial information. These measures can improve the 
transparency of the clinical research process and information dissemination. If 
researchers are provided with improved guidelines around clinical trial information 
dissemination, tools that assist with the dissemination process and have support from 
authorities and publishers, it is a start towards making the clinical trial information 
available in a timely and accurate fashion.  It will be possible to reduce pressure on 
researchers and therefore eliminate bias, fraud, mistakes and this will improve how 
the research process is viewed by the public and increase trust in research.  Next, the 
recommendations in each theme will be discussed in detail. 
6.3. Legal requirement of reporting 
To improve public trust in clinical research, we must promote the access to 
information. Legal requirements should be harmonised and implemented globally. 
One global law on clinical trial reporting and dissemination would reduce 
fragmentation that is currently occurring. The ethical guidelines that exist to ensure 
safety in clinical trials should extend to include that it is a legal requirement to share 
all research data and make them publicly available. All tools and methods that are 
used for dissemination must be covered under this legal requirement, e.g. an 
application to conduct a clinical trial should be accompanied by a document 
certifying that the researcher will register the clinical trial and publicly make the 
results available and supply a publication plan.  
 
Publishers‟ and authorities‟ guidelines on publication and disclosure should be 
standardised. There are currently many published publication and disclosure 
guidelines with some of them providing conflicting guidelines or expanded guidance 
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on a specific topic. The standardisation of these into one comprehensive publication 
guideline, protected by law, for clinical trials would reduce the confusion amongst 
researchers of which guideline should be followed.   
 
Already in 1901, Sir Galton suggested that biomedical data should be stored and be 
accessible to those who wish to verify the work
424
. Currently in the EU, it is a legal 
requirement to register clinical trials on EudraCT but this register was set up as a 
closed database for competent authorities only and information within it remains 
confidential to authorities only. However, there has been agreement that some of 
these fields will be made publicly available soon. There is also no legislation, apart 
from in the US, on reporting clinical trial results within 24 months of trial end. The 
NHS Constitution
425
 in England aims to improve access to research for the public 
and research summaries are published on the National Research Ethics Service 
(NRES) website
xxxii
. They will also be publishing a summary of ethical opinion on 
the NRES website in the future. There is no framework in place to control 
registration and posting of clinical trial results or for the long term preservation of 
clinical trial data.  Eysenbach and Sa called for a code of conduct for publication of 
clinical trial data
426
 but one has not emerged.  
 
The ethical and legal issues surrounding sharing and publication of raw clinical trial 
data need to be worked out. It is not clear even to researchers themselves who owns 
their data
23
.  By registering clinical trials, there is an opportunity to make this type of 
information transparent by asking who owns the data, funding information and to 
what extent can the data be reused and manipulated. Clinical trial registers are still 
not at this stage asking for intellectual property information. In some cases, 
researchers have argued that they cannot release data without risking the safety of 
their study subjects. Various groups have also argued that access to raw data is 
unnecessary as they are poorly defined and there are problems with consent for the 
release of clinical trial data. It is recognised that individual anonymity can be 
difficult to achieve completely
176
 but that specific items in patient information can be 
removed when sharing information to go some way towards achieving anonymity. 
                                                 
 
xxxii http://www.nres.npsa.nhs.uk/researchsummaries/ [Accessed 17 February 2011] 
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The informed consent procedure should include seeking consent on the release of 
research data. 
 
Data have been said to be more absolute than written conclusions and they can 
reused to answer other problems
427
. Currently the overall prevalence of sharing 
research data remains low
428
.  Admirably, the Annals of Internal Medicine invented 
the „reproducible research initiative‟ in 2007 which sets out minimum requirements 
for data sharing to allow reproduction of research
429
. The requirements were for the 
provision of the original protocol, datasets used for analysis and the computer code 
required for analysis. Authors can specify the extent to which they can or will share 
their data and conditions.  This type of standard could be adopted by other journals. 
 
Finally, the research community together with publishers and relevant authorities 
need to agree on standards for the sharing, publication and preservation of research 
data. These standards should be enforced by a legal framework on the requirement to 
register a clinical trial and publicly release all research results. The unique clinical 
trial registration number should be used to identify the clinical trial in publications, 
on registers and websites and inter-link resources. Funders should make sure that the 
researcher has followed requirements for trial registration and release of results. Data 
managers should be the guardians of the data, in data archives, and link the 
information between registers and other resources where the data are shared or 
published. They are also responsible for the long term preservation of the data.  
 
Summary of recommendation:  
 Ethics committees and medicines authorities to enforce inclusion of plans on 
the dissemination of data and publication planning in clinical trial 
application. 
 The research community, authorities and publishers to agree on standards for 
sharing, publishing and preservation of clinical trial data. 
 The data manager role to be formalised as custodians of data. 
 Funders and data managers of clinical trial registers to monitor enforcement 
of data sharing. 
 Journal editors and publishers to provide standards on the preparation of data 
and require clinical trial number to ensure that the trial was registered. 
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 Researchers to obtain consent from patients during recruitment on the 
publication and sharing of all data. 
 Clinical trial registers to adapt their registers for inclusion of data or link to 
the repository where the data is archived and managed. 
 Data archives to adopt data management procedures for long term 
preservation of data. 
 
6.4. Communication planning  
Kahn points out that knowledge transfer begins when a clinical trial is still under 
design
45
, not after the publication of results. A clinical trial should be carefully 
planned and there is a need to provide information on how research can be translated 
into practice.  There needs to be good quality clinical trial design to provide the 
necessary knowledge and answers on effectiveness of new therapy areas. 
Unfortunately there are few checks available to check quality of trial design, 
although the ethics committees will review trial design before approval of a trial. 
The conduct of trials should be to good clinical trial practice (GCP) standards and 
trials should also follow good manufacturing practice (GMP) guidelines. Trials are 
increasingly audited and inspected by authorities to ensure trials are run to these 
standards. 
 
Published studies can take years to make it into practice and it is an unpredictable 
process
63;200
, therefore a plan on how to rapidly communicate and disseminate 
information must be thought of early, even before the start of a clinical trial.  In fact 
researchers should address publication and appropriate reporting guidelines at grant 
application stage
77
 or at the design of a clinical trial
401
. However, it is recognised that 
planning communication early is costly and funders may not want to do this when 
results are not yet known
401
.  It is important that planning should continue 
throughout the lifecycle of a medical intervention. The publication strategy and plan 
should be a part of the clinical trial application which is vetted by the authorities and 
ethics committees. 
 
Wilkes
40
 linear model of dissemination presented earlier (figure 2 p41-2) needs to be 
revised. Figure 18 is a proposal for a cycle of dissemination to replace the linear 
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model. This cycle could be used as a basis when embarking on communication 
planning.  
 
Figure 18: Proposed cycle of dissemination based on Wilkes’ linear model of dissemination  
 
Ideally within the research organisation, a team should be identified that has enough 
awareness of requirements of communication and appropriate tools and guidelines to 
aid the communication process. They should be supported with appropriate training 
and material to prepare a communication and dissemination strategy. This core team 
should be in place already at the pre-clinical stage and make plans for customised 
messages of timing and varying information that needs to go out depending on the 
audience.  
 
A key objective in the plan should be to publicly share all research data collected in 
clinical trials
430. The plan should not be promotional in nature as “science, not 
marketing, should guide us in writing scientific papers”382.   
 
As part of the strategy the team should decide on the appropriate methods used for 
disseminating clinical trial results and use appropriate theory to efficiently and 
1. Information 
need 
2. Research 
3. Research 
data/results  
=> message 
4. 
Dissemination 
method 
5. Tools for 
dissemination 
6. Influence 
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7. 
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effectively disseminate research.  There are some aspects that need to be considered 
during the planning to achieve effective dissemination and influence decision-
making (discussed in section 1.60): 
 Understand the factors that influence dissemination (Duggan & Banwell) 
 Understand the framework of trust and distrust  
 Consider the barriers to effective communication: cultural, socio-economic 
and environmental  
 Implications of the research: who is it for, what are the implications, e.g. 
change in practice, the timing needed for disseminating  
 The knowledge acquisition process and information literacy skills of those 
acquiring the information, consider how to influence practice 
 Public interest of the public in the research process, make research as 
transparent as possible. 
 
The communication strategy should also include interventions and education
35;401
 of 
practitioners for implementation into practice. I know from findings in this thesis 
that health professionals do not get the information that they need at point of care.  
Research shows that opinion leaders, public health bodies and large professional 
bodies should be involved in dissemination activities as these organisations already 
communicate well with their peers and members.  
 
Other research shows that academic detailing, patient messages, formulary/economic 
evidence and communication that appeals to clinicians are effective.  
 
The team should also write and disseminate comprehensive press releases to the 
media scheduled closer to the publication of results
401
. The press releases should 
report on all datasets reported in the clinical trial register and not adopt a selection 
bias to exaggerate findings or leave out important risk factors.  Ideally, the 20 
recommended data sets
350
 and all findings (negative or positive) should be reported 
in a non-promotional and non-sensationalist way. 
 
Publication guidelines help clinical researchers plan their publications and 
dissemination efforts, and organisational policies provide direction. Informal 
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guidelines on ethical practices in conducting research together with regulations and 
legislation should be regularly updated and implemented globally to ensure 
transparency in research. 
 
Well developed organisational publication strategy or organisational disclosure 
policies should guide the communication team in planning the dissemination 
process, and these guidelines should draw upon existing standards and legal 
requirements of reporting clinical trials. 
 
Finally, each organisational policy or strategy should be publicly shared to improve 
the transparency of the research process. 
 
Summary of recommendations: 
 The communication and dissemination strategy and plan should be planned 
early in the clinical trial design and at least by funding application stage. 
 The strategy should be a part of the clinical trial application process and 
checked by the authorities and research ethics committees. 
 Dissemination planning should continue throughout the lifecycle of the 
medical intervention. 
 A dedicated communications team should be set up at the pre-clinical stage 
within the research organisation who are responsible for the strategy. 
 The team should be supported with training and materials to aid the process. 
 The strategy should: 
i) Publicly share all data 
ii) Not be promotional in nature 
iii) Should include interventions and strategy for implementing research into 
practice 
iv) Involve professional bodies, public health bodies and opinion leaders to 
communicate the message(s) 
v) Use theory based dissemination strategies that are proven to work in 
audiences 
vi) Communicate with media in a non-sensationalist way providing all 20 
key data sets as laid out in the clinical trial register 
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vii) Organisational policies on disclosure and publication should be publicly 
available and draw upon existing standards and legal requirements in 
reporting clinical research.  
6.5. Organisation of clinical trial information  
There are many challenges in the organisation of clinical trial data.  Clinical trial 
information is scattered around different resources and sometimes does not exist at 
all because it has not been published or publicly shared in any way. There are ethical 
and legal issues surrounding sharing of raw data and information from clinical trials 
due to intellectual property, data protection. Only 31% of researchers responding to a 
survey are willing to disclose study protocol and financial agreements
431
 and they are 
also reluctant to disclose all data items
431
. 
 
Regulations already exist for the clinical trial process, but these regulations need to 
be expanded. A legal framework addressing all legal issues and sharing of data in 
clinical trial registers together with guidelines and standards for communication and 
reporting would aid the dissemination process of clinical trial information and 
improve the quality of the data and information as well as the methods used for 
dissemination.   
 
I have established that the Internet is a useful tool to communicate clinical trial 
information.  This PhD has shown that the Internet is changing the way in which 
clinical trial information is made available through both formal and informal tools of 
communication.  
 
This PhD has identified the most effective methods of disseminating clinical trial 
information which can exist electronically via repositories and the Internet. These 
methods are shown in Figure 19:  
(1) Sharing data and information via clinical trial registers 
(2) Providing sufficient information in structured abstracts (journal, 
conferences or on the web)  
(3) Publishing succinct messages including how to implement 
information in practice through editorials, commentaries, systematic 
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Reg # 
reviews and case studies published in e-journals or similar online 
publications.  
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
Figure 19: Effective methods of disseminating clinical trial information and inter-linking between 
resources using the unique clinical trial registration number as connector (Reg #) 
 
All resources should be inter-linked and connected via the unique clinical trial 
registration number, which is provided at the first point of registration in the clinical 
trial register.  This framework identifies a greater role for information professionals 
and data managers to facilitate dissemination by interlinking various information 
resources and appraising literature for validity and importance as well as teaching 
information literacy skills to those who require access. It also necessitates closer 
working relationships between information professionals, data managers, 
researchers, publishers, technical system developers and authorities. 
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6.6. The Internet – changing dissemination 
There is evidence that the dissemination of clinical trial information in changing 
with the introduction of new types of online dissemination methods.  The 
advancement of technology, and the Internet, impacts on the research landscape of 
scholarly publishing, policies of research and funding, dissemination of information 
and progress of science. The Internet allows for increased accessibility, visibility, 
interactivity and usability of research. The web also lends itself well to interlinking 
between resources, and linking in this way will improve navigation for the user 
between the different resources visited. The model of scholarly communication
46
 
will see an increase in communication through informal networks via electronic 
media and possibly less formal publication in journals as information is informally 
published on websites and in clinical trial registers. 
 
The Internet is a very useful tool for resource discovery, albeit informal and formally 
published information exists side by side and quality concerns have been identified. 
The Internet makes it easy to be kept up-to-date, through real time access to 
information in various formats. Online opportunities reduce the lag-time between 
manuscript acceptance and publication. Publishing a clinical trial takes an average of 
4-8 years after the end of a clinical trial and if publishing in print it can take a year 
from acceptance of manuscript to final print copy. Because of this time lapse, some 
formats of scholarly communications, such as biomedical information, are more 
effectively published in the electronic environment rather than print
52
. “Our future is 
on the web”183, in particular as data and abstracts can be disseminated immediately 
online.  Currently, clinical trial information on the web appears in many different 
formats.  If research is not formally published, information provided via the web 
could be provided as technical reports and by providing abstracts, both written for a 
public and professional audience.  The formats should be based on appropriate 
quality and content standards.  New opportunities, as online formats of publication 
develop, will change the way in which researchers publish. Blogging, writing 
structured abstracts and organised websites may replace expensive peer-review 
journals offering no restrictions on format, length and style.   
 
Health information professionals are deeply concerned with the quality and authority 
of health information found on the web
432
.  It is surprising that standards for 
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assessing web quality and functionality have not yet emerged.  Internet 
communication methods need management, funding, stewardship, structure, stable 
long-term storage and terminology for retrieval. Eysenbach suggested an open trial 
initiative to define syntax for publishing trials on the web and ensure interoperability 
between clinical trial registers and search engines to harvest information on clinical 
trials
120
.  We therefore need to develop a standard terminology for clinical trial 
information on the web. If these issues were addressed it will improve the quality of 
information found on the Internet. However, we need standards and checklists in line 
with those developed for print publications and a recommendation would be to adapt 
the ICMJE publication guidelines and the WHO 20 data set recommendations into a 
standard for aiding those who publish clinical trial content online.    
 
Summary of recommendations: 
 The Internet is useful for rapid dissemination of clinical trial information, but 
standards for publishing on the web need to be developed 
 Web based information needs to managed, funded and be stable long-term 
 We need to develop appropriate terminology for clinical trial information on 
the web. 
6.7. Clinical trial registers – a central system 
We recognise that there is no centralised system in existence that brings together all 
clinical trial information. The advent of clinical trial registers has improved access to 
clinical trial information and is an attempt at standardising information. Adopting 
technology itself does not improve healthcare, but the exchange and use of health 
information to inform clinical decision making at the point of care does
433
. 
 The challenges with registers are many including allocation of resources, the 
management of registers, the inclusion of standard elements within the register, 
updating and accuracy of information, completeness of records, intellectual property 
concerns, data protection and technical challenges.  Registers need to be improved to 
provide accurate and comprehensive information and no doubt the future will see 
much development in this area led by the World Health Organization. 
 
Clinical trial registers are clearly important in the storage and dissemination of 
clinical trial information, providing information about new, ongoing and closed 
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clinical trials. They can ultimately cover the gap between research and practice, 
linking research information, data and publications. The clinical trial registration 
number should be used to connect the content to the registered clinical trial in all 
material that is disseminated. Clinical trial registers are key components of 
knowledge transfer research allowing monitoring uptake of new evidence and 
identify barriers to implementation of research into practice. They can also be 
searched for information on adverse reactions and answer questions into the 
effectiveness of new research
45
.   
 
Clinical trial registration and the availability of datasets will provide some 
reassurance to the public that clinical trial information is being used for the benefit 
of all. Clinical trial registers will allow us to spot gaps in research and where funding 
and research is needed. Registers can aid systematic reviews of literature reducing 
bias in literature reviews, if all trials are registered, trials with negative results that 
are possibly not published will not skew a systematic review. The registration of 
clinical trials can also avoid duplication of research effort and effort can be spent on 
other studies building on existing registered studies, or answer research questions not 
already studied.  According to JISC 88% of researchers share data even if only with 
collaborators and informal peer exchange network
434
. 43% of researchers say that 
they would like to access others‟ data434.   
 
The purpose of trial registration is to make sure all data bout a trial are available 
publicly. Once registered, researchers should regularly update their entries
435
.  It will 
improve further if full details of study design and the clinical trial protocol were 
shared. Administration time will be cut down for ethics committees, data managers, 
researchers as all research information is centrally stored and managed by data 
managers. Comprehensive clinical trial registers aid information access for all, 
although existing registers are not sufficient to provide the public with information 
about ongoing trials
352
. At the moment the current lack of funding means that 
systems are poorly structured, they lack standards and there are no checks on data 
within the registries. There is a need to improve registers with harmonised standards, 
starting with the mandatory provision of the 20 recognised datasets, inclusion of trial 
design and protocol, checks in place to ensure compliance. There is also a need to 
develop a standard for the technical system set up and management of clinical trial 
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registers. Currently hundreds of registers exist globally with some overlap, different 
structure and functionality and little inter-linking between content. Clinicaltrials.gov 
has emerged as a leading register but after recent evaluation the system has been said 
to fail patients and clinicians at point of care
352
. It seems appropriate to suggest that 
the World Health Organization revisit its technical capacity recommendations for 
registers and set technical standard to enable cross-searching and inter- linking 
together for professionals and patients to find appropriate trials
352
.   
 
Funding of clinical trial registers together with independent management by a not-
for-profit body, and the management of standards by the World Health Organization, 
would improve checks of content and therefore quality. Registries could be funded 
by a possible combination of pharmaceutical companies and the Government, 
although others recommend that clinical trial registers are independently managed 
for improved transparency and to avoid bias.  It is also be a recommendation to 
introduce a formal directory of approved clinical trial registries (according to laid 
down standards), maintained by an appropriate authority.   
 
During researching for this PhD, the WHO announced their involvement in setting 
standards and an introduction of the WHO International Clinical Trial Registry 
Platform (ICTRP)
105
 as well as a directory of Registry Networks. The Registry 
Network currently links to a few clinical trial registries that meet the WHO 
standards. The WHO standards for registers were issued in April 2009
194
. The 
current WHO standards in trial registration consist of the requirement of 20 trial 
registration data sets (TRDS) to be reported
350
 in registers, e.g. around the set up of 
the clinical trial. There is not yet any formal consensus on standards for clinical trial 
results reporting
226
. There are unfortunately no checks in place for monitoring data 
entered and no sanctions levied of failed or incomplete entries. 
 
Transparency pressures from journal publishers
251
 and legislation in Maine 
(USA)
235;436
 on registration should improve access and quantity of data in registers, 
although it is unclear if this will be useful to patients and prescribing physicians 
8
. 
Registers need to be up-to-date, easily and widely accessible for anyone. Journal 
editors should demand registration as a condition of publication and should demand 
publication of result
218
.  
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Bian also recommends a global network committee with local effort for trial 
registration to ensure uniform, international consistency in policy and trial 
registration and therefore data transparency
435
.  The data management profession 
needs to be developed to maintain the clinical trial registration process from clinical 
research to the archive of clinical trial data. 
 
Only legislation will ensure researchers register their trials and disseminate 
information accurately and timely
435
.  
 
Summary of recommendations: 
 Standards for clinical trial registers to be harmonised 
 Registers to be connected 
 A data management profession to manage registers who perform checks, 
ensure accuracy and protects the data long-term 
 Funding to be in place for registers 
 Legal requirement to register clinical trials and provide timely information 
 Sanctions in place for non-compliance 
 Trial registration numbers link between research registration and 
publications. 
6.8. Abstracts – need to be comprehensive 
Abstracts take many forms and are used for many purposes. They may convey 
information at conferences, for journals, in grey literature, on websites and used in 
press releases. We know that often only the abstract is read, even if a full paper has 
been published. The reasons for this are many: many presentations and abstracts 
from meetings remain unpublished
437
, lack of time, no access to full paper, 
publication language and access to informal abstracts that appear on the web. 
 
This PhD identified that abstracts often under-report clinical trials, not providing 
important information such as trial design, results, funding information or clinical 
trial registration number. The lack of this information make abstracts risky document 
for use at point of care and in systematic reviews. We need standards for abstracts 
covering the required elements in line with information that is provided in clinical 
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trial registers and the research questions in the clinical trial design. Abstracts should 
not be promotional in nature and provide guidance for practitioners. They should 
also provide sufficient information for patients who may print the abstract and bring 
to their physician for discussion. It could follow a similar format as a summary of 
product characteristics
xxxiii
 (SmPC) leaflet. 
 
The EQUATOR
438
 network is working towards setting standards in reporting 
research and have made some recommendations for abstract formats. The 
CONSORT checklist
289
 has been adopted by some journal publishers to guide 
authors in the construction of  journal and conference abstracts by providing a 
minimum list of essential items when reporting the results from a randomized 
controlled trials. A recommendation in this PhD is that a standard similar to the 
CONSORT checklist should be developed and widely adopted to aid the drafting of 
any type of abstract for any clinical trial design. 
 
In particular for media, press releases should provide the same information as 
abstracts with sufficient details about the clinical trial and not be promotional or 
selective. It should provide a link to information provided on clinical trial registers, 
publicly published study reports and key journal articles. 
 
Summary of recommendations: 
 Abstracts should not be promotional in nature 
 Abstracts should provide sufficient information about clinical trial design and 
results as well as provide some guidance for practitioners 
 A standard for abstracts should be developed to aid drafting abstracts for any 
type of clinical trial 
 An abstract could look something like an SmPC 
 The abstract should provide the clinical trial registration number. 
 
                                                 
 
xxxiii
 SmPCs are available once a medical intervention has been approved by the competent 
authorities. 
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6.9. The journal – effectiveness in dissemination 
Journals have complex funding and business models that affect the way in which 
they disseminate information, via the web and in print format. New business models 
like the open access model, aim to provide information rapidly at no cost to the user. 
The format of the  journal article has changed very little but journal articles are 
getting longer and readers‟ times are getting shorter. The journal has aimed to bridge 
the gap between clinical research and practice but it is difficult to establish their 
effectiveness in the dissemination information and it has been claimed that they do 
not change practice
49
 and that the existing journal model therefore is not effective
49
. 
Time to publication is long, and the peer review process cause delay and introduce 
further bias.  Journal articles lack information on how to implement the research into 
practice. Not all print journals are fully indexed on search engines and articles are 
difficult to find.  Improved organisation, abstracting (see previous section) and 
indexing, using metadata, of articles will ensure that papers can be found even if not 
published in top journals.  
 
The motives of journal publishers, editors and authors are for a good academic 
reputation and the primary objective is commercial success. Publishers identify the 
quality of journals by articles that have higher citation rates and high impact factors, 
higher circulation and low acceptance rates
69
. The actual primary function of the 
journal is to describe and interpret data and it needs to do this for a varied audience. 
The journal article is usually of a standard length, a one size fits all, with little 
flexibility in providing a large amount of information, data or graphics to illustrate 
content. Journals are selective in their publication of articles, due to editorial policy 
but also lack of space or specialism.  In order to improve transparency of research, 
journals should publish all research
201
 or at least summaries of research that are aids 
to interpreting results. Journals should not publish papers that seem to be selectively 
reporting results and they should not allow sponsored supplements that promote 
products
218
.  If possible, the journal business model should attempt to separate 
product promotion from reporting of clinical trials.   
 
It is the role of the journal to ensure quality of the research it is publishing. It does 
this through three means: 1) instructions to authors 2) peer review and 3) editorial 
processes
77. Authors‟ guidelines have improved over the last few years to include 
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requirements for trial registration, and requiring transparency in authorship and 
funding such as stated in the GPP and ICMJE guidelines.  However, ideally authors‟ 
guidelines could be standardised to avoid author confusion and wasted effort in 
rewriting content in line with guidelines. The guidelines should also be in line with 
current legal and ethical requirements. Peer review has been questioned as a tool for 
assessing accuracy and for approval for publication, but it is the best system we 
currently have and needs to remain in place until a viable alternative is invented. 
Open peer review was tested by Nature and abandoned due to lack of uptake from 
readers. Journal publishers need to invest more time in the editorial process and 
developing the peer review process to ensure transparency and fairness. Currently 
peer reviewers are unpaid, untrained and sometimes inappropriately used, e.g. 
reviewing information from competitors or do not have the adequate skills to review 
certain content. We rely on peer-review of published information to be screening 
content and data to ensure accuracy, reliability and journal editors to check the 
quality of peer reviewers and other editors used by journals.  Some checklists exist to 
aid authors in writing papers, such as CONSORT
143
 which asks the author to discuss 
trial design and methods used. It is a lot to ask a peer reviewer to accurately be able 
to comment on statistical analysis of trial results, design of trial, what is reported and 
how. Journals should not rush to publish manuscripts that have not been through 
quality testing, as this may cause chaos and sensationalism
439
. They must also insist 
on checking source data. 
 
The impact factor system does not determine quality of scientific research
379
. The 
removal of impact factors can remove the pressure on researchers to publish in high 
impact factor journals. Many organisations are moving away from the impact factor 
requirement to an expectation that research is published and made publicly available 
within six months of publication. 
 
It has been suggested that organisational repositories of information can replace 
journals as they organise information and data better. If repositories are peer 
reviewed and indexed using better terminology, they can replace the scholarly 
journal
52
.  However, the era of repositories is not here yet and the journal is still a 
primary method to disseminate clinical trial information. 
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There is room for both the journal article (summary) and  a true object (eg research 
findings, technical report) to exist alongside one another. By publishing all trials we 
save time and effort, protect patients who were in those trials and future patients who 
may rely on those results and will reduce potential bias in systematic reviews 
allowing all studies to be taken into account.  The journal still has an important role 
to play in reporting clinical trial results but an improved journal model is 
recommended. If publishers modified their focus, they can concentrate on publishing 
pre-appraised evidence summaries and clinical bottom-lines. The journal should 
publish abbreviated findings or abstracts from large robust clinical trials, systematic 
reviews and clinical bottom lines. They should highlight implementation of new 
findings, repeat findings in the editorial and allow for opinion in commentaries.  
They should encourage the publication of case reports. They can publish full articles 
online and provide translations into other languages.  Journal summaries could be 
linking to clinical trial registers for access to research data, the study protocol and 
further information about the clinical trials. The summaries should provide 
information on cost-effectiveness, side-effects and barriers to implementation. These 
summaries could be disseminated within practices with no copyright needed for 
dissemination.  Journals should link to information elsewhere and therefore reduce 
the scatter of information
49
. 
 
Summary of recommendations: 
 The role of the journal remains strong in publishing clinical trial information  
 The journal model could change to publish summaries of clinical trial 
information and to stimulate discussion around clinical trials  
 The journal should publish  non-promotional articles and supplements   
 The journal should not reject publication of negative result studies 
 The journal should use its online presence to expand and provide extra value 
content, e.g. translations, systematic reviews, longer articles, commentaries 
etc. 
 Peer review remains an important aspect of assessing quality of content, but 
editorial control and checklists (e.g. CONSORT) need to support the peer 
review system 
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 The impact factor system does not contribute to quality, an alternative is 
recommended 
 Journals should extensively link to clinical trial information content 
elsewhere, e.g. clinical trial registers, websites, related articles etc. 
6.10. An optimal method and a model of effective dissemination of 
clinical trial information 
The PhD shows that we can improve the dissemination process for clinical trials to 
make the clinical research process more transparent and information publicly 
accessible. Ideally we want to disseminate clinical trial information as widely as 
possible in a timely and efficient manner. Access to research information accelerates 
sciences, innovation and discovery
440
 as well as improves the public trust in clinical 
research and science.  
 
Based on the findings in this PhD and recommendations in this chapter, the model of 
the clinical trial process can now be updated to show how we can ensure the 
effective dissemination of clinical trial information (figure 20 and appendix F for a 
larger model).  
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Figure 20: Model of effective dissemination of clinical trial information 
 
Three themes were identified to outline the framework of recommendations for 
improving dissemination: regulations and standards, communication planning and 
organisation of clinical trial information.  The European Clinical Trial directive has 
been said to not harmonise European clinical research but has left research 
fragmented
218
. The existing legal directives also do not adequately support the 
communication of research findings.  We need regulation and standards around the 
reporting, communication and publication of research. We also need to plan 
communication earlier on in clinical research. And finally we need to organise 
clinical trial information appropriately, by sharing and publishing research data and 
summaries. 
6.11. Model walk-through 
Pre-clinical phase 
A research organisation has identified an information need, a research need. A 
promising compound may respond to research questions x and y. Even before 
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clinical trials take place, the compound is undergoing pre-clinical tests. Already at 
this point a pre-defined communication team who has the relevant training and 
support through publication guidelines and existing public disclosure policies will 
draft the dissemination plan.  
 
This plan forms a part of the Clinical Trial Application (CTA). Once the CTA has 
approval, the phase I clinical trial will be publicly registered in a clinical trial register 
and obtain a registration number (Reg #).  
Clinical phase 
Subject recruitment can begin and during the informed consent process, permission 
will be sought from study subjects for the disclosure and sharing of clinical trial data.  
During the clinical phase, several clinical trials are likely to take place each with 
individual research protocols.  Data will be analysed, the clinical trial register 
updated at each trial end, abstracts drafted for conferences, websites and press 
releases and publications will begin to emerge.  
Post-marketing phase 
Once the drug has launched, we are in the post-marketing phase during which some 
other studies may take place. Clinical trial registers should continuously be updated 
and trials marked ended with the sharing of all data, citations for published research 
and links to other publicly available quality information on the web. 
 
Within this framework, three optimal methods for organising and disseminating 
clinical trial information were identified: clinical trial registers, abstracts and 
publications (journals or web based content).  These three methods require 
responsible management, funding and support to become unbiased and make science 
transparent. 
6.12. Definition for what it means to publish 
A research objective for this thesis was to provide a recommended definition of what 
it means to publish. Research has highlighted that there is a need to define what 
constitutes publication on the web
44;51
. Without a definition; the quality, integrity and 
authentication of electronic scientific information will be difficult to determine
44
. We 
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lack a definition of what it means to publish in view of the changes in publishing and 
communication opportunities that have arisen with online tools and dissemination 
via the Internet. Frankel refers to “definitive publication” in the electronic 
environment, and in order to be definitive the material must be publicly available, 
peer-reviewed, available within a system allowing long-term access and 
preservation, material should not be removed, must be identified (ideally with a 
DOI), have bibliographic metadata, and the relevant communities must be made 
aware of its existence
44
. Halliday wrote that the electronic environment suits some 
forms of scholarly communication better and information can be hyperlinked in an 
integrated transparent network
52
. Online material greatly improves linking directly to 
other research, e.g. citations
49
. To some extent institutional repositories are 
addressing these issues and according to the European Commission, the research 
funding agencies must lead the way in determining researchers‟ publishing practices 
71
. Online archives, preservation standards and repositories ensure the preservation 
of scientific information
441
. 
 
The developments in the electronic environment have created opportunities for new 
forms of dissemination and are changing the way in which dissemination is done as 
well as changing how information is accessed. We have not gone into detail about 
access in this thesis, but it is important to stress that the way in which the public and 
health professionals access information is increasingly becoming similar
113;442
.  
 
It is important to take into consideration new developments in dissemination. 
Traditional dissemination methods as we have seen involved talking informally to 
colleagues followed by presentations at conferences followed by a final published 
article. New dissemination methods are more about involving the recipient of the 
information by targeting information and evidence to a specific audience, e.g. 
evidence to get a medicine into a formulary or providing updated news about the 
medicine via a newsletter.  Dissemination of information must be planned early 
on
401
. 
 
I propose a definition inspired by those who have made a point of what it means to 
publish 
44;57
. 
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To publish is a recognised work, contributing to knowledge and searching for the 
truth via a method of dissemination which acts as a record of science.  
The publication allows peers to critique and repeat the scientific research activity 
to complete the scholarly research cycle. Therefore to publish can be in a print, 
verbal (in the form of presentation, podcast or recording) or electronic format.  
The publication should allow for long-term access, be preserved and its  
existence communicated to peers. 
6.13. Conclusion to Chapter 6 
This chapter responded to the research question on whether the dissemination of 
clinical trial information can be improved and make the research process more 
transparent.  Three themes were identified to outline the framework of 
recommendations: regulations and standards, communication planning and 
organisation of clinical trial information. The research shows that we can improve 
and harmonise the dissemination process for clinical trials and make the clinical 
research process more transparent.   By the adoption of these recommendations we 
can save research time and effort, improve the evidence-base, improve future 
research, reduce pressure on researchers which leads to improved transparency and 
public trust in clinical research. Duplication of research will end and research will 
accelerate. When the entire research process and high quality information output is 
publicly accessible and transparent the public good will be served. This will lead to a 
transparent research culture which will ultimately improve public health.  
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7. Chapter 7: Conclusion to the research  
7.1. Introduction 
This chapter presents the summary of the research that has taken place for this thesis. 
Reflections on the research undertaken will be discussed first followed by a 
discussion around the limitations of the research.  A summary of the major findings 
will be provided with a reflection on current developments in the communication of 
clinical trials and how this study contributes overall. The chapter ends with 
presenting suggestions for further research. 
7.2. Reflections on the research process and methodology 
 
Clinical research is a regulation heavy environment and information about clinical 
trials is abundant and very complex. Dissemination activities take many forms and 
there is a lack of organisation of information, which is scattered across many 
resources. At the same time developments on the web has made dissemination or 
publication on the web easier and also made the public expectant to find more 
information on the web. These rapid developments and opportunities are fascinating 
and it is clear that regulations, policies and guidelines within clinical research are not 
up to scratch with telling researchers how to disseminate their research. It was 
challenging to determine how best to research these issues and monitor 
developments over a period of 4 years for this study.  There were also temptations to 
get drawn into related issues of dissemination, in particular fraud and misconduct in 
research as well as economic and political issues such as managing clinical trials in 
developing countries or in specific disease areas that are either high or not so high on 
the research agenda but where there is great public need for research. 
 
The literature review was cumbersome, even if interesting. A lot has been published 
on some of the topics, e.g. opinion pieces on the current regulations of clinical trials, 
sharing research data, clinical trial registries and the future of the journal. It was 
difficult however to find published information around clinical trial information and 
the process of clinical research, an area which has yet to be developed. Many of the 
resources drawn from for this research come from non-peer reviewed sources, e.g. 
magazines, the web and reports, not always good quality research. It was difficult to 
find evidence when a lot of resources consulted are full of opinions of authors.  
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The literature review was ongoing throughout the research process in particular 
when following new developments, e.g. clinical trial registration and legislation 
surrounding clinical trials. There could never be a real „cut-off‟ point for running 
searches for new information, however the final overall check for new relevant 
references was done in November 2010. A few more recent references have been 
included as I came across them in early 2011. 
 
In order to find data to establish an evidence-base this research needed to break 
down the research into many smaller studies. This was time-consuming as each 
research study had to be considered for its value as a contributor to this study.  Most 
of the studies are snapshots in time providing data and information around issues 
discussed in this research as many of them were under development, e.g. clinical 
trial registries, publication guidelines and developments on the web making 
publishing on the web easier.  
 
The thesis followed a mixed method research approach and used qualitative and 
quantitative techniques to examine the dissemination of clinical trial information. 
The study was broken down into segments of smaller studies to draw together a 
comprehensive picture of how clinical research takes place and the information that 
is generated throughout the process of clinical research. Collecting data and 
information through different methods provided this study with a broader 
understanding of the complexities of clinical trial information, dissemination and 
factors affecting dissemination. The research findings allowed me to propose a 
framework for improving the dissemination of clinical trial information to make the 
clinical research process more transparent. 
 
Six central research questions that were posed and examined in this study: 
1. What is clinical trial information? 
2. What do we mean by dissemination? 
3. What methods are used to disseminate information?  
4. Why is a particular method chosen and what factors affect information 
dissemination? 
5. What is effective dissemination? 
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6. Can we improve the dissemination of clinical trial information and make 
the process more transparent? 
 
The two-part research aim became: firstly, to characterise and evaluate clinical trial 
information and the dissemination of that information by constructing a conceptual 
model structuring the processes of information generation.  Secondly, to test the 
model constructed by identifying the dissemination methods used, consider their 
effectiveness and what factors affect dissemination. 
 
By exploring the answers to these research questions, this thesis has revealed the 
status of clinical trial information dissemination by modelling the information that is 
generated in clinical trials, it analysed the methods used and factors that affect 
dissemination, it has proposed a framework of recommendations for improving the 
dissemination of clinical trial information and therefore also making research more 
transparent. 
7.3. Limitations of the research 
 
Some of the limitations were discussed in Chapter 3 where each study‟s research 
methodology is described. Briefly summarised here:  
 
Survey of clinical research professionals:  
 The use of web-based surveys may miss out on respondents reducing 
potential sample. 
 The use of ambiguous terminology where terms are not used consistently 
throughout the clinical research community. 
 Complexity of survey asking many questions around many issues. May have 
benefited from a briefer survey followed by face-to-face interviews. 
 
Most of the studies are snapshots of a moment in time, during a period of rapid 
developments in clinical research during a five year period: 
 The clinical trial registries saw a rapid increase in registrations. 
 The WHO got involved in setting standards for trial registration. 
 New publication guidelines, ethical guidelines and clinical research 
legislation released. 
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Rise of web 2.0 or interactivity via the web: 
 During the five year research the Internet became increasingly popular for 
self-publication through social tools, e.g. blogs etc.  
 The public are increasingly turning to the Internet to find information about 
health. 
 Regardless of this sudden development, little research has been done around 
the dissemination of information on the web, although this will probably 
change in the next few years. 
 
Clinical trial registries – quality of content and functionality: 
 The research on registers was conducted at a time when the WHO had not yet 
announced their involvement in writing standards. Registers were built and 
disappeared rapidly during a short period of time. However, registers that 
exist today are still facing similar issues, e.g. standards, technical difficulty 
etc. 
 
Lack of evidence: 
 Many resources used for the literature review were not peer-reviewed and 
many papers contain personal comments, sometimes very negative, towards 
publishing and the pharmaceutical industry. It is difficult to determine the 
evidence for some of these comments.  
 There is a lack of evidence in many areas discussed in this thesis. Where 
possible my research was compared to existing research, e.g. study of 
functionality and quality of content on clinical trial registries were compared 
with similar studies looking at cancer information on the Internet and 
knowledge of clinical trial registration in the survey were compared to 
similar findings in published survey
443
 that took place after the survey 
presented in this thesis.  
 
Some other limitations were described in Scope (Chapter 1). These were mainly 
around the need to keep the research focussed on the main aim and not get drawn 
into relevant, but too detailed, areas: 
 
 
Korjonen: Clinical Trial Information  206 
 
 Research fraud and misconduct 
 Economic and political issues such as managing clinical trials in developing 
countries or in specific disease areas 
 Information literacy skills 
 Dissemination or complications of information dissemination, e.g. the digital 
divide between developing and developed countries 
 Legal issues, e.g. copyright and intellectual property 
 The scholarly communication process as a whole. 
7.4. Summary of recommendations 
This study has demonstrated the following 8 findings: 
 Clinical trial information is complex sets of information that is generated 
throughout the clinical research process. 
 Although there are some legal requirements of reporting from clinical trials 
to the authorities, there should be further legalities surrounding the sharing of 
data and make results publicly available. 
 The communication of clinical trial information must be planned early on 
even before the start of a clinical trial. The communication plan should be to 
publicly share all research data collected in clinical trials which should not be 
promotional in nature. 
 The most effective methods in disseminating clinical trial information are 
electronic, these methods are 1) clinical trial registries 2) structured abstracts 
in journals and on the web 3) publication of succinct message on how to 
implement research in practice in publications (not necessarily journals). 
 Peer review remains an important aspect of assessing quality, but should be 
accompanied by checklists and editorial control. 
 The impact factor system is not helpful in the publication of clinical trials 
 All publication methods should interlink to related resources online. 
 The definition of what it means to publish needs to change and this includes 
updating the scholarly communication cycle. 
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7.5. Reflections on the recommendations 
I stated in the introduction of Chapter 6 that it is not an easy to task to make 
recommendations. The clinical research industry is a major industry with big players 
such as governments, pharmaceutical companies, research organisations, charities 
and stakeholders who all have their own personal interest in their work or 
investment. It is also difficult to predict the future and events that may have an effect 
on the industry. Within the information environment there are also rapid changes, the 
Internet is growing and changing providing new opportunities for individuals to 
express themselves.  
 
The framework that was provided in Chapter 6 was based on the research conducted 
in this thesis and not dissimilar to some concerns expressed by other experts in the 
field or issues that have been identified elsewhere. They are not radical but even a 
small change may impact on the existing routine in clinical research, creating more 
bureaucracy, taking up more valuable research time, but making research more 
transparent and improving public access to information.   
 
In order to „check‟ the feasibility of my recommendations, they were circulated to a 
group of „experts‟ for comments. These comments proved valuable and give the 
research some clout. Since writing the last few drafts of this thesis, more 
transparency efforts are being made in clinical research, some which are very similar 
to some of my recommendations provided. This is encouraging and satisfying, 
making the findings in this research significant and providing realistic opportunities 
for making research more transparent. 
7.6. Reflections on current developments in the dissemination of clinical 
trial information 
As stated above, whilst working on this thesis a number developments took place 
which improved aspects of clinical research and also confirmed findings of my 
research. 
 
 A paper443 was published on clinical trial registration which concluded that 
trialists require further information before making decisions with regards to 
voluntary trial registrations. A key finding in my survey was that clinical 
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research professionals have some knowledge but are not always confident 
when it comes to clinical trial registration. Another paper in 2008 reporting 
on survey results on public disclosure clinical trial registration identified that 
public disclosure of funding and the study protocol were issues
431
. 
 In late 2010 a handbook on clinical trials communication444 was published 
discussing the need for planning and writing strategies for communicating 
clinical trials globally. This is in line with my findings that communicating 
needs to begin early on in a clinical trial. It also covers the issue of releasing 
clinical research results.  
 Early in the research it was established that there are too many clinical trial 
registers, the quality of the content is poor, and the scatter of information is 
large across many resources. The WHO announced in 2007
105
 the need to set 
standards for registers and inter-link registers to make it easier to search for 
the public. 
 New legislation in the US (FDAA) on mandatory trial registration445 and a 
paper published on the necessary legislation on trial registration in 2010
435
. 
 The Declaration of Helsinki was updated with recommendations for trial 
registration in 2008
360
. 
 A book was published covering issues around clinical trial registries in 
2006
94
, showing the need for in-depth information around the issues. 
 Published evaluations of clinical trial registers‟ functionality and content, 
more recently one paper on clinicaltrials.gov and its failures (these studies 
are reviewed in Chapter 5). 
 The rise of organisations and more meetings around communication of 
clinical trials, e.g. Equator
73
, GPP
240
 and several medical writers‟ 
associations.  
 After finalising the recommendations of the proposed cycle of dissemination 
above, a paper
35
 was discovered presenting thirty-three diagrams modelling 
different aspects of the scientific communication process. Jarvelin‟s IDEF0 
based diagrams, in particular diagram AO, breaking down the life-cycle of 
research, and A3, on communicating the results of research, closely resemble 
my cycle of dissemination and the framework of effective dissemination. The 
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models presented strongly confirm the need for models to outline research 
processes. 
7.7. Further research recommendation 
Since research is a process, it attempts to answer some questions as well as generate 
new questions.  
 
A suggestion for continuing this research would be to perform further in-depth 
analyses of aspects of clinical research and information management in order to 
establish the most consistently effective methods of dissemination for clinical trial 
information: 
 
 The communication planning in clinical research and specifically what 
happens to information from research. 
 In a meta-ethnographic approach investigate the dissemination of clinical 
trial information in a specific disease area or perhaps situation, e.g. a crisis.  
 The development of a review tool for checking quality on websites that 
publish clinical trial information. 
 The organisation of clinical trial information, e.g. quality and content of 
clinical trial registers and information found on the Internet.  
 Informatics systems and standards that can be helpful in the development of 
repositories for clinical trial information.  
 The opportunities and possibilities of making research results publicly 
available, e.g. new forms of publishing. 
7.8. Conclusion 
 
This chapter has summarised the research undertaken, reflections on the research 
process, limitations to the research, contributions to the evidence-base and provided 
further research recommendations. 
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 Appendix A: Constructing a model of information generation and dissemination 
for a new intervention undergoing clinical research   
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Appendix B Feature and functionality range of clinical trial registries (Part 1 & 2) 
 
 
Part 1 
CTR
Basic search 
tool
Advanced 
search tool Registration Search fields Results display
ClinicalTrials.gov y y n Search terms Recruitment and study status given
Recruitment Title
Study type Condition
Condition Intervention
Intervention Outcome measures
Sponsor Eligibility
Study id Contacts
Location More information
Age Identification number
Phase
Funding
Date registered or updated
Study by topic
Studies on map
Display full text view, tab
view, contact locations,
related studies
IFPMA register y n y Terms to search for (pop up box) Indication
Terms to exclude Trial id
Location Trial description
ISRCTN* y n n Search box ISRCTN id
Results order Sponsor
Direction Public title
Maximum results Scientific title
Display as print friendly Acronym
Ethics approval
Study hypothesis
Study design
Country of recruitment
Disease
Eligibility
Status and dates
Outcome measures
Funding
Website
Contact details
Edit date
MRCT* y n n Search box Source of record (CTR)
Results order +as above
Direction
Maximum results
Features Display of fields
y = available n=Not available
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Part 2 
CTR
Basic search 
tool
Advanced 
search tool Registration Search fields Results display
UKCTR* y n n Search box as above
Results order
Direction
Maximum results
Tick CTR to search
Pharmaceutical Industry y n n Keyword Company
 Clinical Trial Database Or View all records Serial number
Brand name
Generic name
Trial title
Objective
Therapeutic area
Indication
Phase
Design
Source
Participating countries
Comparators
Interventions
Patient groups
Primary endpoint
Sample
Status
Date
Duration
Publication status
Publication name
Contact email
UKCRN Portfolio y y n Topic Title
Title Id number
Chief Investigator Topic
ISRCTN Funding
UKCRN Study Id Study type
Research summary Design
Or Topic search Disease
with subtopics list Phase
Status
Sample size
Geography
Eligibility
Investigator name
Contact details
Sponsor
WHO ICTRP y y n Title 21 datasets of the WHO
Intervention
Condition
CTR
Recruitment status
Primary sponsor
Secondary id
Countries of recruitment
Date registered
Centerwatch y n y Keyword Written in narrative, no
Disease/condition decided data sets.
Trial location Aimed at recruiting.
Or list by disease topic
MedTrials n n n Only a list of current trials Gives narrative
Aimed at recruiting.
Clinical Connection y n n Keyword City
Zip State
Distance zip
Study summary
Eligibility
Reward
Location
Contact number
Online form to submit
Features Display of fields
y = available n=Not available
*within Current Controlled Trials 
 
  
 
 
 
Korjonen: Clinical Trial Information  250 
 
Appendix C: Comparison of the WHO TRDS and data fields and review of content 
provided within clinical trial registers  
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Appendix D Publication guidelines 
ICMJE Uniform Requirements 
for registering trials prior to 
publishing and disclosure 
(worldwide)  
1979 
 
Produced by the International Committee of 
Medical Journal Editors (ICMJE) to aid editors and 
authors create accurate and easily accessible 
reports of biomedical studies.  Covers ethical 
principles of medical manuscripts and the technical 
aspects of preparing and submitting scripts. First 
published in 1979 it has undergone revision many 
times. 
ICH E3 (worldwide)   
1995 
 
The objective of this guideline is to allow the 
compilation of a single core clinical study report 
acceptable to all regulatory authorities of the ICH 
regions. The guideline is intended to assist 
sponsors in the development of a report that is 
complete, free from ambiguity, well organised and 
easy to review. Although it doesn‟t provide 
guidelines on how to publish a paper, it has often 
been quoted as providing the right guidelines for 
how the content should contain in a publication. 
CONSORT statement 
(worldwide)  
1996 
 
The Consort statement is an evidence-based, 
minimum set of recommendations for reporting 
RCTs. It offers checklist for authors to prepare 
reports of trial findings, facilitating complete and 
transparent reporting, and aiding their critical 
appraisal and interpretation. 
GPP Good Publication 
Practice for Pharmaceutical 
Companies (worldwide) 2000 
Written in 2000 and circulated to pharmaceutical 
companies for consultation.  The guidelines were 
designed to increase transparency of processes 
involved in the publication of industry-sponsored 
trials and to establish standards. The guidelines 
apply to publications arising from industry-funded 
clinical studies of marketed products.  In 
September 2008 Blackwell Wiley announced that 
the GPP guidelines should undergo review and are 
seeking collaborators. 
PhRMA Principles: disclose 
trial results of all hypothesis-
testing trials (USA) 2004 
The Pharmaceutical Research and Manufacturers 
of American (PhRMA) represent research-based 
pharmaceutical companies and biotechnology 
companies. Drafted and adopted these principles to 
set out its relationship with individuals and other 
entities involved with the clinical research process. 
Disclosure of clinical trial results is one chapter out 
of four principles. These principles were revised 
June 2004. 
IFPMA (International 
Federation of Pharmaceutical 
Manufacturers Association) 
Joint position statement: 
January 2005 a joint position statement was signed 
between the International Federation of 
Pharmaceutical Manufacturers & Associations 
(IFPMA), European Federation of Pharmaceutical 
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registering and disclosing 
clinical trials and their results 
(worldwide)  
2005 
 
Industry Association (EFPIA), Japan 
Pharmaceutical Manufacturers Association (JPMA) 
and PhRMA. They agreed on principles regarding 
the disclosure of information relating to clinical 
trials that they sponsor. Covers clinical trial 
registration and the disclosure of trial results, 
implementation dates and a compliance statement. 
They encouraged companies to make public how 
they will adhere to the signed standards. 2005 and 
2006 saw pharmaceutical companies issue their 
own guidelines or policies with regards to the 
registration of trials and disclosure. 
EMWA publication guidelines 
(EU) 2005 
To define ethical standards for professional medical 
writers who prepare papers for publication in 
medical journals. The guidelines provide support 
for recognised authorship criteria and lay out the 
professional responsibilities of medical writers to 
ensure that the papers they write are scientifically 
valid and are written in accordance with accepted 
ethical standards. 
WAME publication guidelines 
(worldwide)  
2005 
 
A comprehensive policy on publication ethics:; 
including description of authorship, peer review, 
editorial decision, originality, scientific misconduct 
etc. A basis for journal editors to draft their own 
policies, the document makes recommendations on 
the best solutions to address ethical problems. 
COPE (worldwide)  
1999 
The guidelines address: study design and ethical 
approval, data analysis, authorship, conflict of 
interests, the peer review process, redundant 
publication, plagiarism, duties of editors, media 
relations, advertising, and how to deal with 
misconduct. 
Council of Science Editors 
White Paper on Promoting 
Integrity in Scientific Journal 
Publications (worldwide)  
2006 
The policy was created as a resource as an aid for 
all editors who are establishing and benchmarking 
their journals' policies and procedures. It covers 
roles and responsibilities of all parties involved in 
publishing and scientific misconduct. 
AMWA Code of Ethics (USA)  
1994 
These principles take into account the important 
role of biomedical communicators in writing, 
editing, and developing materials in various media 
and the potential of the products of their efforts to 
inform, educate, and influence audiences. 
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Appendix E: Comparing pharmaceutical disclosure policies against ICMJE 
Uniform Requirements headings for quality of content 
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Appendix F: Model for effective clinical trial information dissemination (also 
Figure 20) 
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APPENDIX G: SURVEY QUESTIONNAIRE OF CLINICAL RESEARCH PROFESSIONALS 
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APPENDIX H: POSTER PRESENTED AT CONFERENCE OF THE INSTITUTE OF CLINICAL RESEARCH  
MARCH 2008 
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APPENDIX I: PUBLISHED PAPER ON RESULTS OF SURVEY OF CLINICAL RESEARCH PROFESSIONALS  
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